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CHAPTER 1
General introduction
Modified from:
The Th17 pathway as a Therapeutic Target in 
Rheumatoid Arthritis and other Autoimmune and 
Inflammatory Disorders
Debbie M. Roeleveld1, Annemarie E.M. van Nieuwenhuijze1, Wim B. van 
den Berg1, Marije I. Koenders1
Biodrugs 2013; 27: 439-52
1Dept of Experimental Rheumatology, Radboud university medical center, 
Nijmegen, The Netherlands
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RHEUMATOID ARTHRITIS AND T CELLS
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting up to 1% 
of the population worldwide. The RA pathology is characterized by progressive 
inflammation of synovial joints, resulting in damage to cartilage and bone [1]. 
The synovium of affected joints becomes hyperplastic, pannus is formed, and 
monocytes, lymphocytes, and polymorphonuclear cells (PMNs) infiltrate into 
the synovial lining and cavity (Figure 1). Although the etiology of RA remains 
to be not fully understood, research indicated an important role for various 
cell populations including B- and T-lymphocytes, innate immune cells, synovial 
fibroblasts, and osteoclasts in the pathogenesis of this disease [2,3]. 
T cells are suggested to be important in the pathogenesis of RA as there is 
an abundance of those cells in synovial tissue and fluid of RA patients [4], 
and there is a positive association between specific major histocompatibility 
complex (MHC) class II alleles and RA [5]. Moreover, an important role for T 
cells in various arthritis animal models has been demonstrated [6-8], and 
RA symptoms improved upon treatment of patients with T cell-directed 
Figure 1.  Schematic representation of a healthy and an arthritic joint.
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GENERAL INTRODUCTION
therapeutics [9]. To date, 7 different T helper cell subsets have been identified: 
Th1, Th2, Th9, Th17, Th22, follicular T helper cells (Tfh), and regulatory T (Treg) 
cells, each with their own set of inducing factors and effector cytokines, as 
schematically depicted in figure 2 [10]. 
TH17 CELLS AND EFFECTOR CYTOKINES 
Th17 cells produce amongst others IL-17, IL-21, and IL-22. Thereby protecting 
the host against bacterial and fungal infections, but also promoting the 
development of autoimmune diseases like RA. The first association made 
between Th17 cells and a genetic polymorphism contributing to RA pathology, 
was when a SNP in the IL-4 receptor gene appeared to influence the levels 
of Th17 cells and cytokines. RA patients homozygous for this particular SNP 
Figure 2.  T helper cell subsets. Overview of identified T helper subsets (bold) with their 
differentiation inducing factors (next to arrows), most important transcription factors (depicted 
within cell), and effector cytokines (italic). AhR, aryl hydrocarbon receptor; Bcl6, B-cell lymphoma 
6; Foxp3, forkhead box p3; GM-CSF, granulocyte macrophage colony stimulating factor; IL, 
interleukin; IRF4, interferon regulating factor 4; RORγt, retinoic acid-related orphan receptor-γ t; 
Tfh, T follicular helper; TGF, transforming growth factor; Th, T helper; TNF, tumour necrosis factor 
IFN-γ
IL-17
IL-21
IL-22
GM-CSF
IL-4
IL-9
TGF-β
IL-10
IL-21IL-22
Th2
Th9
Treg
TfhTh22
Th17
Th1
GATA3
Tbet
RORγt
AhR Bcl6
Foxp3
PU.1
IRF4
TGF-β
IL-4
TGF-β
IL-6
IL-21
Naive T cell
IL-6
TNF-α
TGF-β
IL-6
IL-21
IL-12
IL-4
523905-L-bw-Roeleveld
Processed on: 13-9-2018 PDF page: 10
CHAPTER 1
10
showed increased serum levels of Th17 cells itself, as well as of its cytokines 
IL-17 and IL-22 [11]. 
The role of IL-17 in RA has been studied extensively. Expression levels of this 
cytokine were significantly elevated in RA synovium [12,13], and CD4+IL-17+ 
(Th17) cell numbers were increased in peripheral blood mononuclear cells of 
patients with RA compared with healthy controls. Interestingly, those Th17 cell 
numbers correlated with the number of swollen joints and C-reactive protein 
levels of RA patients. Concentrations of IL-17 in peripheral blood mononuclear 
cell (PBMC) supernatants from RA patients were also significantly higher 
compared with healthy controls [14]. The cytokine is involved in different 
processes of arthritis development, for instance by increasing the production 
of pro-inflammatory cytokines (e.g. IL-1β, IL-6, TNF-α), chemokines (e.g. CCL2, 
CCL7, CXCL8), and matrix-degrading enzymes (e.g. MMP-1, -2, -9, -13) in a 
range of cell types [15]. By the increased production of chemokines like CCL2 
and CCL7, IL-17 promotes the rapid recruitment of monocytes and neutrophils 
[16]. During the process of bone destruction, IL-17 stimulates RANK ligand 
(RANKL) expression by osteoblasts and synovial fibroblasts, thereby promoting 
osteoclastogenesis [17] (Figure 3). In contrast, Th1 and Th2 key cytokines 
IFN-γ and IL-4 inhibit osteoclastogenesis [13,17]. The role of IL-17 during RA is 
elaborately reviewed in chapter 4 of this thesis. 
Two other cytokines produced by Th17 cells, IL-21 and IL-22, also promote 
bone erosion during RA [18,19]. Elevated expression of IL-21 was detected 
in synovium, synovial fluid and serum from RA patients compared to healthy 
controls. IL-21 is indicated to promote osteoclastogenesis in RA and contribute 
to bone destruction in inflamed joints by enhancing expression of RANKL 
[19]. But IL-21 is not only involved in promoting osteoclastogenesis during 
RA, it is involved in other pathways as well. For example, the cytokine can 
enhance the proliferative response of naïve mouse T cells upon T cell receptor 
(TCR) stimulation, suggesting that IL-21 contributes to the initial expansion 
of pathogenic T cell populations [20]. In addition, IL-21 is able to induce the 
recruitment of both neutrophil and monocyte cell populations [21], and is 
known to counteract the effects of regulatory T cells (Tregs) by decreasing 
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the sensitivity of Th17 cells for suppression by those cells [22]. IL-21 receptor 
deficient (IL-21R-/-) mice are completely resistant to the development of 
spontaneous arthritis [23], which is partly due to the sensitivity of their Th17 
cells for suppression by Tregs. Administration of a potent neutralizing agent to 
IL-21 in two distinct animal RA models resulted in amelioration or reversal of 
the RA phenotype, which was correlated with enhanced IFN-γ production and 
suppressed IL-6 serum levels [20].
Figure 3.  Regulation of osteoclastogenesis by Th17 cells in RA synovial tissue. Expression of 
RANKL by osteoblasts or synovial fibroblasts is stimulated by IL-17 and other pro-inflammatory 
cytokines. RANK-mediated signaling is upregulated, promoting osteoclastogenesis. Secretion of 
IFN-γ and IL-4 by respectively Th1 and Th2 cell subsets inhibits osteoclastogenesis. Th, T helper 
cell; IL, interleukin; RANKL,  receptor activator of nuclear factor kappa B ligand; IFNγ, interferon γ.
Th17
IL-17
IL-21 IL-22
Th1
Th2
Osteoblast or
synovial broblast
Osteoclast
precursor cell
RANKL
Pro-
inammatory
Osteoclast
IFN-γ
IL-4
523905-L-bw-Roeleveld
Processed on: 13-9-2018 PDF page: 12
CHAPTER 1
12
In addition to IL-17 and IL-21, IL-22 has been linked to RA pathology as well. 
Levels of this cytokine were shown to be increased in serum of RA patients 
as compared to healthy controls [18,24,25], and in synovial fluid as compared 
to osteoarthritis (OA) patients [18]. Serum IL-22 levels positively correlated 
with various clinical disease parameters like disease activity score (DAS)28 
[25], rheumatoid factor (RF) serum levels [18,25], and anti-cyclic citrullinated 
peptide (CCP) antibodies [18]. Moreover, patients with high IL-22 serum 
levels suffered from more severe bone erosions [24,25], possibly resulting 
from increased RANKL expression on RA synovial fibroblasts (RASF) by IL-22. 
This subsequently promotes osteoclastogenesis and might account for the 
enhanced bone pathology by IL-22 [18,26]. In addition to increasing RANKL 
expression, IL-22 stimulates proliferation of RASF, and production of MCP-1 by 
those cells [27]. Remarkably, historic data on the role of IL-22 in murine models 
for rheumatoid arthritis describe both pro- and anti-inflammatory roles for this 
cytokine and appear to be contradictory [26,28-33], leaving the exact function 
of IL-22 in experimental arthritis unclear. The role of IL-22 in RA is further 
reviewed in chapter 4 of this thesis.
DIFFERENTIATION OF THE TH17 CELL SUBSET
The way Th17 cells are regulated has been a source of debate over the last 
years. The initial consensus was that, in contrast to Th17 differentiation in 
mice, human Th17 differentiation is not dependent on TGF-β signalling. It was 
suggested that TGF-β might act indirectly on Th17 differentiation rather than 
directly, favouring Th17 cell expansion by suppressing expression of the Th1 
transcription factor T-bet. Hereby the generation of Th1 cells is suppressed, 
while Th17 cells are less susceptible to the suppressive effects of TGF-β [34]. 
In addition, naïve human T cells were proposed to be able to differentiate 
into Th17 cells by stimulation with a combination of IL-1 and IL-6/IL-23, so 
independent of TGF-β, or even solely by IL-23 [35,36]. However, in those studies 
the endogenous source of TGF-β (e.g. serum and platelets) was not carefully 
controlled. Subsequently performed studies using serum-free medium and in 
which naïve T cells were carefully sorted resolved these issues, showing that 
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TGF-β was indispensable in human Th17 differentiation as well [37-39]. Thus, 
regulation of Th17 differentiation from naïve T cells appears to be quite similar 
in both humans and mice after all. 
Differentiation of Th17 cells is driven by the enhanced expression of the 
transcription factor orphan nuclear receptor γt (RORγt), induced by TGF-β and 
IL-6 or IL-21 acting in synergy [40,41]. TGF-β is produced by multiple lineages of 
leukocytes and stromal cells, but might also be secreted by Tregs. Additionally, 
Figure 4.  Regulation of Th17 cell differentiation. Th17 differentiation is stimulated by TGF-β 
in combination with IL-6 or IL-21, which enhances expression of RORγt. Binding of TGF-β to its 
receptor activates the Smad2 pathway, inducing both Foxp3 and RORγt expression. Additionally, 
activated Smad2 and Smad3 relieve SOCS3-mediated inhibition of STAT3, which is activated 
by IL-6 and IL-21  receptor binding. Thereby relieving Foxp3-mediated suppression of RORγt, 
enhancing RORγt expression and inducing Th17 differentiation. TGF-β, transforming growth 
factor β; IL, interleukin; SOCS3, suppressor of cytokine signalling 3; STAT3, signal transducer 
and activator of transcription 3; Foxp3, forkhead box p3; RORγt, retinoic acid-related orphan 
receptor-γ t; Th, T helper cell.
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Th17 cells can express high amounts of TGF-β themselves, the growth factor 
hereby acting in an autocrine manner to maintain Th17 cells [40,42,43]. 
IL-6 is secreted in high amounts by cells from the innate immune system, B 
cells and subsets of activated T cells, but also by resident cells in the joints 
like fibroblasts. Receptors for IL-6 (IL-6R) are expressed on naïve T cells and 
binding of its ligand activates signal transducer and activator of transcription 
3 (STAT3). This phosphorylation step is necessary but not sufficient to induce 
RORγt expression. TGF-β signalling activates the Smad2 pathway, leading to 
the expression of both Foxp3 (stimulating Treg differentiation) and RORγt 
(for Th17 induction) [44]. IL-6 and IL-21-induced expression of suppressor 
of cytokine signalling 3 (SOCS3) is inhibited upon TGF-β signalling through 
Smad2/3, leading to enhanced and prolonged activation of STAT3 in naïve T 
cells [44,45]. This STAT3 activation in the presence of IL-6 and TGF-β relieves 
Foxp3-mediated suppression of RORγt, thereby enhancing RORγt expression 
and facilitating the Th17 transcriptional program (Figure 4). 
The TGF-β and IL-6/IL-21 mediated Th17 cell differentiation is enhanced 
by TNF-α and IL-1β, important pro-inflammatory cytokines involved in RA 
pathogenesis [41]. Although naïve T cells do not express receptors for IL-1 and 
IL-23, they are induced after exposure to TGF-β and IL-6/IL-21 [39,46]. Hence, 
differentiating Th17 cells become responsive to these cytokines required for 
the maintenance of Th17 cells [43,47-50]. IL-23 synergizes with IL-6 enhancing 
differentiation, survival, and stabilization of Th17 cells [48,50,51]. Despite 
this support of IL-23 and IL-6, the Th17 cell-phenotype is still quite unstable. 
Various mixed Th17 cell phenotypes have been observed, likely determined by 
their inflammatory environment. Th17 cells might transform into Th1-like cells 
and start to produce IFN-γ and other inflammatory cytokines under chronic 
inflammatory conditions [52]. IFN-γ is able to up-regulate IL-12Rβ2 on Th17 
cells, enhancing their sensitivity to IL-12, resulting in a Th17/Th1 phenotype 
that stably co-expresses RORγt and T-bet [53].
Differentiation of Th17 cells can be inhibited by cytokines secreted by Th1 and 
Th2 T cell subsets: IFNγ and IL-4 [54]. In addition, the development of Tregs 
inhibits Th17 differentiation. Both Tregs and Th17 cells are regulated by TGF-β, 
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a balance between the two T cell subsets is crucial for immune homeostasis. In 
RA patients this balance is disturbed: patients with RA showed increased levels 
of Th17 cells, whereas their Treg numbers were decreased [54]. Furthermore, 
functional capability of Tregs in RA patients was limited [55]. A balance 
between Treg and Th17 levels seems crucial for immune homeostasis and a 
T cell imbalance might lead to the development of autoimmune disorders. 
This shows the importance of proper regulation of cytokines involved in T cell 
development, and thereby in maintaining homeostasis of the immune system. 
CLINICAL USE OF TH17-RELATED BIOLOGICALS IN RA
Proinflammatory cytokines contribute to autoimmunity, maintain chronic 
synovitis, and drive bone damage during RA pathogenesis. Therefore, it 
became a therapeutic priority to antagonize their effects by targeting specific 
cytokines or their receptors in RA patients [56]. The first clinically successful, 
cytokine-specific therapies for the treatment of RA were the anti-TNF-α agents. 
Currently, five different TNF-blockers are used to treat patients with RA, namely 
infliximab, etanercept, adalimumab, golimumab and certolizumab. In clinical 
trials TNF-blockers were shown to be safe as well as very efficient, comparable 
to methotrexate (MTX). However, the efficacy was greater when combining 
the two drugs [57]. The costs of TNF-blockers are over $13.000 USD per year, 
as compared to the costs of less than $130 USD for MTX treatment. Therefore, 
MTX is recommended to be part of the first treatment strategy of RA. In 
patients responding insufficiently to MTX, TNF-blockers can be added to the 
therapy [57]. Since the use of etanercept and infliximab, introduced in 1998 
and 1999 respectively, almost 2 million RA patients have been treated with 
anti-TNF-α agents. Although the use of TNF-α inhibitors was shown to be very 
efficient in RA treatment, approximately 30% of patients still fail to respond 
adequately [56]. Therefore, agents blocking other pathways of RA pathogenesis 
are required. It was observed that in patients not responding to treatment 
with TNF-α inhibitors during RA therapy, circulating Th17 cell numbers were 
significantly higher compared to patients responding to treatment [58,59]. 
Once more, this emphasizes the importance of Th17 cells and Th17-derived 
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cytokines in RA pathology, and these might therefore be potential additional 
therapeutic targets in RA.
Two monoclonal antibodies (mAbs) targeting IL-17, secukinumab and 
ixekizumab, have been developed and tested in clinical trials for their use in 
treating RA. Both agents induced small but clinically relevant responses in RA 
patients who failed to respond to synthetic and/or biologic disease modifying 
anti-rheumatic drugs (DMARDs) [60-65]. When treating RA patients with 
the anti-IL-17-receptor antibody brodalumab on the other hand, no clinical 
response was observed [66,67]. Reported safety profiles were similar to that 
of other biological agents. Preclinical research using SCID mice engrafted 
with human RA synovial tissue demonstrated that secukinumab shows the 
best therapeutic effects when targeting joint inflammation characterized 
by high CD3+ T cell numbers [68]. This indicates that further profiling of RA 
patients using local or systemic biomarkers will help to apply more effective 
personalized medicine. 
Furthermore, biologicals targeting different pathways have been shown to 
(indirectly) reduce IL-17 production in preclinical studies and in RA patients. 
Experiments using the JAK inhibitor tofacitinib treatment in SCID-HuRAg 
mice showed reduced synovial inflammation and invasion into the implanted 
cartilage [69]. Although inhibition of the JAK pathway by tofacitinib in other 
disease models has demonstrated enhancement of Th17 differentiation 
and even acceleration of experimental autoimmune encephalomyelitis 
(EAE) development [70,71], tofacitinib reduced Th17 development and 
inhibited inflammation and destruction of the joint during collagen-induced 
arthritis (CIA). In this model, tofacitinib reduced RA severity by decreasing 
phosphorylation of STAT3, thereby reducing expression of several cytokines 
such as the IL-6 family and subsequently reducing Th17 differentiation [72]. 
In a phase II double-blind study using tofacitinib in patients with active RA, 
disease activity was reduced as well, represented by a significant increase 
of the percentages of ACR20 responses compared to control groups [69]. 
Additionally, the B-cell targeting biological rituximab, which is successful in 
RA treatment, also reduces Th17 cell numbers and expression of RORγt and 
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IL-22 in synovial tissue, correlating with reduced inflammation and improved 
clinical outcome [73]. 
Agents inhibiting IL-12 and IL-23, the latter being an important mediator of 
Th17 responses, have been developed as well. IL-23 is a heterodimer consisting 
of a p19 and a p40 subunit, the latter also being an IL-12 subunit. IL-12 is an 
important mediator of Th1 responses, and consists besides the p40 subunit of 
a p35 subunit, which shares 40% homology with the IL-23 subunit p19 [56]. 
A study in RA patients assessing the safety and efficacy of the small molecule 
apilimod mesylate, which inhibits IL-12/IL-23, has shown that this inhibitor 
is unable to induce robust clinical improvement of the phenotype. ACR20 
response was reached in only 6% of patients on day 29 and in 25% of patients 
on day 57, similar to the percentage of responders in the control group [74]. In 
line with these results, no effects of ustekinumab, an anti-IL-23/23 p40 antibody, 
and guselkumab, an anti-IL-23 antibody, on RA severity where observed [75]. 
In contrast to the promising preclinical findings in animal models [76], 
targeting the IL-1 pathway has evoked only marginal clinical responses [77]. 
Although several agents targeting the IL-1 pathway have been developed 
including anakinra (recombinant IL-1 receptor antagonist), rilonacept (IL-1β 
inhibitor), canakinumab (anti-IL-1β antibody), AMG108 (fully human anti-IL1 
receptor mAb), soluble IL-1 receptor, and pralnacasan (synthetic caspase-1 
inhibitor), anakinra is currently the only agent approved by the Food and Drug 
Administration for the treatment of RA. Since only modest benefits of this drug 
were observed, its usefulness in RA treatment is limited [56,78].
Monoclonal antibodies targeting IL-6 were ineffective in clinical trials, 
causing the formation of immune complexes that prolong serum half-life 
of the cytokine [79]. In contrast, IL-6-mediated effects were more efficiently 
suppressed using antibodies targeting the IL-6 receptor. Tocilizumab is such 
an antibody, being administered to RA patients with inadequate responses 
to anti-TNF-α agents. Treatment with tocilizumab restores the disturbed 
Th17/Treg balance in patients with RA by suppressing Th17 development 
[80,81], significantly improving the disease phenotype [82]. In addition to 
the promising tocilizumab monotherapy, clinical tests using both MTX and 
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tocilizumab showed that this combination is very effective in achieving rapid 
and sustained improvements in the RA disease severity [83]. 
Since TGF-β is important in Th17 development and consequently in RA 
pathogenesis, it is an interesting growth factor to target in RA treatment. TGF-β 
is abundantly expressed in the human body where it is involved in several 
important growth processes and in maintaining homeostasis. Therefore, 
serious concerns have been expressed regarding the safety of TGF-β blocking 
in human patients. Until now, no studies have been reported testing the 
safety and efficacy of TGF-β inhibitors in patients with RA. However, the use 
of TGF-β blocking agents in other diseases has been tested in mice, monkeys 
and patients. Surprisingly, those inhibitors were well tolerated in most cases, 
suggesting that TGF-β inhibitors might be safe and applicable in RA treatment 
as well [84-86]. 
OUTLINE OF THIS THESIS
Despite the development of numerous biological agents targeting a whole 
array of biological pathways involved in the development and progression 
of rheumatoid arthritis, approximately 30% of patients still fail to respond 
adequately to currently available treatment. Hence, the identification of 
new therapeutic targets remains a high priority. Interestingly, in patients not 
responding to treatment with the potent TNFα-inhibitors during RA therapy, 
numbers of circulating Th17 cells were significantly higher as compared 
to responding patients, suggesting Th17 cells might be interesting new 
therapeutic targets. In this thesis we describe the potency of targeting various 
candidates of the Th17 pathway in the treatment of rheumatoid arthritis.
In Chapter 1 the pathogenicity of Th17 cells and its effector cytokines in 
Rheumatoid Arthritis was reviewed. This thesis continues by focusing on 
cytokines driving differentiation of Th17 cells (Chapter 2 & 3). Firstly, we 
investigated the dual role in experimental arthritis of one of the key drivers 
of Th17 development, IL-21 (Chapter 2). To this end, we induced antigen-
induced arthritis (AIA) or chronic streptococcal cell wall (SCW) arthritis in IL-
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21 receptor-deficient (IL-21R-/-) mice. IL-21 deficiency protected against severe 
inflammation and joint destruction during AIA and chronic SCW arthritis. In 
line with arthritis development, IL-17 levels during AIA were reduced, and 
synovial lymphocytes isolated during SCW arthritis showed mainly reduced IL-
17+IFNγ+ T cells in the absence of IL-21. Interestingly, during the acute phases 
of SCW arthritis, joint swelling scores were significantly increased in IL-21R-/- 
as compared to wild type (WT) mice. This is presumably caused by reduced 
expression of the anti-inflammatory suppressor of cytokine signaling 1 (SOCS-
1) and SOCS-3, and clearly displays the dual role of IL-21 during experimental 
arthritis. Subsequently, we investigated the therapeutic potency of combined 
inhibition of IL-21, and the other Th17-inducing factor IL-6, in reducing the 
development of Th17 cells and experimental arthritis (Chapter 3). In vitro and 
in vivo Th17 differentiation was reduced more potently when both IL-6 and 
IL-21 pathways were inactive. Concordantly, development of AIA and collagen-
induced arthritis (CIA) were strongly reduced in IL-6-/- x IL-21R-/- mice, or DBA-1 
mice treated with a soluble IL-21 receptor and anti-IL-6 receptor antibodies 
respectively.
In the second part of this thesis (Chapter 4-7), the focus was shifted to the Th17 
effector cytokines IL-17 and IL-22. In Chapter 4, the roles of both IL-17 and IL-22 
in the pathogenesis of rheumatoid arthritis, as well as recent developments 
in cytokine immunotherapy are reviewed. As to date the role of IL-22 in RA 
development remains unclear and published data appears contradictory, we 
aimed to further clarify the role and mechanism of IL-22 during the development 
of experimental arthritis. Firstly, we focused on cytokine interactions of IL-22 
within the inflammatory environment (Chapter 5). Adenoviral overexpression 
of IL-22 neither induced joint pathology in naïve mice, nor did it affect IL-17-, 
IL-1β-, or TNFα-induced joint inflammation. In addition, excessive IL-22 did not 
aggravate or alleviate disease severity during SCW and K/BxN serum transfer 
arthritis, indicating this cytokine does not play a role in innate immune-driven 
experimental arthritis. Hence, we subsequently studied the role of IL-22 in a 
chronic arthritis model depending on the adaptive immune system. Using IL-
1Ra-/- mice that spontaneously develop arthritis, a highly potent protection from 
arthritis development was detected in mice also deficient for IL-22, displaying 
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a clear pro-inflammatory phenotype for the cytokine in this disease model. 
No additional effect on arthritis progression was observed upon anti-IL-17 
treatment in arthritic IL-1Ra-/- x IL-22-/- mice. Most interestingly, we detected 
highly reduced anti-hnRNP autoantibodies in IL-1Ra-/- mice also deficient for IL-
22. As our IL-22-knockout approach during adaptive immune-driven arthritis 
showed reduced arthritis indicating a pro-inflammatory role for this cytokine, 
we subsequently aimed to determine whether we could induce the opposite, 
disease-aggravating effect while overexpressing IL-22 during CIA (Chapter 6). 
As expected, when injecting the well-validated IL-22 adenovirus intra-articularly 
(i.a.), an aggravation of local disease severity was observed, confirming the pro-
inflammatory role of IL-22. When injecting the virus systemically on the other 
hand, mice were potently protected from arthritis development, indicating an 
anti-inflammatory role for IL-22. As with IL-21, we hypothesize this protection 
is mediated via a systemic, SOCS3-dependent pathway, as splenic mRNA 
expression of this anti-inflammatory mediator is significantly reduced in mice 
systemically overexpressing IL-22. Finally, we investigated whether IL-22 would 
be a suitable new target in RA treatment, by treating mice with CIA with IL-22-
neutralizing antibodies (Chapter 7). In addition, we tested the feasibility of 
SPECT/CT imaging with 111In-labeled anti-FAP antibody (28H1) in monitoring 
these therapeutic effects, and compared the imaging data with conventional 
disease readouts like macroscopic scoring and histological analysis. While a 
clear protective effect of IL-22 neutralization before CIA onset was observed 
on disease development, neutralizing the cytokine during later phases of CIA 
could not prevent progression of joint pathology. SPECT/CT imaging with 
111In-28H1 was a great tool to specifically monitor therapy responses, and is 
potentially more sensitive in disease monitoring as compared to the gold 
standard method of macroscopic arthritis scoring. 
In the final chapter of this thesis we summarize and discuss all described data, 
and provide directions for future studies on the intriguing world of the Th17 
cells and cytokines as therapeutic targets in rheumatoid arthritis (Chapter 8).
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ABSTRACT
Objective. The cytokine interleukin-21 (IL-21) can have both proinflammatory 
and immunosuppressive effects. The purpose of this study was to investigate 
the potential dual role of IL-21 in experimental arthritis in relation to Th17 cells. 
Methods. Antigen-induced arthritis (AIA) and chronic streptococcal cell wall 
(SCW) arthritis were induced in IL-21 receptor–deficient (IL-21R-/-) and wild-
type mice. Knee joints, synovial tissue, and serum were analyzed for arthritis 
pathology and inflammatory markers. 
Results. During AIA and chronic SCW arthritis, IL-21R deficiency protected 
against severe inflammation and joint destruction. This was accompanied by 
suppressed serum IgG1 levels and antigen-specific T cell responses. Levels 
of IL-17 were reduced during AIA, and synovial lymphocytes isolated during 
SCW arthritis for flow cytometry demonstrated that mainly IL-17+ interferon-γ 
(IFNγ)–positive T cells were reduced in IL-21R-/- mice. However, during the 
acute phases of SCW arthritis, significantly higher joint swelling scores were 
observed, consistent with enhanced tumor necrosis factor and IL-6 expression. 
Interestingly, IL-21R-/- mice were significantly less capable of up-regulating 
suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 messenger RNA. IL-21 
stimulation also affected the Toll-like receptor 2 (TLR-2)/caspase recruitment 
domain 15 response to SCW fragments in vitro, indicating that impaired SOCS 
regulation in the absence of IL-21 signaling might contribute to the increased 
local activation during SCW arthritis. 
Conclusion. In contrast to the proinflammatory role of IL-21 in adaptive 
immunity, which drives IL-17+IFN+ cells and joint pathology during chronic 
experimental arthritis, IL-21 also has an important immunosuppressive role, 
presumably by inhibiting TLR signaling via SOCS-1 and SOCS-3. If this dual 
role of IL-21 in various immune processes is present in human disease, it could 
make IL-21 a difficult therapeutic target in rheumatoid arthritis.
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DUAL ROLE OF IL-21 IN EXPERIMENTAL ARTHRITIS
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune disease of unknown 
etiology, characterized by chronic joint inflammation and destruction of 
articular cartilage and bone. Hyperplasia of the synovial lining and influx of 
proinflammatory cells leads to thickening of the synovium, and production 
of soluble mediators like cytokines, enzymes, and oxygen radicals by both 
resident and infiltrating cells contributes to the final destruction of the joint 
matrix. 
Tumor necrosis factor α (TNFα) and interleukin-1 (IL-1) are the most extensively 
studied cytokines in the arthritis process, and biologic treatments neutralizing 
TNFα have shown good clinical effects in many RA patients. However, for RA 
patients who do not respond well to current available therapies, the search 
for new therapeutic strategies continues. Since nonresponders to anti-TNF 
treatment show an increased percentage of Th17 cells in the circulation [1], 
additional new therapies targeting the Th17 cell pathway might provide good 
candidates. Previous studies of the potential of the major Th17 cell cytokine 
IL-17 in various mouse models demonstrated arthritis suppression by anti–
IL-17 treatment, especially when IL-17 blocking was combined with anti-TNF 
treatment in protecting against cartilage damage [2], or when human RA 
synovial tissue was confirmed to be rich in CD3+ T cells before treatment in 
the RA synovium SCID mouse model [3]. 
Another Th17 cell–derived candidate is IL-21, a pleiotropic cytokine that binds 
to the IL-21 receptor (IL-21R), consisting of the common cytokine receptor γ 
chain and the specific IL-21R subunit [4]. IL-21 is not produced solely by Th17 
cells, but is also produced by follicular helper T (Tfh) cells and natural killer (NK) 
T cells. The IL-21 receptor is expressed on a variety of hematopoietic immune 
cells, including T and B cells, dendritic cells (DCs), and NK cells, as well as on 
tissue cells including endothelial cells and fibroblasts. IL-21 acts on B cells 
and plays an important role in normal Ig production and B cell differentiation 
into plasma cells [5–7]. In addition, IL-21 contributes to antibody production 
indirectly via its effect on Tfh cell generation and germinal center formation 
[8]. More interestingly, IL-21 also acts as an autocrine cytokine of activated 
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T cells, since it induces Th17 cell differentiation of both human and murine 
naive CD4+ T cells in the presence of transforming growth factor β [9–11]. In 
vivo studies also demonstrated that Th17 cell differentiation and responses are 
disturbed in the absence of IL-21 or its receptor [9,10,12]. 
Increased levels of IL-21 are found in serum and synovial fluid of RA patients 
compared to osteoarthritis patients and healthy controls [1,13], suggesting 
a role for IL-21 in the pathogenesis of RA. Enhanced IL-21R expression was 
found in RA synovial fibroblasts and macrophages, although regulation of IL-
21R could not be induced by the most common proinflammatory cytokines, 
IL-1 and TNF [14]. IL-21 on T cells induces the secretion of proinflammatory 
cytokines like TNFα and interferon-γ (IFNγ) and enhances the expression of 
RANKL [13,15]. Synovial fibroblasts show increased expression of various 
matrix metalloproteinases as well as RANKL upon IL-21 stimulation [13]. 
The involvement of IL-21 in autoimmune disease was previously shown in 
various disease models. IL-21 deficiency protected against experimental 
autoimmune encephalomyelitis [9], and blocking IL-21 in MRL/lpr mice 
reduced signs of experimental systemic lupus erythematosus [12]. Neutralizing 
IL-21 in experimental arthritis already showed a role for IL-21 in rat adjuvant-
induced arthritis and murine collagen-induced arthritis (CIA), with reduced 
clinical signs of disease and improved histologic scores [16]. However, the link 
between IL-21 and Th17 cells was not made in these studies. The objective of 
this study was to investigate the effect of IL-21R deficiency on joint pathology 
in relation to Th17 cells during chronic experimental arthritis.
MATERIALS AND METHODS
Animals. IL-21R–deficient mice were provided by Pfizer. C57BL/6J mice as wild-
type (WT) controls were obtained from Elevage Janvier. All mice were housed 
in filter-top cages under specific pathogen–free conditions, and a standard 
diet and water were provided ad libitum. The mice were used between ages 
10 and 12 weeks. All animal procedures were approved by the institutional 
ethics committee.
523905-L-bw-Roeleveld
Processed on: 13-9-2018 PDF page: 33
2
33
DUAL ROLE OF IL-21 IN EXPERIMENTAL ARTHRITIS
Materials. Methylated bovine serum albumin (mBSA) was purchased from 
Sigma-Aldrich. RPMI 1640 medium, TRIzol reagent, oligo(dT) primers, and 
Moloney murine leukemia virus (MMLV) reverse transcriptase (RT) were 
obtained from Life Technologies. Primers were purchased from Biolegio. SYBR 
Green Master Mix was purchased from Applied Biosystems. Cytokine kits for 
the Luminex multianalyte system (Milliplex) were obtained from Millipore.
Induction of antigen-induced arthritis (AIA). Mice were immunized with 
100 µg of mBSA emulsified in 100 µl Freund’s complete adjuvant (CFA; Difco). 
Injections were divided over both flanks. Heat-killed Bordetella pertussis 
(RIVM) was administered intraperitoneally as an additional adjuvant. Two 
subcutaneous booster injections with a total of 50 µg mBSA in CFA were given 
in the neck region 1 week after the initial immunization. Three weeks after 
these injections, primary AIA was induced by injecting 60 µg of mBSA in 6 µl 
phosphate buffered saline (PBS) into the right knee joint, resulting in chronic 
arthritis.
Preparation of streptococcal cell wall (SCW) fragments and induction 
of SCW arthritis. Streptococcus pyogenes T12 organisms were cultured 
overnight in Todd-Hewitt broth. Cell wall fragments were prepared as 
described previously [17]. The supernatant resulting from centrifugation at 
10,000g was used throughout the experiments. These preparations contained 
11% muramic acid. Unilateral arthritis was induced by intraarticular injection 
of 25 µg of SCW fragments (rhamnose content) in 6 µl pyrogen-free saline into 
the right knee joints of naive mice.
Measurement of 99mTc uptake. Joint inflammation was measured by 99mTc-
pertechnetate uptake in the knee joint. Mice were sedated with chloral hydrate 
and injected intraperitoneally with 20 µCi of 99mTc. Thirty minutes afterward, 
γ-particle radiation was assessed by use of a collimated sodium iodide 
scintillation crystal with the knee in a fixed position. Arthritis was scored as the 
ratio of the 99mTc uptake in the arthritic right knee joint to that in the control left 
knee joint. Right:left knee joint 99mTc uptake ratios >1.1 were taken to indicate 
inflammation of the right knee joint.
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Histology. For standard histology of the knee joints, tissue was fixed for 4 days 
in 10% formalin, decalcified in 5% formic acid, and subsequently dehydrated 
and embedded in paraffin. Standard frontal sections of 7 µm were mounted 
on SuperFrost slides (Menzel-Gläser). Hematoxylin and eosin staining was 
performed to study joint inflammation. The severity of inflammation in the 
knee joints was scored as the amount of infiltrating cells on a scale of 0–3 
(0 = no cells, 1 = mild cellularity, 2 = moderate cellularity, and 3 = maximal 
cellularity). To study proteoglycan (PG) depletion from the cartilage matrix, 
sections were stained with Safranin O followed by counterstaining with fast 
green. PG depletion was determined using an arbitrary scale of 0–3, ranging 
from normal, fully stained cartilage to destained cartilage completely depleted 
of PGs. The degree of chondrocyte death was scored on a scale of 0–3, ranging 
from no empty lacunae to complete loss of chondrocytes in the cartilage layer. 
Histopathologic changes in the knee joints were scored in the patella and 
femur/tibia regions on 5 semiserial sections of the joint spaced 70 µm apart. 
Scoring was performed in a blinded manner by 2 independent observers (RJM, 
MIK).
Measurement of anti-mBSA and anti-SCW antibodies. Levels of anti-mBSA 
or anti-SCW antibodies in sera of arthritic mice were analyzed by enzyme-linked 
immunosorbent assay. Briefly, 10 ng of mBSA or SCW fragments were coated 
onto 96-well plates overnight. Plates were washed, and nonspecific binding 
sites were blocked with 1% BSA in PBS–Tween (0.05%). Serial 2x dilutions 
of sera, starting with an initial dilution of 20x, were incubated in the plates 
for 1 hour. The plates were then washed, and isotype-specific horseradish 
peroxidase–labeled goat anti-mouse Ig (1:1,000 dilution) was added for 1 hour 
at room temperature; 5-aminosalicylic acid was used as substrate. Absorbance 
was measured at 450 nm.
Lymphocyte stimulation test. Spleens were isolated and disrupted, and 
erythrocytes were lysed in 0.16M NH4Cl (pH 7.2). The cell suspension was 
washed with saline and enriched for lymphocytes by allowing antigen-
presenting cells to adhere to plastic culture flasks for 45 minutes. Cells (2 x 
105/well) were cultured for 72 hours at 37°C in an atmosphere of 5% CO2, in 
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RPMI 1640 (Gibco Invitrogen) supplemented with 5% fetal calf serum (FCS), 1 
mM pyruvate, and 50 mg/liter of gentamicin in the presence of 2-fold serial 
dilutions of antigen (mBSA or SCW fragments). For the last 16 hours, the cells 
were labeled with 0.25 µCi 3H-thymidine. After harvesting, incorporation of 
3H-thymidine was measured and the increase in counts per minute caused by 
stimulation with specific antigen was determined.
Synovial washouts. To determine levels of several cytokines and chemokines 
in patellae washouts, patellae with surrounding soft tissue consisting of the 
tendon and synovium were dissected in a standardized manner. Patellae were 
cultured in RPMI 1640 medium containing 0.1% BSA (200 µl/patella) for 1 hour 
at room temperature. Afterward, supernatant was harvested and centrifuged 
for 5 minutes at 1,000g. Cytokine levels were determined using the Luminex 
multianalyte technology.
Luminex analysis. To determine levels of the cytokines and chemokines 
in serum samples and synovial washouts, we used Luminex multianalyte 
technology in combination with multiplex cytokine kits (Milliplex; Millipore). 
Cytokines were measured in 25 µl of synovial washout or in serum diluted 1:3 
in assay buffer. The sensitivity of the multiplex kit was <1 pg/ml.
Isolation of synovial cells. The protocol was kindly provided by Prof. Shimon 
Sakaguchi (Osaka University, Osaka, Japan) and adjusted. After mice were 
killed, the joint synovium was dissected. Briefly, synovial biopsy samples were 
incubated with enzymatic digestion buffers (Liberase; Roche) for 30 minutes 
at 37°C. Next, a 70-µm nylon cell strainer (BD Falcon) was used to process the 
digested tissue. The cell preparation was collected in RPMI with 10% FCS. To 
isolate the single mononuclear cells, Lympholyte-M (Cedarlane) was used 
according to the manufacturer’s protocol. Subsequently, the isolated cells 
were prepared for intracellular flow cytometry.
Intracellular flow cytometry. Cells were stimulated for 4–6 hours with 
phorbol myristate acetate (50 ng/ml; Sigma- Aldrich), ionomycin (1 µg/ml; 
Sigma-Aldrich), and GolgiPlug (1 µl/ml; BD Biosciences). Next, for intracellular 
detection of IFNγ and IL-17, cells were washed, fixed, and permeabilized 
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according to the manufacturer’s protocol (eBioscience) and incubated with 
anti-IFNγ (BD Biosciences) and anti–IL-17 (BD Biosciences) antibodies.
RNA isolation and RT reaction. Mice were killed by cervical dislocation, 
immediately followed by dissection of the patella with adjacent synovium. 
Two biopsy samples with a diameter of 3 mm (1 from the lateral side and 1 
from the medial side of the synovial tissue) were punched out using a biopsy 
punch (Stiefel). The synovium samples were immediately frozen in liquid 
nitrogen. Total RNA was extracted in 1 ml TRIzol reagent. Afterward, RNA was 
precipitated with isopropanol, washed with 70% ethanol, and redissolved in 
water. Isolated RNA was treated with DNase before being reverse-transcribed 
into complementary DNA using oligo(dT) primers and MMLV RT.
Quantitative polymerase chain reaction (PCR). Quantitative real-time 
PCR was performed using the ABI/Prism 7000 Sequence Detection System 
for quantification with SYBR Green and melting curve analysis (Applied 
Biosystems). PCR conditions were as follows: 2 minutes at 50°C and 10 minutes 
at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C, 
with data collection in the last 30 seconds. For all PCRs, SYBR Green Master 
Mix was used in the reaction. Primer concentrations were 300 nmoles/liter. 
All PCRs were performed in a total volume of 25 µl. Relative quantification of 
the PCR signals was performed by comparing the cycle threshold (Ct) value, 
in duplicate, of the gene of interest for each sample with the Ct values of the 
reference gene GAPDH.
Statistical analysis. Differences between experimental groups were tested 
using the Mann-Whitney U test or Kruskal- Wallis test, unless stated otherwise. 
P values less than 0.05 were considered significant. Results are expressed as 
the mean ± SEM unless stated otherwise.
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RESULTS
IL-21R deficiency protects against severe inflammation and bone 
destruction during AIA 
The role of IL-21 in experimental arthritis was first studied in the mouse model of 
chronic AIA using IL-21R–deficient mice and their WT controls. Measurements 
of 99mTc after intraarticular injection with the antigen mBSA showed similar 
joint swelling in both groups in the first 2 days of arthritis. However, on day 4, 
a more rapid decline was observed in IL-21R–deficient mice compared to WT 
controls (Figure 1A). More importantly, histologic analysis on day 7 of arthritis 
demonstrated significantly reduced joint inflammation, cartilage destruction, 
and bone erosion in the absence of the IL-21 receptor (Figure 2). This reduced 
joint pathology in IL-21R-/- mice was accompanied by suppressed adaptive 
immune responses; specific subsets of anti-mBSA antibodies and also antigen-
specific lymphocyte proliferation were significantly decreased by IL-21R 
deficiency (Figures 1B and C). 
Interestingly, basal serum IgG1 and IgG2b levels were already reduced by IL-
21R deficiency (IgG1 was reduced from a mean ± SEM of 0.41 ± 0.06 mg/ml 
to 0.29 ± 0.07 mg/ml; IgG2b was reduced from 1.05 ± 0.21 mg/ml to 0.38 ± 
0.05 mg/ml), as has also been demonstrated by others [5]. However, during 
experimental arthritis, only the antigen-specific IgG1 anti-mBSA antibodies 
were reduced in the absence of IL-21 signaling, while total IgG and IgG2b 
were not affected (Figure 1B). In addition, the cytokines IL-6 and IL-17 and 
the chemokine CXCL1 were significantly reduced in synovial washouts from 
IL-21R-/- mice on day 7 of AIA (Figure 1D). These data indicate an important 
proinflammatory role for IL-21 in driving adaptive immunity and chronic 
destructive arthritis during murine AIA.
Enhanced local activation in IL-21R–deficient mice during SCW arthritis 
In addition to the AIA model, the role of IL-21/IL-21R signaling was investigated 
in SCW arthritis. In this model, a single injection of SCW fragments into the 
knee joint results in local acute inflammation, and subsequent repeated 
weekly injections turn this acute inflammation into a chronic destructive 
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arthritis. In contrast to our findings in the AIA model, IL-21R–deficient mice 
showed enhanced joint swelling at various time points during SCW arthritis, 
most significantly as soon as day 1 after arthritis induction (Figure 3A). This 
enhanced swelling was accompanied by significantly enhanced synovial TNF 
and IL-6 messenger RNA (mRNA) expression on day 1 and a trend toward higher 
IL-6 and CXCL1 levels in synovial washouts on day 22 (Figure 3B), indicating 
enhanced local activation in the absence of IL-21R. However, systemic cytokine 
levels at this time point did not show any difference between IL-21R-/- and WT 
mice. More remarkably, at the time that mice were killed (day 28), cytokine 
Figure 1. Interleukin-21 receptor (IL-21R) deficiency results in a decrease in arthritis with 
less destruction paired with reduced adaptive immune response. IL-21R deficiency during 
the induction of primary antigen-induced arthritis results in a more rapid decrease in joint 
swelling (ratio of 99mTc uptake in the arthritic right knee joint [R] to that in the control left knee 
joint [L]) (A; n = 6–8 mice per group). Serum levels of methylated bovine serum albumin (mBSA)–
specific IgG1 antibodies are decreased on day 7 in IL-21R-/- mice (B; n = 8 mice per group). 
Proliferation of mBSA-specific splenic lymphocytes is reduced in IL-21R-/- mice (C). Nonadherent 
spleen cells were stimulated with various concentrations of mBSA or 1 µg/ml concanavalin A 
(Con A) for 72 hours, followed by 18 hours of incubation with 0.25 µCi 3H-thymidine (n = 7 
mice per group). Results are shown as netto counts (cpm stimulation – cpm background). IL-21R 
deficiency reduces levels of IL-6, CXCL1 (keratinocyte chemoattractant), and IL-17 in synovial 
washouts from arthritic mice (D; n = 6 mice per group). Values are the mean ± SEM. * = P < 0.05; 
** = P < 0.01; *** = P < 0.001 by Student’s t-test. WT = wild-type; OD/50 = optical density at 50% 
transmittance; TNFα = tumor necrosis factor α; IFNγ = interferon-γ.
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levels in IL-21R-/- mice were significantly reduced compared to those in WT 
controls (Figure 3C), in contrast to the previous enhanced local activation.
Figure 2. Histopathologic effects of IL-21R deficiency during antigen-induced arthritis 
(AIA). Total knee joints were isolated for histopathologic analysis (n = 8 mice per group). IL-
21R deficiency during AIA results in suppressed joint inflammation, cartilage proteoglycan (PG) 
depletion, chondrocyte death, and bone erosion on day 28 (A). Values are the mean ± SEM. * = P 
< 0.05; ** = P = 0.01 by Student’s t-test.  Histologic sections show infiltrating cells (hematoxylin 
and eosin staining) (B) and cartilage PG depletion (Safranin O staining) (C) in frontal knee 
sections. Images are representative of 8 mice per group. Original magnification x 50. See Figure 
1 for other definitions.
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Figure 3. IL-21R deficiency in a streptococcal cell wall (SCW) arthritis model results in 
enhanced local activation. IL-21R deficiency during chronic SCW arthritis resulted in increased 
joint swelling (A). Joint swelling was measured by 99mTc uptake (n = 8–9 mice per group). IL-21R 
deficiency during chronic SCW arthritis enhanced synovial IL-6 and TNF mRNA expression (B; n 
= 4 mice per group) and did not significantly affect proinflammatory cytokine levels in synovial 
washouts from arthritic mice on day 22 (B; n = 6–8 mice per group). In contrast to findings on 
day 22, serum cytokine levels of IL-1β, IL-6, and IL-10 were reduced by day 28 (C; n = 6–8 mice 
per group). Values are the mean ± SEM. * = P < 0.05; *** = P < 0.001 by Student’s t-test. NS = not 
significant (see Figure 1 for other definitions).
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Reduced joint pathology and IL-17+IFNγ+ Th cells in IL-21R-/- mice during 
SCW arthritis
To study the absolute effect of IL-21R deficiency on joint pathology during this 
SCW arthritis model, knee joints were isolated on day 28 for histologic analysis. 
As shown in Figures 4A and B, the arthritic joints of IL-21R-/- mice showed a 
significant reduction in joint inflammation, in contrast to the enhanced joint 
swelling during the course of the arthritis. In addition, the protective effect 
of IL-21R deficiency against cartilage damage was also visible, as both PG 
depletion and chondrocyte death were clearly suppressed compared to that in 
WT controls (Figures 4A and C). Consistent with the results during AIA, antigen-
specific B and T cell responses were reduced in IL-21R-/- mice (Figures 5A and B). 
Figure 4. Histopathologic effects of IL-21R deficiency during the chronic phase of 
streptococcal cell wall (SCW) arthritis. Total knee joints were isolated for histopathologic 
analysis (n = 8 mice per group). IL-21R deficiency during chronic SCW arthritis suppresses the 
influx of infiltrating cells, cartilage proteoglycan (PG) depletion, and chondrocyte death on day 
28 (A). Values are the mean ± SEM. * = P < 0.05; ** = P < 0.01 by Student’s t- test. Histologic 
sections stained with hematoxylin and eosin show infiltrating cells (B) and chondrocyte death 
(C) in frontal knee sections. Images are representative of 8 mice per group. Original magnification 
x 50 in B; x 200 in C. See Figure 1 for other definitions.
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Figure 5. Decreased adaptive immune responses in IL-21R–deficient mice during chronic 
streptococcal cell wall (SCW) arthritis. Serum levels of SCW-specific IgG1 and IgG3 antibodies 
were decreased on day 28 in IL-21R-/- mice (A; n = 6–8 mice per group). Proliferation of SCW-
specific splenic lymphocytes was reduced in IL-21R-/- mice (B). Nonadherent spleen cells were 
stimulated with various concentrations of SCW fragments or 1 μg/ml Con A for 72 hours, 
followed by 18 hours of incubation with 0.25 μCi 3H-thymidine (n = 7–8 mice per group). 
Results are shown as netto counts (cpm stimulation – cpm background). Representative dot 
plots of isolated cells gated on CD4 (C) and bar graphs depicting counts from 6 mice per group 
(D) show that the percentage of IL-17+/IFNγ+ cells was decreased in IL-21R-/- mice, whereas the 
percentages of IL-17+/IFNγ- and IL- 17-IFNγ+ cells were not (n = 6 mice per group). Values are the 
mean ± SEM. * = P < 0.05 by Student’s t-test. See Figure 1 for other definitions.
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The reduced IL-17 levels during AIA in IL-21R-/- mice suggested that T cells and, 
in particular, Th17 cells might be affected by the absence of IL-21R signaling. 
Therefore, during the chronic SCW arthritis model we dissected synovial tissue 
of the arthritic knee joints and isolated the infiltrating cells for flow cytometric 
analysis. As demonstrated in Figure 5C, the percentages of CD4+ Th17 cells 
(IL-17+IFNγ–) and Th1 cells (IL-17–IFNγ+) were not changed in IL-21R-/- mice. 
However, double-positive IL-17+IFNγ+ (Th17/Th1) T cells were greatly reduced 
by IL-21R deficiency (Figures 5C and D), suggesting a potential role for IL-21 in 
driving these double-positive Th17/Th1 cells and mediating joint pathology. 
IL-21 induces suppressor of cytokine signaling (SOCS) expression and 
reduces the Toll-like receptor (TLR)/caspase recruitment domain (CARD) 
response to SCW fragments
To further investigate enhanced local activation during SCW arthritis in IL-21R-/- 
mice, we studied the expression of TLR-2 and CARD-15, which are crucial for the 
response to SCW fragments. Basal synovial levels of TLR-2 and CARD-15 mRNA 
expression were equal in IL-21R-/- and WT mice, and the up-regulation of these 
receptors 4 days after the injection of SCW fragments was also comparable (data 
not shown). Since triggering of TLR-2/CARD-15 not only results in induction 
of proinflammatory cytokines but also in negative feedback via SOCS, we 
also studied the regulation of SOCS expression. Quantitative PCR analysis of 
synovial tissue demonstrated that besides a nonsignificant reduction in the 
basal level of SOCS-1, IL-21R-/- mice had clearly impaired up-regulation of 
SOCS-1 and SOCS-3 during arthritis (Figure 6A). The decreased expression of 
SOCS-3 protein on day 4 was confirmed by immunohistochemical staining of 
sections of knee joints from IL-21R-/- mice (Figure 6B).
This IL-21–dependent up-regulation of SOCS-1 and SOCS-3 was confirmed in 
subsequent in vitro experiments in which we cultured splenocytes from IL-21R-/- 
and WT mice with or without recombinant IL-21 for 24 hours. As demonstrated 
in Figure 6C, cells from IL-21R-/- mice again showed a nonsignificant reduction 
in basal levels of SOCS-1 and SOCS-3. Furthermore, cells from WT mice had 
enhanced SOCS-1 and SOCS-3 mRNA levels upon IL-21 stimulation, whereas 
cells from IL-21R-/- mice did not respond. Interestingly, cells stimulated with 
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SCW fragments after pre-exposure to IL-21 produced less IL-6 and CXCL1 than 
did cells not exposed to IL-21 (Figure 6D), suggesting that IL-21–mediated 
SOCS up-regulation can functionally inhibit responses to TLR-2/CARD-15 
triggering. This suggests that lack of SOCS up-regulation in the absence of 
IL-21 signaling may contribute to enhanced local activation in IL-21R-/- mice 
during SCW arthritis.
Figure 6. IL-21R–deficient mice show impaired up-regulation of suppressor of cytokine 
signaling 1 (SOCS-1) and SOCS-3 during arthritis. IL-21R deficiency results in suppressed 
up-regulation of SOCS-1 and SOCS-3 during streptococcal cell wall (SCW) arthritis on day 4 (A; 
n = 6 mice per group). Shown are representative histologic sections of immunohistochemical 
staining of SOCS-3 on day 4 (B). For each mouse strain, original magnification x 50 in left panels; 
x 200 in right panels. Stimulation of spleen cells from WT mice with IL-21 up-regulates SOCS-1 
and SOCS-3 (C; n = 6 mice per group). In spleen cells from WT mice, increases in IL-6 and CXCL1 
(keratinocyte chemoattractant [KC]) levels are suppressed after 2 hours of exposure to IL-21 
followed by 24 hours of stimulation with SCW (n = 6 mice per group), while spleen cells from IL-
21R– deficient mice fail to show this response (D). Values are the mean ± SEM. * = P < 0.05; *** = 
P < 0.001 by Student’s t-test. NS = not significant (see Figure 1 for other definitions).
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DISCUSSION
In the present study, we demonstrated that IL-21R deficiency during AIA 
causes clearly reduced inflammation and PG depletion as well as protection 
against severe destruction of cartilage and bone. However, IL-21R-/- mice 
show enhanced local activation early after the induction of SCW arthritis, 
accompanied by impaired up-regulation of SOCS-1 and SOCS-3. Therefore, this 
is the first study to describe a dual role of IL-21 in experimental arthritis, on 
the one hand driving adaptive immunity via proinflammatory IFNγ+IL-17+ Th 
cells, while on the other hand suppressing TLR responses with a potential role 
for inhibitory SOCS signaling. 
CD4+ T cells play an important role in the arthritis process. Where genetic 
studies revealed an important contribution of genes related to T cell activation, 
such as the HLA–DR4 allele, PTPN22, and CTLA-4 [18], clinical evidence of the T 
cell contribution was obtained by the successful treatment of RA patients with 
CTLA-4Ig (abatacept) [19]. A new subset of T cells, the Th17 cell, has recently 
emerged as a major pathogenic T cell involved in RA pathogenesis. While 
the role of IL-17, the main cytokine produced by Th17 cells, has already been 
studied extensively in experimental arthritis (for review, see ref. 20) and other 
autoimmune and inflammation models (for review, see ref. 21), the role of the 
other Th17 cell cytokines IL-21 and IL-22 remains to be further elucidated.
To investigate the role of IL-21 in experimental arthritis, we used IL-21R-/- mice 
during AIA. In this chronic destructive arthritis model, IL-17 was previously 
demonstrated to be expressed in the synovial tissue [22], and recombination-
activating gene 1–deficient and CD4-deficient mice showed clear protection 
from arthritis pathology [23]. In our current study, joint swelling and histologic 
inflammation during AIA were significantly reduced in IL-21R-/- mice. In addition, 
lack of IL-21R expression protected against PG depletion and chondrocyte 
death as parameters of cartilage destruction, and bone erosions were also less 
prominent in IL-21R-/- mice, indicating a clear proinflammatory role for IL-21 
in arthritis. This was consistent with previous studies of IL-21 blocking in CIA 
[16] and with the observation that IL-21R deficiency completely blocks arthritis 
development in K/BxN mice [24].
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IL-21 has a broad spectrum of responsive cell types, including cells from 
the innate as well as the adaptive immune system [4]. The role of IL-21 in B 
cell responses has been intensively investigated [5–7], and in our study, we 
confirmed that IL-21 is an important player in antigenspecific antibody 
responses. IL-21R deficiency resulted in significant inhibition of Th2 cell–related 
IgG1 and Th1 cell–related IgG3 antibody levels in the serum of arthritic mice. 
Since the SCW-specific IgG2b subclass was not affected by IL-21R deficiency, 
and our study and those of others showed a general suppression of IgG1 and 
IgG2b basal levels in IL-21R-/- mice [5], we conclude that the suppressed IgG1 
levels are not merely due to a generic difference between WT and knockout 
mice, but that this reduced antibody response is a specific IL-21–dependent 
effect. While antigen-specific T cell responses were highly suppressed in 
the absence of IL-21 signaling, an inhibitory effect on T cell cytokines in the 
arthritic joint could only be found for IL-17 levels in synovial washouts, while 
no differences were observed for the Th1 cell cytokine IFNγ. 
We attempted to confirm our findings of IL-21 as a proinflammatory cytokine 
in experimental arthritis by inducing chronic SCW arthritis in IL-21R-/- mice. 
By local intraarticular injection of TLR-2/CARD-15 ligands (25), this acute 
macrophage-driven arthritis becomes T cell dependent after repeated weekly 
exposure to the antigen [26]. Consistent with our findings in the AIA model, 
IL-21R deficiency during SCW arthritis resulted in reduced antigen-specific T 
and B cell responses. To study the effect of IL-21 on Th cells in closer detail, 
flow cytometry was performed on lymphocytes isolated from synovial tissue. 
This analysis showed comparable percentages of CD4+IL-17+ Th17 cells in IL-
21R-/- mice and WT controls, but it also showed a remarkable effect of IL-21R 
deficiency on CD4+ T cells that produce both IFNγ and IL-17. 
From this additional arthritis model we might conclude that IL-21R deficiency 
indeed suppresses adaptive immunity and, in particular, double-positive Th1/
Th17 cells, although the protective effects on histologic scores of inflammation 
and destruction were less pronounced than in the chronic AIA model. However, 
it is of great interest that throughout the SCW arthritis model, continuously 
enhanced joint swelling was observed in the IL-21R-/- mice as compared to 
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the WT controls. Also, in the synovial washouts from the arthritic joint, no 
suppression of cytokines and chemokines could be found, as was previously 
reported for the AIA model. On the contrary, enhanced local activation was 
observed with significantly elevated IL-6 and TNF mRNA on day 1 and a trend 
toward increased levels of IL-6 and CXCL1 on day 22. The aggravated response 
to SCW fragments in IL-21R-/- mice could not be explained by a difference 
in expression levels of TLR-2 and CARD-15, the receptors responsible for a 
reaction to the SCW fragments [25], since equal mRNA levels were found in 
synovial biopsy samples of both mouse strains. Since IL-21R deficiency does 
not interfere with K/BxN serum–induced arthritis [24], acting through immune 
complexes, Fcγ receptors, and complement activation, the aggravated 
response of IL-21R-/- mice to SCW fragments cannot be generalized to all innate 
immune responses.
In vitro stimulation assays showed that IL-21 can induce SOCS expression. 
These suppressor of cytokine signaling proteins act as negative regulators and 
inhibit cytokine pathways as well as TLR signaling [27]. In our IL-21R-/- mice, 
the basal expression level of SOCS-1 was already slightly reduced compared to 
those in WT controls; remarkably, however, IL-21/IL-21R signaling seems to be 
essential for SOCS up-regulation during experimental arthritis. While control 
mice demonstrated a massive increase in SOCS expression, the upregulation 
of SOCS-1 and SOCS-3 was clearly impaired in IL-21R-/- mice. We assume that in 
vivo, soon after the injection of SCW fragments, infiltrating lymphocytes (e.g., 
γ/δ T cells and NK T cells) contribute to increased IL-21 levels, as ~40 pg/ml of IL-
21 could be detected in synovial washouts on day 1 of SCW arthritis (data not 
shown). In addition to the in vivo SOCS differences, in vitro responses to SCW 
fragments were significantly suppressed in the presence of IL-21, suggesting 
that IL-21–induced SOCS expression affects this innate TLR response. IL-
21–driven SOCS-dependent inhibition of lipopolysaccharide signaling was 
previously described for monocyte-derived DCs in vitro [28], and our findings 
suggest that this mechanism might well account for the enhanced joint 
swelling and proinflammatory cytokine expression in IL-21R-/- mice during 
SCW arthritis. 
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In summary, studying the role of IL-21 in arthritis, we have seen 2 independent 
mechanisms that determine the final outcome of joint inflammation and 
destruction: 1) IL-21 as a proinflammatory cytokine driving adaptive immunity, 
with a specific effect on double-positive IFNγ+IL-17+ Th cells, and 2) IL-21 as a 
negative regulator of TLR responses, presumably via induction of SOCS-1 and 
SOCS-3 expression as demonstrated in TLR-2–dependent SCW arthritis. The 
net effects of inhibiting IL-21 will depend on the environment. IL-21 will act in 
a more proinflammatory capacity in T cell–driven arthritis like our AIA model, 
in which the memory response is independent of TLR pathways (Abdollahi-
Roodsaz, et al: unpublished observations), whereas in inflammation that is still 
partly driven through the innate system with TLR involvement, such as during 
SCW arthritis, IL-21 can also demonstrate its antiinflammatory capacity.
IL-21 seems to have a dual role in immune responses during arthritis, turning 
off an initial innate response mediated through TLRs and up-regulated in 
adaptive immune responses to continue to drive a chronic inflammatory 
response. If this dual role of IL-21 in various immune processes is present in 
human disease, it could make IL-21 a difficult therapeutic target in RA.
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ABSTRACT
Th17 cells and their cytokines are linked to the pathogenesis of rheumatoid 
arthritis, a chronic autoimmune disease characterized by joint inflammation. 
Th17 development is initiated by combined signaling of TGF-β and IL-6 or 
IL-21, and can be reduced in the absence of either IL-6 or IL-21. The aim of 
this study was to assess whether combinatorial IL-6/IL-21 blockade would 
more potently inhibit Th17 development, and be more efficacious in treating 
arthritis than targeting either cytokine. We assessed in vitro Th17 differentiation 
efficacy in the absence of IL-6 and/or IL-21. To investigate in vivo effects of IL-6/
IL-21 blockade on Th17 and arthritis development, antigen-induced arthritis 
(AIA) was induced in IL-6-/- x IL-21R-/- mice. The therapeutic potential of this 
combined blocking strategy was assessed by treating mice with collagen-
induced arthritis (CIA) with anti-IL-6R antibodies and soluble (s)IL-21R.Fc. We 
demonstrated that combined IL-6/IL-21 blocking synergistically reduced in 
vitro Th17 differentiation. In mice with AIA, absence of IL-6 and IL-21 signaling 
more strongly reduced Th17 levels and resulted in stronger suppression of 
arthritis than the absence of either cytokine. Additionally, anti-IL-6/anti-IL-21 
treatment of CIA mice during the arthritis induction phase reduced disease 
development more potent than IL-6 or IL-21 inhibition alone, as effective as 
anti-TNF treatment. Collectively, these results suggest dual IL-6/IL-21 inhibition 
may be a more efficacious therapeutic strategy compared to single cytokine 
blockade to suppress arthritis development.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects up to 
1% of the population worldwide. It is characterized by chronic inflammation 
leading to destruction of bone and cartilage of synovial joints [1]. Although 
the use of biologicals blocking a specific pathogenic target considerably 
improved symptoms and prognosis of some RA patients, approximately 30% 
of the patients still fail to respond adequately to currently available treatment 
[2-5]. Interestingly, anti-TNFα non-responders were shown to have increased 
levels of T helper (Th)17 cells in their circulation [5-7], suggesting Th17 cells and 
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Th17-derived cytokines might be interesting alternative therapeutic targets in 
RA. Th17 cells produce various pro-inflammatory cytokines like IL-17, IL-21, and 
IL-22, that have been linked to RA pathogenesis [8-14]. Arthritis animal models 
have further elucidated the role of these Th17 cytokines in the processes 
of joint inflammation and destruction of cartilage and bone [15,16]. These 
findings indicate that Th17 cells and their cytokines are important contributors 
to the pathogenesis of chronic and destructive joint inflammation during RA.
Differentiation of Th17 cells from naïve CD4+ T cells is mediated by the 
enhanced expression of the transcription factor RAR-related orphan nuclear 
receptor γt (RORγt), originally thought to be induced exclusively by the 
combined signaling of TGF-β and IL-6 [17,18]. However, later it was shown that 
signaling of TGF-β combined with the autocrine signaling of IL-21 could drive 
Th17 differentiation as well [19-21]. Both IL-6 and IL-21 induce upregulation of 
the IL-23 receptor (IL-23R) in naïve CD4+ T cells, making those cells responsive 
to IL-23. IL-23 can subsequently amplify the differentiation of Th17 cells [20,22]. 
When either the IL-6 or IL-21 signaling pathway is absent, differentiation of 
naïve T cells towards Th17 cells is reduced. However, to date it is not known 
whether Th17 differentiation can be further reduced when both IL-6 and IL-21 
pathways are blocked. Therefore, the purpose of this study was to determine 
whether IL-6/IL-21 combinatorial pathway blockade has additional inhibitory 
effects on Th17 differentiation, and more effectively reduces development 
of T cell-dependent experimental arthritis. Firstly, we assessed the effects 
of complete IL-6/IL-21 pathway inhibition on Th17 differentiation in vitro. 
Secondly, we used IL-6-/- x IL-21R-/- mice to study the in vivo effects of cytokine 
pathway blockade on Th17 differentiation and development of experimental 
arthritis. Finally, we investigated the therapeutic potential of our combined 
blocking strategy by treating mice with collagen-induced arthritis (CIA) with 
anti-IL-6R antibodies and soluble (s)IL-21R.Fc. 
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MATERIALS AND METHODS
Mice. Wild type (WT) C57Bl6/J mice and DBA-1 mice were purchased from 
Janvier-Elevage (Le Genest Saint Isle, France), and breeding pairs of the IL-21R-
deficient mice on a C57Bl6/J background were provided by Pfizer. Breeding 
pairs of the IL-6−/− mice, back-crossed eight times with C57Bl6/J, were a kind 
gift from Dr Manfred Kopf (Basel, Switzerland)[23]. Animals were used between 
10 and 12 weeks of age and were housed in filter-top cages under specific 
pathogen-free conditions. Microbiome synchronization was promoted by 
housing purchased WT mice near the genetically modified mice for a period of 
at least one week, before initiating experiments. A standard diet and water were 
provided ad libitum. Before being sacrificed by cervical dislocation, mice were 
anesthetized using 2-3% isoflurane. All animal procedures were approved by 
the ethics committee of the Radboud University Nijmegen (approval numbers 
2014-045, 2010-002, and 2012-207).
In vitro stimulation of CD4+ T cells. Naïve murine T helper cells were 
negatively selected from spleen, isolated from IL-21R-/- or WT C57Bl6/J mice 
using a mouse naïve CD4+ T Cell Isolation Kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Naïve CD4+ T cells were cultured for four days in 6-wells 
plates at 37°C, 5% CO2, in RPMI-1640 medium containing 5% fetal calf serum 
(FCS), 50 µm β-mercaptoethanol, 50 µg/ml gentamycin, and 1% pyruvate. The 
following Th17 stimulation cocktail was added, with or without recombinant 
mouse (rm)IL-6 (50 ng/ml; eBioscience, San Diego, CA, USA): anti-CD3 (5 µg/
ml; eBioscience; adsorbed to the wells over night at 4°C), anti-CD28 (2.5 µg/ml; 
eBioscience), anti-IL-2 (5 µg/ml; eBioscience), TGF-β (1 ng/ml; eBioscience), IL-1β 
(10 ng/ml; kind gift of Pfizer), and TNFα (10 ng/ml; eBioscience). Differentiation 
efficacy was determined with flow cytometry. Supernatant cytokine levels 
were determined using the Luminex multianalyte technology, in combination 
with Milliplex cytokine kits (Merck Millipore, Darmstadt, Germany). 
In vivo study protocol I: Antigen-induced arthritis (AIA) in knockout mice. 
AIA was induced in WT, IL-21R-/-, IL-6-/-, and IL-21R-/- x IL-6-/- mice as previously 
described [24]. Inflammation of the knee joint was measured by 99mTechnetium 
(99mTc) pertechnetate uptake. Joint swelling was scored as the ratio of 99mTc 
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uptake of the arthritic right (R) and control left (L) knee joint. Joint swelling 
of the right knee joint was indicated as R:L ratios >1.1. Mice were sacrificed by 
cervical dislocation either at day 2 or day 7 after arthritis induction, and serum 
and joints were collected for further analysis. Draining lymph nodes (dLN) of 
mice sacrificed two days after arthritis induction were isolated to determine 
Th17 levels. 
In vivo study protocol II: Antibody treatment during collagen-induced 
arthritis (CIA). CIA was induced as described previously [25]. Arthritis 
development was macroscopically scored on a scale of 0-2 per paw, according 
to changes in redness and/or swelling of the paws. IL-6 signaling was inhibited 
with a single bolus intraperitoneal (i.p.) injection with 8 mg of a rat anti-mouse 
IL-6 receptor antibody (MR16-1; kind gift of Chugai Pharmaceutical Co. Ltd). 
IL-21 was neutralized by three i.p. injections per week with 200 µg soluble 
(s)IL-21R.Fc (Pfizer, New York, NY, USA), from now on referred to as anti-IL-21 
therapy [26,27]. Treatment was initiated at the day of immunization (day 0, 
early treatment), or at the day of booster injection (day 21, late treatment). 
Both treatments were administered as single and combination treatments. 
The TNFα inhibitor Enbrel (200 µg; Pfizer) and rat IgG1 (200 µg; Pfizer) were 
injected as positive and negative control respectively, both i.p. 3 times a week. 
Mice were terminally bled at day 35 to determine serum antibody levels. 
Subsequently ankle joints were isolated for X-ray and histological analysis, and 
draining popliteal and inguinal lymph nodes were isolated to determine T cell 
levels.
Histology. Isolated joints were fixed for at least four days in 4% formaldehyde, 
decalcified in 5% formic acid, dehydrated, and embedded in paraffin. Standard 
frontal sections of 7 µm were mounted on SuperFrost slides (Menzel-Gläser, 
Braunschweig, Germany), and stained with haematoxylin and eosin (H&E), or 
Safranin O (SO). Joint arthritis severity was scored on an arbitrary scale of 0-3, 
as previously described [28]. Histopathological changes were scored on three 
semiserial sections of the joint, in a blindfolded manner.
Flow cytometry. Cells were stimulated four hours with phorbol myristate 
acetate (PMA; 50 ng/ml; Sigma-Aldrich, Saint Louis, MO, USA), ionomycin (1 
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µg/ml; Sigma-Aldrich) and the Golgi-traffic inhibitor Brefeldin (1 µl/ml; BD 
Biosciences, Franklin Lakes, NJ, USA). Differentiated T cells or isolated LN cells 
were stained with anti-CD3-PE (BD Biosciences) and anti-CD4-APC (Biolegend, 
San Diego, CA, USA), fixed and permeabilized using BD Cytofix/Cytoperm (BD 
Biosciences), followed by intracellular staining with anti-IL-17-FITC (Biolegend), 
anti-IFNγ-FITC (BD Biosciences), or appropriate isotype-matched control 
antibodies (all from BD Biosciences). Cells were measured on a FACSCalibur 
using the CellQuest software (BD Biosciences), and analyzed using FlowJo 
software (version 7.6.5).
Measurement of anti-mBSA and anti-CII antibodies. Levels of anti-mBSA 
and anti-CII antibodies were determined in serum using enzyme-linked 
immunosorbent assay (ELISA). In short, 10 ng of mBSA or 100 ng of bovine 
type II collagen were coated onto 96-well plates overnight. Nonspecific 
binding sites were blocked with 1% BSA in PBS-Tween (0.05%) for anti-mBSA 
antibody detection, and with a 5% milk powder solution for anti-CII antibody 
detection. Serial dilutions of mouse sera were incubated for 1 hour, before 
adding isotype-specific horseradish peroxidase-labeled goat anti-mouse Ig 
(1:1000). After incubation of another hour, 5-aminosalicyclic acid was added as 
a substrate, absorbance was subsequently measured at 450 nm.
Statistics. To determine the level of statistical significance between means of 
experimental groups, the Kruskal-Wallis with a Dunns post-test, or a one-way 
ANOVA with a Bonferroni post-test was applied as indicated, using GraphPad 
Prism version 5. P values less than 0.05 are considered significant. Results are 
expressed as Tukey box plots.
RESULTS
Combined blocking of IL-6 and IL-21 synergistically inhibits in vitro Th17 
differentiation
To investigate the exchangeability of IL-6 and IL-21 and potential additive 
or synergistic effects of these cytokines during Th17 differentiation, we first 
determined the differentiation efficacy of naïve T cells towards Th17 cells in the 
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presence of both IL-6 and endogenous IL-21. After culturing, 86% of CD4+ cells 
were positive for IL-17 (Fig 1A and 1B), and produced high levels of IL-17 (Fig 
1C). Subsequently, we determined Th17 differentiation efficacy in the absence 
of either IL-6 or IL-21 signaling. Without IL-6, naïve T cells reached only 46% 
of Th17 development upon stimulation, while Th17 differentiation efficacy of 
naïve IL-21R-/- T cells was similar to that observed after stimulation of WT cells 
(Fig 1A and 1B). Interestingly, when both IL-6 and IL-21 signaling pathways were 
absent, only 17% of CD4+ cells differentiated into Th17 cells after culturing (Fig 
1A and 1B), and IL-17 secretion was reduced by 50% (Fig 1C). High endogenous 
IL-21 levels were detected in supernatants of cultures with IL-6 (Fig 1D), 
potentially contributing to Th17 development in an autocrine fashion [19-21]. 
Finally, secretion of IL-22 in supernatant of those cultures was confirmed (Fig 
1E). This shows that by blocking IL-6 and IL-21 signaling pathways in vitro, Th17 
differentiation is dramatically reduced, thereby providing excellent rationale 
for further in vivo studies.
Th17 differentiation and arthritis severity are potently reduced by 
combinatorial blockade of IL-6 and IL-21 signaling pathways
We next investigated the in vivo effects of IL-6 and IL-21 pathway blockade on 
Th17 differentiation and the development of experimental arthritis. The T cell-
driven AIA model was induced in WT, IL-6-/-, IL-21R-/-, and IL-6-/- x IL-21R-/- mice, and 
the number of Th17 cells in draining LNs was assessed two days after arthritis 
onset. Expression of various T (CD3, CD4, CD8) and B (CD45R, CD19, CD22) cell 
markers was unaffected in spleens of IL-6-/- x IL-21R-/- mice as compared to WT, 
indicating normal lymphocyte development (data not shown). Among total 
measured cell population of WT mice, 0.3% was CD4+IL-17+ (Fig 2A). In line 
with our in vitro data, Th17 levels were reduced in mice lacking IL-6 signaling, 
and in mice in which both IL-6 and IL-21R were absent. Remarkably, in contrast 
to our in vitro data (Fig 1), IL-21R-/- mice also showed significantly reduced Th17 
numbers in vivo (Fig 2A). In addition to its importance in T cell development, 
IL-21 has been implicated in B cell  development and antibody production 
[29,30], processes relevant to RA and important in this experimental arthritis 
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Figure 1. Highly reduced Th17 differentiation in the absence of both IL-6 and IL-21 
signaling. WT and IL-21R-/- naïve T cells were stimulated for four days with a differentiation 
cocktail either with or without IL-6 as described in Methods. Representative flow cytometry dot 
plots reflecting the IL-17+ fraction of the CD4+ population. Gates were set at a maximum of 
0.3% IL-17-positive cells in the ‘fluorescence minus one’ control per condition, without addition 
of IL-17A antibodies (A). Summary of the relative proportion of IL-17+ cells within the CD4+ 
population (B). Culture supernatant levels of IL-17 (C), IL-21 (D), and IL-22 (E). 6-10 mice/group; 
*p<0.05, **p<0.01, ***p<0.001 versus WT + IL-6; ###p<0.001 versus WT – IL-6; ^p<0.05, ^^^p<0.001 
versus IL-21R-/- + IL-6; A - Kruskal-Wallis, B-D - One-way ANOVA.
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model as well. Hence, we were interested in determining the effect of a lack 
in IL-6 but especially in IL-21 on antibody production in AIA. Unexpectedly, 
we did not observe any effect on antibody titers in mice deficient only for the 
IL-21R (Fig 2B). However, mice lacking both IL-6 and IL-21R expression showed 
reduced antibody production as compared to WT controls (Fig 2B), suggesting 
that combined deficiency of IL-6 and IL-21 can significantly suppress the 
development of disease-relevant antibodies.
Figure 2. IL-6 and IL-21 play an important role during in vivo Th17 differentiation and 
antibody production. AIA was induced in WT, IL-6-/-, IL-21R-/-, and IL-6-/- x IL-21R-/- mice. Draining 
lymph node CD4+IL-17+ cell fraction two days after arthritis induction as measured using flow 
cytometry (A; n=10/group). Serum IgG1, IgG2b, and total IgG levels as measured by ELISA (B; 
n=5/group). *p<0.05, **p<0.01, ***p<0.001 versus WT; ##p<0.01 versus IL-6-/-; ^^^p<0.001 versus 
IL-21R-/-; A - One-way ANOVA, B - Kruskal-Wallis.
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In line with lowered Th17 levels, reduced joint swelling was measured in the 
absence of IL-6 or IL-21R, as compared to WT controls (Figs 3A-C). Interestingly, 
joint swelling was reduced more potently in IL-6-/- x IL-21R-/- mice compared 
to mice lacking either IL-6 or IL-21R expression early in disease development 
(Figs 3A and 3B). Even though joint swelling of WT mice started to decline four 
days after arthritis induction, joint swelling was still significantly lower in all 
knock out groups (Fig 3C). Importantly, when assessing histologically scored 
inflammation, cartilage proteoglycan (PG) depletion, and bone erosion at this 
time point, we observed significantly reduced damage in IL-6-/-, IL-21R-/-, and 
IL-6-/- x IL-21R-/- mice as compared to the WT controls for all parameters (Fig 3D).
Figure 3. Antigen-induced arthritis severity is potently reduced by combinatorial blockade 
of IL-6 and IL-21 signaling pathways. Joint swelling of WT, IL-6-/-, IL-21R-/-, and IL-6-/- x IL-21R-/- 
mice at day 1 (A), day 2 (B), and day 4 (C) after arthritis induction, depicted as ratio between right 
and left knee joint, measured by 99mTechnetium pertechnetate uptake in the joint (n=6/group). 
Histologically scored inflammation, bone erosion (both H&E staining, scale bar 500 µM), and 
cartilage proteoglycan depletion (SafO staining, scale bar 200 µM) (D; n=10/group). *p<0.05, 
**p<0.01, ***p<0.001 versus WT; #p<0.05, ###p<0.001 versus IL-6-/-; ^p<0.05 versus IL-21R-/-; A+B 
One-way ANOVA, C+D Kruskal-Wallis.
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Overall, this study confirmed the importance of IL-6 and IL-21 during Th17 
development in vivo, and showed higher potency of blocking both cytokine 
pathways above blocking either one in reducing the severity of arthritis.
Combination therapy with anti-IL-6R antibodies and sIL-21R.Fc more 
potently suppresses disease development than targeting either cytokine 
during the induction phase of experimental arthritis
To determine the therapeutic potential of combined IL-6/IL-21 signaling 
pathway blockade during experimental arthritis, mice with CIA were treated 
with anti-IL-6R antibodies and/or sIL-21R.Fc starting either from the day of 
immunization (day 0, early treatment), or from the day of the booster injection 
(day 21, late treatment). 
Surprisingly, mice receiving early anti-IL-6R antibody and/or anti-IL-21 
treatment, only showed a showed a minor trend towards lower Th17 levels 
in their LNs as compared to isotype control mice (Fig 4A). This trend in Th17 
reduction was not present when treatment was initiated later in the disease 
process, i.e. at the day of booster injection. Th1 levels were largely unaffected, 
except for a minor trend towards an increase in mice receiving early combination 
treatment (Fig 4B). In contrast to observations in our AIA study using knockout 
mice (Fig 2B), we did not observe any changes in antibody profile when using 
this anti-IL-6/anti-IL-21 treatment strategy in mice with CIA (Fig 4C). 
Even though the effect of cytokine neutralization on Th17 levels was minor, 
we observed potent clinical effects of this treatment strategy. Mice receiving 
early αIL-6R antibody treatment showed potently reduced disease incidence 
compared to isotype-treated mice, with only 60% of these mice having arthritis 
at day 35 (Fig 5A). Interestingly, arthritis incidence was further reduced when 
mice were treated with the anti-IL-6R/anti-IL-21 combination therapy, resulting 
in only 40% of mice developing arthritis.
This greatly reduced disease incidence shows the potential of the early IL-6/
IL-21 combination strategy over single cytokine inhibition in blocking arthritis 
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development, with comparable efficacy as the positive control group receiving 
TNFα inhibitors. In contrast to early anti-IL-6R therapy, late treatment with anti-
IL-6R antibodies could not inhibit arthritis; all mice developed arthritis already 
around day 23 (Fig 6A). 
Remarkably, mice treated with the late anti-IL-6R/anti-IL-21 combination 
therapy show a clear protective effect on arthritis incidence; only 60% of those 
mice developed arthritis before the end of the study (day 30). Unfortunately, 
none of the late experimental treatments had an effect on arthritis severity, 
as joint  swelling (Fig 6B), radiological bone damage (Fig 6C), and histological 
damage (Fig 6D), were all comparable to levels measured in the isotype 
control group. In mice treated from the day of immunization with anti-IL-6 
and anti-IL-21 treatment on the other hand, clinical arthritis severity based 
on swelling and redness of the four paws was greatly reduced in comparison 
Figure 4. Effect of anti-IL-6 and/or anti-IL-21 treatment on Th17, Th1, and antibody 
development in CIA mice. Th17 (A) and Th1 (B) levels in draining lymph nodes as measured 
using flow cytometry, and anti-CII antibody level in serum (C) as measured by ELISA of mice with 
CIA receiving anti-IL-6 and/or anti-IL-21 treatment. n=5/group; **p<0.01 versus Rat IgG1; A+C – 
Kruskal-Wallis, B - One-way ANOVA.
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with the isotype control group (Fig 5B). Unexpectedly, we found reduced 
radiological scored bone damage only to be significant in early anti-IL-6R 
antibody receiving mice, with no additional value of blocking IL-21 (Fig 5C). 
Interestingly, histological damage was reduced more potent in mice receiving 
anti-IL-6/IL-21 combinatorial treatment than in mice receiving single anti-IL-6 
or anti-IL-21 treatment (Fig 5D), altogether suggesting higher efficacy of this 
combination treatment strategy over single cytokine blockade during the 
induction phase of the disease. 
Figure 5. Arthritis incidence and severity of mice receiving anti-IL-6 and/or anti-IL-21 
treatment during the induction phase of the disease. Collagen-induced arthritis was initiated 
in DBA-1 mice, subsequently treated with anti-IL-6R antibodies and/or sIL-21R.Fc from the day 
of the immunization injection (d=0; n=5/group). Arthritis incidence (A) and severity (B) based 
on macroscopic scoring. Bone damage as measured using the Faxitron depicted as radiological 
damage (C). Histologically scored inflammation, bone erosion (both H&E staining, scale bar 
500 µM), and cartilage proteoglycan depletion (SafO staining, scale bar 200 µM) (D). *p<0.05, 
**p<0.01 versus Rat IgG1; One-way ANOVA.
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DISCUSSION
IL-6 and IL-21 are important mediators in the differentiation of Th17 cells 
[17-19]. The redundancy and possible additive or synergistic effects of the 
IL-6 and IL-21 pathways, as well as the therapeutic potential of combined 
pathway blockade in Th17-driven autoimmunity remain unclear. This study on 
the role of IL-6 and IL-21 during Th17 differentiation and the development of 
Figure 6. Arthritis incidence and severity of mice receiving anti-IL-6 and/or anti-IL-21 
treatment late in disease development. Collagen induced arthritis was initiated in DBA-1 
mice, subsequently treated with anti-IL-6R antibodies and/or sIL-21R.Fc from the day of booster 
injection (d=21; n=5/group). Arthritis incidence (A) and severity (B) based on macroscopic 
scoring. Bone damage as measured using the Faxitron depicted as radiological damage (C). 
Histologically scored inflammation, bone erosion (both H&E staining, scale bar 500 µM), and 
cartilage proteoglycan depletion (SafO staining, scale bar 200 µM) (D). *p<0.05 versus Rat IgG1; 
One-way ANOVA.
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experimental arthritis revealed synergistic effects of IL-6 and IL-21 signaling 
pathways in driving Th17 differentiation in vitro, and indicated that the IL-6/
IL-21 combination blocking strategy may be a highly effective way of treating 
patients with early rheumatoid arthritis.
In accordance with previously reported data on in vitro Th17-differentiation 
[17,18], we showed significantly lower levels of IL-17-producing CD4+ cells 
when differentiating naïve T cells in the absence of IL-6. However, we observed 
no reduction in Th17 differentiation when solely IL-21 signaling was blocked, 
indicating that IL-21 is not a critical factor during Th17 differentiation in vitro. 
Data from earlier studies on the role of IL-21 in in vitro Th17 differentiation are 
ambivalent. IL-21 is suggested to be essential for differentiation of Th17 cells 
[20], whereas others claim IL-21 is capable of, but not necessary for, driving 
Th17 development [31,32], the latter being in line with the current study. 
Although we cannot fully explain this discrepancy, the reason might lie within 
the concentrations of the various cytokines and antibodies used to drive T 
cell differentiation, or within the mouse strain used to isolate naïve T cells. 
Interestingly, when both IL-6 and IL-21 pathways were inactive, differentiation 
of naïve T cells towards Th17 cells was almost completely blocked, clearly 
showing the synergy between the two pathways in driving Th17 differentiation 
in vitro. 
Accordingly, significantly reduced Th17 levels were present in draining lymph 
nodes of arthritic mice in which the IL-6 pathway was blocked, two days after 
induction of the AIA model. Moreover, blocking both IL-6 and IL-21 pathways 
resulted in almost undetectable Th17 levels, showing the importance of these 
two cytokines in driving Th17 differentiation in vivo. As IL-6 and IL-21 are both 
important in inducing IL-23 receptor expression in naïve CD4+ T cells, this 
combined blockade might reduce IL-23R expression levels, and thereby IL-
23 signaling, to a minimum, possibly contributing to the major reduction in 
Th17 levels [20,22], In line with previously published data, arthritis severity was 
significantly reduced in IL-6-/- mice as compared to WT controls, two days after 
arthritis induction [33]. Earlier work of our group showed reduced arthritis 
severity in IL-21R-/- mice as compared to WT controls [24], the present study 
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confirms these data. Additionally, both studies show reduced IL-17 production 
by CD4+ cells of mice lacking expression of the IL-21 receptor. Interestingly, as 
opposed to this T cell effect, previous studies showed the reducing effect of 
IL-21 blockade on arthritis development could be attributed to a defect in B 
cell development rather than in T cell development in the K/BxN and collagen-
induced arthritis (CIA) murine arthritis models [34,35]. In contrast to our study, 
Th17 responses were unaffected in IL-21R-/- mice with CIA [35], as well as in IL-
21R-/- mice with experimental autoimmune encephalitis (EAE) and myocarditis 
(EAM) [32]. The exact reason for this discrepancy in mechanism of disease 
reduction remains unclear, but might reflect the pleiotropic character of IL-
21, with the genetic and inflammatory context influencing the functioning of 
the cytokine. Regardless of the mechanism of action, a block in IL-21 reduced 
experimental arthritis development in the majority of reported studies, 
including the present study. Of high interest, our double blocking strategy was 
most effective in reducing arthritis severity, which is in concordance with Th17 
levels of those animals. These data hint towards therapeutic potential of using 
a combined IL-6/IL-21-blocking treatment strategy.
Indeed, when treating mice with both anti-IL-6R antibodies and sIL-21R.
Fc either during the induction phase of arthritis (day 0) or in a later stage of 
the disease (day 21), arthritis incidence levels could potently be reduced, 
confirming the therapeutic potency of this strategy in a RA mouse model. Also 
in comparison with mice treated solely with anti-IL-6R antibodies, a compound 
currently used to effectively treat RA patients [36] and known as Tocilizumab 
(JW Pharmaceutical, Seoul, South Korea), the combination treatment proved 
to be much more potent in preventing arthritis development. This holds 
true when treatment was initiated early during arthritis development, but 
especially when first therapeutic injections were administered in a later stage 
of the disease, where the anti-IL-6R antibodies could not prevent disease 
onset. Tocilizumab is a humanized anti-IL-6R monoclonal antibody that has 
been tested in the clinic both as a monotherapy, as well as in combination with 
disease-modifying anti-rheumatic drugs (DMARDS), the first-line treatment 
for RA patients. Tocilizumab monotherapy potently inhibited structural joint 
damage, and led to increased percentages of patients achieving ACR20, 50 
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and 70 responses. Additionally, the number of patients achieving remission 
as defined by a Disease Activity Score in 28 Joints (DAS28) lower than 2.6, 
was increased in Tocilizumab-treated patients [37-40]. Samson et al. suggest 
that the successes of Tocilizumab may be attributed to a correction of the 
imbalance between the pathogenic Th17 cells and the protective regulatory T 
(Treg) cells that is found in part of the RA patients [41]. They showed decreased 
Th17 levels in peripheral blood of RA patients after Tocilizumab treatment, 
whereas Treg numbers were increased. As arthritis development in mice was 
more effectively reduced by our combination treatment than by the anti-IL-6R 
antibodies, a similar response may be expected when treating patients with 
Th17-driven joint pathologies, suggesting the potential of adding an anti-IL-21 
treatment to the currently used Tocilizumab monotherapies.
In addition to reduced incidence after anti-IL-6R/anti-IL-21 treatment, disease 
severity of arthritic mice receiving early combination therapy was reduced. 
Interestingly, neither anti-IL-6R antibodies, nor anti-IL-21 therapy as single 
treatments could reduce arthritis severity in the severe and progressive 
collagen-induced arthritis model. A partial difference in the outcome of anti-
IL-6R antibody treatment is present compared to earlier studies [27,42], which 
may be due to different study design. In line with our data, no protective effect 
was observed when this treatment was initiated later in disease development. 
Radiological bone damage of the knee and ankle joints was significantly 
reduced only in mice receiving early treatment with anti-IL-6R antibodies 
alone, a trend towards reduction was observed when combined with anti-IL-21 
therapy, to levels comparable to that of anti-TNFα treated mice. Histological 
damage was only reduced by the combination treatment, again to levels 
comparable to those observed in mice treated with TNFα inhibitors.
Interestingly, a clear trend towards reduced Th17 levels in draining lymph 
nodes of mice receiving either early single or combination treatment was 
present, despite the late time point of analysis (day 35). In contrast, no reduced 
Th17 levels were observed when treatment was initiated later in disease 
development. Data of mice treated with anti-IL-6R antibodies initiated at both 
time points confirm previously published data [42]. Although our in vitro data 
523905-L-bw-Roeleveld
Processed on: 13-9-2018 PDF page: 70
CHAPTER 3
70
demonstrated synergy between IL-6 and IL-21 in Th17 differentiation, this was 
not clearly reflected by Th17 levels in draining lymph nodes of arthritic mice 
during our in vivo studies. Determination of T cell levels in inflamed synovium 
may provide more information on local differences in T cell subsets. 
Over the past few years, clinical trials have been performed testing various IL-
17-targeting agents for a number of autoimmune diseases, amongst others 
Rheumatoid Arthritis. In RA patients who failed to respond to synthetic and/
or biologic DMARDs, both ixekizumab and secukinumab, two agents targeting 
the IL-17A ligand, induced small but clinically relevant responses. Reported 
safety profiles were similar to that of other biological agents [43-48]. In 
contrast, no clinical response was observed when treating RA patients with 
the anti-IL-17-receptor antibody brodalumab [49,50], a clear explanation for 
the differences in efficacy of ligand versus receptor targeting is lacking. Even 
though these studies indicate targeted inhibition of the IL-17A ligand may 
have therapeutic value in the treatment of RA, pharmaceutical companies 
appear to shift the application of their anti-IL-17 therapies to other rheumatic 
diseases like psoriatic arthritis [51,52] and ankylosing spondylitis [53]. Most 
likely because obtained clinical effects of IL-17 blocking strategies in RA were 
below expectation, especially when comparing with the impressive therapy 
responses observed in patients suffering from plaque psoriasis [54].
As IL-17 and other Th17-derived cytokines are important contributors to RA 
pathology [8-16], identifying other ways to target this pathway remains a high 
priority. With this study we demonstrated that full inhibition of both IL-6 and IL-
21 effectively abrogates Th17 differentiation, and that, despite the minor effect 
on Th17 development, a combination therapy neutralizing both cytokine 
pathways is more effective in treating early T cell-driven experimental arthritis 
than targeting either cytokine. This indicates that anti-IL-6/IL-21 combination 
therapy might be an interesting new strategy to treat early RA patients or to 
sustain RA remission.
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ABSTRACT
Over the past few years, the importance of T helper (Th)17 cells in the 
pathology of Rheumatoid Arthritis (RA) has become apparent. RA is a systemic 
autoimmune disease that affects up to 1% of the population worldwide. It is 
characterized by an inflamed, hyperplastic synovium with pannus formation, 
leading to bone and cartilage destruction in the joints. By the production of 
its effector cytokines like interleukin(IL)-17 and IL-22, the T helper 17 subset 
protects the host against bacterial and fungal infections, but also promotes 
the development of various autoimmune diseases like RA. Hence, Th17 cells 
became very interesting targets in RA treatment. Up to now, several therapies 
targeting the Th17 cells or its effector cytokines have been tested, or are 
being tested still. This review clarifies the role of Th17 cells and cytokines in 
the pathogenesis of RA, and provides a clear overview of the clinical trials 
using immunotherapy to target this particular T helper subset or the two main 
effector cytokines by which the Th17 cells exert their function, IL-17 and IL-22.
INTRODUCING THE TH17 CELLS
Th17 cells are a subset of T cells named after their signature cytokine, IL-17. In 
addition to IL-17, these T cells secrete various other proinflammatory cytokines 
like IL-21, IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and tumor necrosis factor α (TNFα). The chemokine receptors expressed on the 
surface of Th17 cells are c-c chemokine receptor (CCR)2, CCR4, and CCR6 [1,2]. 
Differentiation of naïve T cells into Th17 cells is regulated by a combination 
of transforming growth factor β (TGF-β), also essential for the development 
of the anti-inflammatory regulatory T cells, and at least one of the following 
cytokines IL-6, IL-21, IL-1β, and IL-23 in both mice [3-5] and humans [4-8] 
(Figure 1). TGF-β stimulates RAR-related orphan receptor γt (RORγt) expression 
by T cells while inhibiting the production of IL-17 at the same time. The 
aforementioned proinflammatory cytokines relieve this inhibition, inducing 
IL-17 expression by the Th17 cells [8]. Additionally, both interferon γ (IFNγ) and 
IL-4, known to be key Th1 and Th2 cytokines respectively, have been shown to 
suppress differentiation of Th17 cells [9,10]. 
523905-L-bw-Roeleveld
Processed on: 13-9-2018 PDF page: 79
4
79
IL-17 AND IL-22 IN RHEUMATOID ARTHRITIS PATHOGENESIS
Figure 1. Th17 pathway: differentiation and effector function. The induction of Th17 
development and cytokine secretion with subsequent stimulatory actions are shown. 
G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony 
stimulating factor; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; MMP, matrix 
metalloproteinase; PGE2, prostaglandin E2; RANKL, receptor activator of nuclear factor κB 
ligand; TGF-β, transforming growth factor β; Th, T helper; TNFα, tumor necrosis factor α; VEGF, 
vascular endothelial growth factor.
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RA is an auto-immune disease characterized by chronic inflammation of 
synovial joints, leading to destruction of cartilage and bone. Accumulating 
evidence indicates the relevance of T cells in the pathogenesis of RA: there is an 
abundance of T cells in synovial tissue and fluids [11], and there is an association 
between specific major histocompatibility complex (MHC) class II alleles and 
RA [12]. Moreover, T cells play an important role in animal models of arthritis 
[13-15], and improvement of RA symptoms by T cell directed therapeutic 
approaches has been observed [16]. The first association made between Th17 
cells and a genetic polymorphism contributing to RA pathology, was when a 
SNP in the IL-4 receptor gene appeared to influence the levels of Th17 cells and 
cytokines. RA patients homozygous for this particular SNP showed increased 
serum levels of Th17 cells itself, as well as of its cytokines IL-17 and IL-22 [17]. 
Interestingly, levels of IL-17 producing T cells are significantly increased in 
peripheral blood of RA patients as compared with healthy controls, strongly 
correlating with the disease activity [18-21]. In addition, increased levels of Th17 
cells were observed in RA synovium, as compared to synovium from healthy 
controls [22]. Furthermore, elevated levels of IL-22 producing CD4+ cells in the 
peripheral blood of RA patients were observed. A positive correlation between 
the levels of IL-17+ and IL-22+ cells was present, however only 20% of the IL-
17+CD4+ cells also produced IL-22. Moreover, T cells producing IL-22 but not 
IL-17 were shown as well [18]. 
A recent study demonstrated that in RA patients not responding to treatment 
with the, overall very effective, biologicals targeting TNFα, increased levels 
of both Th17 cells and cytokines were observed [23]. In addition, in mice it 
was shown that anti-TNF treatment caused an expansion of the pathogenic 
Th17 population [24]. Since the group of anti-TNF non-responders accounts 
for 30% of the RA patients, it is important to investigate other treatment 
options in those patients. As Th17 cells seem to be linked with anti-TNF non-
responsiveness, those cells or its effector cytokines might be interesting new 
targets in RA therapy. 
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THE KEY TH17 CYTOKINE: IL-17
During a search for novel molecules exerting immune functions, the cytotoxic 
T lymphocyte associated antigen-8 (CTLA-8) was isolated. This molecule has 
a very restricted tissue distribution, it could only be detected in mouse T cell 
hybridoma clones. Screening of the CTLA-8 cDNA sequence revealed an AU-
rich repeat in the 3’ untranslated region of the mRNA, which was previously 
found in the mRNA of various cytokines, growth factors, and oncogenes. The 
protein showed 57% homology to a protein of the herpesvirus Saimiri (HSV13), 
a T lymphotropic virus [25]. A variety of cell types was shown to respond to 
both recombinant HVS13 and mCTLA-8 the way they respond to cytokines. 
For instance, nuclear factor (NF)-κB is activated, IL-6 secretion by fibroblasts is 
induced, and T cell proliferation is stimulated. Hence, the new name IL-17 was 
proposed for mCTLA8, and viral IL-17 (vIL-17) for HSV13. 
In the sequel of this discovery, a cDNA was cloned encoding human IL-17. As 
with the mouse IL-17 the cDNA sequence showed a high degree of homology 
to HVS13, and the expression profile was restricted. The human IL-17 mRNA 
could only be detected in activated CD4+ T cells, but not in resting peripheral 
blood mononuclear cells (PBMCs), resting CD4+ T cells, CD8+ T cells, B cells, 
monocytes, or in various human organs [26,27]. After activation of CD4+ and 
CD8+ with phorbol 12-myristate 13-acetate (PMA) and ionomycin human IL-
17 was solely detected in CD4+ supernatant. Thereby, secretion by activated 
CD4+ T cells of hIL-17 was confirmed at the protein level [27]. These CD4+ T 
cells producing the proinflammatory IL-17 have been designated later as T 
helper 17 cells [28].
IL-17 binds to the IL-17 receptor (IL-17R) that is widely expressed throughout 
the body. The IL-17R is a heteromeric complex consisting of the IL-17R A and 
C subunits,  IL17RA and IL17RC [29,30]. Binding of IL-17 to its receptor induces 
signaling via TRAF6 and NF-κB, but also through the MAPK and C/EBP pathways 
[31].
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Relation to arthritis pathology
Many reports have linked IL-17 to the pathogenesis of RA. First of all, expression 
levels of IL-17 mRNA as well as protein were demonstrated to be higher in joints 
from RA patients compared to joints derived from healthy control subjects 
[22,32]. Moreover, strong correlations of serum and synovial fluid levels of IL-
17 with various markers for RA disease severity like erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), and rheumatoid factor (RF) were shown in 
untreated RA patients. In addition, a clear correlation was observed between 
serum and synovial IL-17 levels with DAS28 scores [33]. 
In the early stages of RA pathogenesis, angiogenesis plays an important 
role. IL-17 potently contributes to this process, by stimulating fibroblast like 
synoviocytes (FLS) to produce vascular endothelial growth factor (VEGF) [34]. 
Concordantly, local overexpression of IL-17 increased the vascularity in mouse 
ankles, and in matrigel plugs the cytokine promoted the growth of blood 
vessels [35]. Additionally, IL-17 induced the secretion of various cyto- and 
chemokines like IL-6, IL-8, prostaglandin E2 (PGE2), and granulocyte colony 
stimulating factor (G-CSF) from synovial fibroblasts. Neutralizing IL-17 using 
a monoclonal antibody (mAb) blocked this induction, indicating that the 
effect is specific to this Th17 cytokine [27]. As with synovial fibroblasts, IL-17 
increased secretion of a select group of cytokines (e.g. IL-1β, TNFα, and IL-6) 
by human macrophages upon stimulation with recombinant protein [36]. In 
addition to the increased expression of these (proinflammatory) cytokines, IL-
17 increased production of various matrix degrading enzymes, namely matrix 
metalloproteinase (MMP)-1, -2, -9, and -13 in whole synovial tissue, synovial 
fibroblasts, and cartilage [32] (Figure 1).
In mice, the adenoviral overexpression of IL-17 enhanced collagen-induced 
arthritis. Here, the onset of the disease was accelerated, synovial inflammation 
was enhanced, and joint destruction was markedly increased [37]. Additionally, 
the Th17 cytokine was shown to promote osteoclastic bone erosion during 
collagen arthritis in murine synovium and bone marrow. By stimulating the 
expression of the receptor activator of nuclear factor κB ligand (RANKL), the 
cytokine increased the RANKL/osteoprotegerin (OPG) ratio [38]. Furthermore, 
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intra-articular injections of IL-17 in normal, non-arthritic, mouse joints induced 
the development of inflammation and depletion of cartilage proteoglycans, 
leading to degradation of the tissue [39,40]. Conversely, IL-17-/- mice showed 
considerably suppressed collagen induced arthritis (CIA) compared to wild 
type (WT) mice, and these knockout mice showed that an important role 
of IL-17 during CIA lies within the priming of collagen-specific T cells [41]. 
Furthermore, treatment of arthritic CIA mice with neutralizing anti-IL-17 
antibodies resulted in significantly reduced severity. This was accompanied 
by potently suppressed radiological damage of the knee and ankle joints. 
Moreover, reduced joint inflammation and prevention of cartilage and bone 
destruction were observed on histological level. On protein level, lower 
systemic IL-6 expression and fewer IL-1-positive and RANKL-positive cells in 
the synovium were observed in anti-IL-17-treated mice [37,42]. By neutralizing 
endogenous IL-17 in another arthritis model, antigen-induced arthritis (AIA), 
joint inflammation and bone erosion could be prevented. In addition, both 
synovial RANKL and Cathepsin K mRNA expression levels were suppressed [43]. 
In a spontaneous model of experimental arthritis, the IL-1Ra-/- model, the level 
of IL-17 expression in murine spleen is markedly enhanced. Mice also deficient 
in IL-17 showed no spontaneous development of arthritis, indicating the 
important role of the cytokine in this arthritis model [44]. In  severe combined 
immunodeficient (SCID) mice engrafted with human RA synovial tissue, only 
samples with abundant CD3+ T cell levels showed great therapeutic potential 
upon treatment with anti-IL-17-antibodies as determined by serum hIL-6 levels 
[45].
Interestingly, various additive and synergistic effects were observed between 
IL-17 and another cytokine know to be important in RA pathogenesis, 
TNFα. For instance, combining IL-17 with TNFα increased IL-6 secretion in an 
additive way, compared to secretion induced solely by IL-17.  Additionally, 
the combination of IL-17 and TNFα induced GM-CSF secretion by synovial 
fibroblasts, while the two cytokines separately showed no effect on GM-CSF 
secretion [27]. In murine knee joints, overexpression of solely IL-17 or TNFα 
resulted in joint inflammation and bone erosion. When overexpressing both 
cytokines, strikingly enhanced levels of joint inflammation and destructive 
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capacity were observed. Additionally, S100A8, IL-1β, and MMP mRNA 
was strongly upregulated when both cytokines were overexpressed [46]. 
Treating mice during established arthritis with the combination of a soluble 
IL-17 receptor and TNF binding protein significantly inhibited further joint 
inflammation and cartilage destruction, more potently than either of the two 
anti-cytokine treatments alone [46].
Since IL-17 has been linked to RA pathogenesis, not only by its expression but 
also functionally in both human ex vivo systems and animal arthritis models, 
this cytokine seems the first likely candidate for the development of new anti-
rheumatic drugs.
IL-22
In addition to IL-17, Th17 cells express various other (proinflammatory) 
cytokines, amongst others IL-22. Interestingly, after stimulating this T helper 
subset with IL-23, IL-22 was the most prominent gene being expressed [47]. 
Initially, IL-22 was named the IL-10-related T cell-derived inducible factor (IL-TIF). 
As this name suggests, this cytokine is a member of the IL-10-cytokine family 
showing an amino acid identity of 22% with IL-10 [48,49]. The IL-22 receptor 
complex consists of the two subunits IL-22R1 and IL-10R2, sharing the latter 
with the anti-inflammatory protein IL-10 [50]. Both IL-22R1 and IL-10R2 are 
members of the class II cytokine receptor family which, in general, use the Jak-
Stat signaling pathway. IL-22 predominantly exerts its function by activating 
STAT3. In contrast to the IL-10R2, which is ubiquitously expressed, the IL-22R1 
expression pattern is rather restricted. This indicates that the specificity of IL-22 
activity is determined by the expression of the IL-22R1 subunit [51]. In addition 
to this IL-22 receptor complex, an IL-22-inhibiting protein was identified. At 
first, this protein was designated CRF2-10. A homology of 33% was observed 
between CRF2-10 and the IL-22R1 chain of the IL-22 receptor complex, but it 
lacked the transmembrane and cytoplasmic domains of the subunit. When 
it was shown that IL-22 activity via the receptor complex was blocked in the 
presence of CRF2-10, it was named the IL-22 binding protein [52,53].
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Relation to arthritis pathology
Recent studies demonstrated that IL-22 serum levels were increased in a large 
part of RA patients compared to healthy volunteers [21,54,55]. Those cytokine 
levels positively correlate with serum titers of rheumatoid factor and anti-cyclic 
citrullinated peptide antibodies [54]. Interestingly, 33% of the RA patients 
showing increased IL-22 serum levels suffered from bone erosions, against 
only 4% of the patients with normal serum levels of IL-22. Hence, elevated IL-
22 serum levels are significantly associated with erosive RA [55].
Treatment of RA synovial fibroblasts (RASF) with rIL-22 increased levels of 
RANKL mRNA and protein expression in a dose-dependent manner. Coculturing 
human monocytes with IL-22-prestimulated RA synovial fibroblasts lead to 
differentiation of those monocytes into osteoclasts, altogether showing the 
potential of IL-22 to induce osteoclastogenesis via upregulation of RANKL[54]. 
Moreover, addition of IL-22 to cultured RASF increased their proliferation and 
the expression of monocyte chemoattractant protein 1 (MCP-1) [56] (Figure 1). 
This chemokine recruits dendritic cells, monocytes, and memory T cells to sites 
of inflammation [57,58]. 
Mice deficient for IL-22 were shown to be less susceptible to the development 
of CIA. Both disease incidence and arthritis severity in IL-22-/- mice were 
decreased, as well as the degree of inflammation in the synovium. Additionally, 
arthritic knockout mice showed reduced hyperplasia of the synovial tissue and 
less pannus formation as compared to wild type mice [59]. Interestingly, mice 
deficient for IL-22 do not always show a protective phenotype. In concordance 
with the aforementioned knockout study, CIA mice treated with an IL-22-
neutralizing antibody before arthritis development showed less severe disease. 
It was observed that in the initiation phase of CIA IL-22 cooperated with IL-17 
to drive pathogenesis. During established disease on the other hand, IL-22 
counterregulated the proinflammatory actions of IL-17, thereby promoting 
the resolution of the experimental arthritis. In addition, in later stages of 
disease development IL-22 serum levels were shown to negatively correlate 
with arthritis scores, and local administration of IL-22 reduced inflammation in 
the joints. These data show the dual role IL-22 might play in arthritis pathology 
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[60]. In IL-1Ra-/- mice with severely inflamed synovium, increased levels of both 
IL-22 and the IL-22 receptor were observed. Treating those mice with anti-IL-
22-antibodies significantly reduced inflammation and bone erosion [61].
ADVANCES IN CYTOKINE IMMUNOTHERAPY
To control the disease process with abrogation of inflammation, Disease 
Modifying Anti-Rheumatic Drugs (DMARDs) like methotrexate (MTX) and 
sulfasalazine are administered to RA patients. In addition, progress in the 
understanding of the cellular and molecular mechanisms of RA pathogenesis 
has led to the development of a new type of treatment using biologicals. 
These biological agents can target a specific mediator of the disease, for 
example the proinflammatory cytokine TNFα. Although the development 
and use of TNFα inhibitors considerably improved prognosis of some RA 
patients, approximately 30% of patients still fail to respond adequately to 
this treatment. It was observed that in patients not responding to treatment 
with TNFα inhibitors during RA therapy, circulating Th17 cell numbers were 
significantly higher compared to patients responding to treatment [23,62,63], 
suggesting that Th17 cells and Th17-derived cytokines might be interesting 
additional therapeutic targets in RA.
Targeting Th17 development
Agents inhibiting various pathways in Th17 signaling have been developed. 
A very effective drug with one of its actions inhibiting differentiation of 
naïve T cells into Th17 cells is Tocilizumab (TCZ). This humanized monoclonal 
antibody inhibits IL-6 signaling by binding to the IL-6 receptor. Since IL-6 is 
an important cytokine in Th17 differentiation, blocking this cytokine pathway 
leads to reduced Th17 levels [64]. Clinical studies have shown that treatment 
with TCZ, either combined with DMARDs or as a single treatment, significantly 
decreased disease severity, measured as increased percentages of the ACR20, 
ACR50, ACR70, and EULAR responses. In addition, DAS28 scores and systemic 
markers such as CRP levels were decreased [65-68]. With only slightly increased 
levels of mild or moderate adverse events as compared to placebo receiving 
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controls, and very few serious adverse events [65,66], Tocilizumab has proven 
to be a very potent drug in treating RA pathology. However, not all attempts 
to reduce arthritis severity by inhibiting Th17 differentiation are as effective 
as the TCZ trials. For instance, blocking IL-23 signaling by treating patients 
with apilimod mesylate could not increase ACR20 responses [69]. In contrast, 
another drug tested in clinical trials, the JAK3 inhibitor Tofacitinib, showed 
great efficacy in reducing RA pathology. The number of RA patients reaching 
ACR20 criteria was significantly increased in patients treated with Tofacitinib. 
This drug exerts its function by blocking signaling via the JAK/STAT pathway, 
which is important in Th17 differentiation. In vitro experiments have shown 
that by incubation of CD4+ T cells with Tofacitinib, proliferation as well as 
differentiation into Th17 cells was inhibited [70,71]. Moreover, this reduced T 
cell proliferation was confirmed in Tofacitinib treated SCID mice [71]. 
RORγt is a transcription factor required for induction of IL-17 transcription 
by Th17 cells, and might be inhibited for therapeutic purposes as well. Two 
separate molecules have shown to successfully block RORγt activity. Firstly, the 
SR1001 high-affinity synthetic ligand specifically binds to RORγt. Thereby, it 
diminishes the affinity for co-activators and increases affinity for co-repressors. 
Hence, transcriptional activity of RORγt is suppressed, resulting in inhibited 
differentiation of Th17 cells. No clinical studies have been performed with this 
drug yet, but in murine autoimmune models it showed effective suppression 
of the disease [72]. The second RORγt inhibitor is digoxin, which blocks the 
activity of the transcription factor by binding to its ligand binding domain. 
Thereby, Th17 differentiation is suppressed as demonstrated in murine and 
human CD4+ T cells, as well as in a murine autoimmune disease model [73,74].
In addition, well-known drugs already long-time approved and used in 
RA treatment, MTX, Anakinra and Rituximab, were shown to have an effect 
on Th17 levels. When MTX and Anakinra (an IL-1 receptor antagonist) were 
administered to patients as a combination treatment, significantly decreased 
levels of Th17 were observed, as well as decreased levels of IL-21 in serum [75]. 
Furthermore, treatment of patients with Rituximab (a monoclonal antibody 
resulting in depletion of CD20-positive (B) cells) inhibited Th17 responses. This 
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was associated with a decrease in inflammation and better clinical outcome. 
Interestingly, this Th17 inhibition was lost in the absence of B lymphocytes, 
indicating that B cells are able to modulate Th17 responses. After 12 weeks of 
Rituximab treatment, a clear reduction in Th17 cell number was observed, as 
well as decreased levels of IL-17, IL-21, and IL-22 [76].
Recently, various other Th17-regulating components have been tested. Ursolic 
acid (UA) is found in most plant species, and has been shown to exert anti-
inflammatory and anti-oxidative activities. Treatment of CIA mice significantly 
reduced the incidence and severity of the disease. Additionally, reduction of 
pSTAT3, IL-17, RORγt, and Th17 cells were observed. This inhibitory effect of UA 
was confirmed in an in vitro model of Th17 differentiation [77]. Furthermore, 
ARID-5A was shown to inhibit RORγt-induced Th17 differentiation, 
accompanied by reduced production of IL-17 [78]. Further research into these 
compounds is required, but both may have great therapeutic potential in 
suppressing Th17-related autoimmune diseases like RA.
Suppression of IL-17 signaling
In addition to drugs targeting the differentiation of Th17 cells, various 
immunotherapies have been developed targeting the main effector side of 
the Th17 cell, the IL-17 signaling pathway. Combined treatment of RA patients 
with DMARDs and Ixekizumab, an anti-IL-17 antibody, significantly decreased 
DAS28 scores. In addition, increased percentages of ACR20, ACR50, and ACR70 
responders were observed, without the presence of any serious adverse events 
[79]. Another anti-IL-17 antibody, Secukinumab, suppressed RA severity as 
well. Unfortunately, Genovese et al showed that this suppression was not as 
effective as with Ixekizumab, since only non-significant positive trends towards 
some individual ACR components were observed [80]. However, Hueber et 
al showed that Secukinumab treatment of RA patients did induce clinically 
relevant responses [81]. What causes this inconsistency in results is unclear, 
baseline Th17 levels between the patients in the separate studies might have 
been different, subsequently leading to different IL-17-responses. Momentarily, 
plural clinical trials are in process testing Secukinumab efficacy and safety in 
RA patients, which could possibly clarify the potency in RA treatment [82-85].
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Not only the Th17 cytokine itself, but also its cytokine receptor is a target of 
drug development for RA treatment, albeit less effective. The anti-IL-17 receptor 
antibody Brodalumab did not induce a clinical response in RA patients [86]. 
Interestingly, this antibody was shown to decrease disease severity in patients 
with Psoriatic Arthritis (PA). PA patients treated with Brodalumab showed 
higher percentages of ACR20 and ACR50 responses as compared to placebo 
controls [87,88]. This shows that, even though the same cell types are involved 
in their pathogenesis, the diseases are not the same and therefore may require 
different ways of treatment.
Finally, a therapeutic approach using active immunization against IL-17 has 
been tested. High levels of anti-IL-17 antibodies were induced by immunization 
of mice with IL-17 virus-like particles. Those mice showed reduced disease 
incidence and severity, as well as slower disease progression after induction of 
CIA [89]. Using IL-17 virus-like particles might therefore be an interesting new 
way to target IL-17 signaling.
IL-22
Hitherto, no results of clinical trials are reported targeting either the IL-22 
cytokine itself, or the IL-22 receptor complex. Nevertheless, it has been shown 
that by incubating FLS with the vasoactive intestinal peptide (VIP), expression 
of the IL-22 receptor 1 subunit is down regulated both on mRNA as well as on 
protein level. Subsequently, the IL-22 stimulatory effects on FLS are suppressed 
[90]. However, thus far only in vitro results are published, and animal studies 
using VIP in a RA setting have to be performed to confirm the efficacy of VIP on 
IL-22 signaling and RA development and progression.
Currently, various clinical trials targeting the IL-22 pathway are in process, and 
one trial assessing the safety and efficacy of different doses of an anti-IL-22 
antibody in RA patients has been completed [91]. Unfortunately, no results of 
this phase II clinical trial have been published thus far.  
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CONCLUDING REMARKS
The emerging evidence clarifying the significant role that Th17 cells and 
cytokines play in RA pathology has put the focus on targeting this pathway in 
RA therapy. Various treatments targeting this pathway have been developed, 
or are currently under development. Although not all effective, the majority 
of Th17-targeting treatments have shown to potently suppress symptoms of 
a large group of RA patients. However, while developing new drugs we have 
to bear in mind that blocking the Th17 pathway, a pathway protecting us from 
various bacteria and fungi could increase the risk of developing infections 
by those organisms. In addition, IL-22 has been shown to play a dual role in 
various auto inflammatory mouse models [47,60,92,93], so extra attention is 
required when blocking IL-22 in clinical trials. The largest therapeutic potential 
might be achieved by blocking both IL-17 and IL-22 with one component. 
An interesting, promising, new technology for targeting multiple antigens in 
such a way is the peptide-antibody genetic fusion. Recently, a fusion molecule 
using an IL-17 binding peptide and an anti-IL-22 antibody has been developed 
[94]. This fusion protein has not yet been tested in in vivo settings, but the 
methods sounds promising. Taken together, targeting the Th17 pathway 
shows great therapeutic potential in treating RA, and together with other new 
developments like the aforementioned anti-IL-22 antibodies and IL-17/IL-22-
fusion protein, will have a significant impact on life quality of patients suffering 
from RA. 
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ABSTRACT
Objective. IL-22 is a T cell-derived cytokine that has both pro- and anti-
inflammatory functions. High IL-22 levels are detected in serum and synovium 
of rheumatoid arthritis (RA) patients and have been shown to positively 
correlate with disease activity markers and more erosive disease. In lung 
inflammation, the presence of IL-17 has been suggested to determine the 
inflammatory effect of IL-22, being protective in the absence, and pathogenic 
in the presence of IL-17. Nevertheless, the exact contribution of IL-22 to RA 
pathology remains unclear. Therefore, we aimed to further elucidate the role 
of IL-22 during experimental arthritis, focusing on cytokine interactions within 
the inflammatory environment. 
Methods. To investigate the potential of IL-22 to drive joint inflammation and 
destruction, IL-22 was overexpressed using an adenoviral construct, alone or 
in combination with IL-17, TNF or IL-1. Adenoviruses were injected into the 
knee joint of  naïve mice or during streptococcal cell wall (SCW) or K/BxN 
serum-transfer arthritis, both T cell- and IL-22-independent arthritis models. 
Furthermore, the role of IL-22 in the pathogenesis of T cell-driven arthritis 
was studied by additional gene deletion for IL-22 in the spontaneous IL-1Ra-/- 
mouse model. In these IL-1Ra-/-IL-22-/-  double-knockout mice, the effect of 
additional anti-IL-17 treatment was investigated using neutralizing antibodies. 
Results. Despite the rapid upregulation of catabolic genes like IL-6, KC, 
S100A9 and RANKL in the synovium, IL-22-overexpression neither induced 
joint pathology in naïve mice, nor aggravated disease severity during innate 
immune-driven experimental arthritis. Additionally, IL-22 did not affect IL-
17-, IL-1β-, or TNFα-induced joint inflammation. Interestingly, compared to 
the spontaneous arthritis development in classical IL-1Ra-/- mice, the absence 
of IL-22 significantly reduced disease incidence and severity in this model. 
In line with suppressed arthritis development, anti-hnRNP autoantibodies 
were reduced in IL-1Ra-/-IL-22-/- mice. Remarkably, in the absence of IL-22 the 
therapeutic efficacy of anti-IL-17 treatment on arthritis progression was lost. 
Conclusion. Our overexpression studies show that addition of IL-22 to a local 
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arthritis process does not affect the course of disease. Furthermore, the IL-
1Ra-/- experiment not only confirms the pro-inflammatory role of IL-22 in the 
development of T cell-driven experimental arthritis, it also demonstrates a 
novel role for IL-22 in the formation of anti-hnRNP autoantibodies. Finally, we 
demonstrated  that the presence of IL-17 is not a determinant for the pro- or 
anti-inflammatory character of IL-22 in experimental arthritis.
INTRODUCTION
Rheumatoid Arthritis (RA) is a chronic autoimmune disease primarily 
involving the synovial joints. It is characterized by chronic inflammation 
causing damage to bone and cartilage of affected joints, resulting in pain 
and functional disabilities in patients suffering from this disease [1]. In RA 
patients, the concentration of IL-22 in synovial fluid was higher compared with 
osteoarthritis (OA) patients [2], and increased serum levels of interleukin (IL)-22 
have been observed as compared to healthy controls [2-4]. Those serum levels 
not only correlated with disease activity score (DAS)28 [4], but also with serum 
levels of rheumatoid factor (RF) [2,4] and anti-cyclic citrullinated peptide (CCP) 
antibodies [2]. Additionally, patients with high IL-22 serum levels showed more 
severe bone erosions [2,4]. 
Important IL-22-producers are Th17 cells [5], but the cytokine is also produced 
by Th22 cells [6], γδ T cells [7], NK T cells [8], and group 3 innate lymphoid cells 
(ILC3) [9]. Reported data on IL-22 in experimental arthritis show both pro- 
and anti-inflammatory actions for this cytokine. Its role in autoimmunity and 
inflammation appears to be contradictory [10-14], and has been suggested 
to be determined by the presence or absence of IL-17 in a model for airway 
inflammation [15]. The exact function of this cytokine in experimental arthritis 
remains poorly defined. Therefore, the purpose of our study was to further 
unravel the role and mechanism of action of IL-22 during experimental arthritis, 
in particular focusing on the cytokine interactions within the inflammatory 
environment.
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MATERIALS AND METHODS
Mice. C57BL/6N mice were purchased from Janvier-Elevage (Le Genest Saint 
Isle, France). IL-1Ra-/- mice on a BALB/c background were kindly provided 
by Dr. Martin Nicklin (University of Sheffield, UK), and IL-22-deficient mice 
on a BALB/c background were kindly provided by Pfizer. IL-1Ra-/-IL-22-/- mice 
were bred in our own facility. Animals were used between 10 and 12 weeks 
of age unless specified otherwise, and were housed in filter-top cages under 
specific pathogen-free conditions. A standard diet and water were provided ad 
libitum. Before being sacrificed by cervical dislocation, mice were anesthetized 
using 2-3% isoflurane to enable blood collection. All procedures performed 
on animals in this study were in accordance with established guidelines and 
regulations, and were reviewed and approved by the animal ethics committee 
of the Radboud University Nijmegen.
Adenoviral vectors. The adenoviral expression vector for murine (m)IL-22 
(AdIL-22), mIL-17 (AdIL-17), and mTNFα (AdTNFα)  were kindly provided by 
Dr. Jay K. Kolls (Children’s Hospital of Pittsburgh, Pittsburgh), the adenoviral 
expression vector for human (h)IL-1β (AdIL-1β) was a kind gift of Dr. Carl D. 
Richards (McMaster University, Ontario, Canada), and the adenoviral construct 
for luciferase (AdLuc) was generated in-house. All viruses are replication-
deficient and have the transgene under control of a CMV promoter. 1 x 107 
plaque-forming units of adenoviruses were injected intra-articularly (i.a.) in 
naïve mice, or one day prior to induction of streptococcal cell wall (SCW) or K/
BxN serum-transfer arthritis.
Induction of K/BxN serum-transfer arthritis. K/BxN T cell receptor-
transgenic mice on a C57BL/6 background (K/B) were a kind gift from Prof. 
Christophe Benoist and Prof. Diane Mathis (Harvard Medical School, Boston, 
MA). By crossing K/B mice with NOD/Lt animals, arthritic K/BxN mice were 
obtained in the Nijmegen animal facility. 150µl serum derived from those mice 
was injected intraperitoneally (i.p.) in C57BL/6N mice on day 0 and on day 2. 
Mice were sacrificed on day 4 or day 7 of the experiment, and knee joints were 
subsequently isolated for histological analysis.
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Induction of streptococcal cell wall arthritis. Streptococcus pyogenes T12 
organisms were cultured overnight in Todd-Hewitt broth. Cell wall fragments 
were prepared as described previously [16]. Arthritis was subsequently 
induced by injecting 25 µg SCW fragments into the knee joints of C57BL/6N 
mice, resulting in local, acute inflammation. Mice were sacrificed by cervical 
dislocation seven days after arthritis induction, and knee joints were 
subsequently isolated for histological analysis.
Spontaneous arthritis development in IL-1Ra-/- mice. IL-22-/- mice were 
crossed with the arthritis-susceptible IL-1Ra-/- mice. IL-1Ra-/-IL-22+/+ and IL-
1Ra-/-IL-22-/- mice were scored weekly for arthritis incidence and severity from 
the age of 5 weeks until sacrifice at the age of 15 weeks. Macroscopic disease 
severity was scored on a scale of 0-2 per hind paw, 0-4 per mouse. At the end 
of the study, serum was collected to determine autoantibody levels using 
ELISA, ankle joints were collected for histological analysis, and popliteal and 
inguinal lymph nodes were isolated to determine T cell populations using flow 
cytometry. In a subsequent therapeutic study, arthritic IL-1Ra-/- mice either 
wild-type or deficient for IL-22 were treated with anti-IL-17 antibodies (125 
µg/mouse; MAB421; R&D Systems, Minneapolis, MN, USA) or rat IgG2A isotype 
control (R&D Systems) twice a week by intraperitoneal injections. Treatment 
was started in established arthritis, with mice having a total macroscopic score 
of 0.5 - 0.75 on a scale of 0-4, and after a treatment period of four weeks, mice 
were sacrificed and ankle joints were collected for histological analysis. 
Histology. Isolated joints were fixed for at least four days in 4% formaldehyde, 
decalcified in 5% formic acid, and subsequently dehydrated and embedded in 
paraffin. Standard frontal sections of 7 µm were mounted on SuperFrost slides 
(Menzel-Gläser, Braunschweig, Germany). H&E staining, and SO staining were 
performed to study pathologic features of the joint. The severity of arthritis in 
the joints was scored on an arbitrary scale of 0-3, where 0 = no pathology and 
3 = maximal pathology, as previously described for three different parameters 
(joint inflammation, proteoglycan (PG) depletion from the cartilage matrix, and 
bone erosion) [17]. Histopathological changes were scored on three semiserial 
sections of the joint, spaced 140 µm apart, in a blindfolded manner.
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mRNA isolation and quantitative real-time PCR. For mRNA isolation of 
the synovial tissue, lateral and medial pieces were punched out from mouse 
synovium surrounding the patella, using a 3 mm biopsy punch (Stiefel, 
Wachtersbach, Germany). The synovial punches were pooled per knee 
joint and immediately frozen in liquid nitrogen. Subsequently, the punches 
were disrupted and homogenized using the MagNA Lyzer (Roche, Basel, 
Switzerland). Total RNA was isolated using TRIzol reagent (Sigma-Aldrich, Saint 
Louis, MO, USA), according to manufacturer’s protocol. After isolation, RNA 
was treated with DNAse, and reverse-transcribed into complementary DNA 
(cDNA) as previously described [12]. Gene expression levels were determined 
on the StepOnePlus sequence detection system (Applied Biosystems, Foster 
City, CA, USA) using SYBR Green technology (Applied Biosystems) and 2µM 
primers (Biolegio, Malden, the Netherlands). Primer sequences were as follows: 
Gapdh 5’-GGC-AAA-TTC-AAC-GGC-ACA-3’ (forward) and 5’-GTT-AGT-GGG-
GTC-TCG-CTC-CTG-3’ (reverse); IL-22 5’-GGT-GCC-TTT-CCT-GAC-CAA-AC-3’ 
(forward) and 5’-CGT-CAC-CGC-TGA-TGT-GAC-A-3’ (reverse); Tnfα 5’-CAG-ACC-
CTC-ACA-CTC-AGA-TCA-TCT-3’ (forward) and 5’-CCT-CCA-CTT-GGT-GGT-TTG-
CTA-3’ (reverse); Il-6 5’-CAA-GTC-GGA-GGC-TTA-ATT-ACA-CAT-G-3’ (forward) 
and 5’-ATT-GCC-ATT-GCA-CAA-CTC-TTT-TCT-3’ (reverse); Kc 5’-TGG-CTG-GGA-
TTC-ACC-TCA-A-3’ (forward) and 5’-GAG-TGT-GGC-TAT-GAC-TTC-GGT-TT-3’ 
(reverse); S100a9 5’-GGC-AAA-GGC-TGT-GGG-AAG-T-3’ (forward) and 5’-CCA-
TTG-AGT-AAG-CCA-TTC-CCT-TTA-3’ (reverse); Mcp1 5’-TTG-GCT-CAG-CCA-
GAT-GCA-3’ (forward) and 5’-CCT-ACT-CAT-TGG-GAT-CAT-CTT-GCT-3’ (reverse); 
Mmp3 5’-TGA-AGC-CAC-CAA-CAT-CAG-GA-3’ (forward) and 5’-TGG-AGC-TGA-
TGC-ATA-AGC-CC-3’ (reverse); Mmp9 5’-GGA-ACT-CAC-ACG-ACA-TCT-TCC-A-3’ 
(forward) and 5’-GAA-ACT-CAC-ACG-CCA-GAA-GAA-TTT-3’ (reverse); Rankl 
5’-CTG-AGG-CCC-AGC-CAT-TTG-3’ (forward) and 5’-GTT-GCT-TAA-CGT-CAT-
GTT-AGA-GAT-CTT-G-3’ (reverse). Specific gene expression was normalized for 
expression of the reference gene Gapdh. To allow for statistical analysis, the 
-ΔCt value of samples with mRNA levels below detection limit was set at -30.
Cytokine and chemokine measurements. Isolated synovium was cultured in 
200 µl RPMI 1640 medium containing 0.1% BSA for 1 hour at room temperature. 
Subsequently, supernatant was harvested and centrifuged for 5 minutes at 
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1000 x g. Cytokine levels in synovial washouts and murine serum samples were 
determined using the Luminex multi-analyte technology, in combination with 
BioRad cytokine kits (BioRad) according to manufacturer’s protocol.
Flow cytometry. Cells isolated from joint draining popliteal and inguinal lymph 
nodes or spleen were stimulated for four hours with phorbol myristate acetate 
(PMA; 50 ng/ml; Sigma-Adrich), ionomycin (1 µg/ml; Sigma-Aldrich), and the 
Golgi-traffic inhibitor Brefeldin (1 µl/ml; BD Biosciences, Franklin Lakes, NJ, 
USA). Next, cells were stained with anti-CD3-PE (BD Biosciences) or anti-CD3-
APC (eBioscience, San Diego, CA, USA) and anti-CD4-FITC (BD Biosciences) or 
anti-CD4-APC (Biolegend, San Diego, CA, USA), fixed and permeabilized using 
BD Cytofix/Cytoperm (BD Biosciences), followed by intracellular staining with 
anti-IL-17-FITC (Biolegend), anti-IFNγ-FITC (BD Biosciences), anti-IL-4-PE (BD 
Biosciences), anti-FOXP3-FITC (eBioscience), or appropriate isotype-matched 
control antibodies. Cells were measured on a FACSCalibur using CellQuest 
software (BD Biosciences), and analyzed using FlowJo software (version 7.6.5).
Measurement of total IgG level. Total IgG antibody levels were determined 
in serum of IL-1Ra-/- mice using enzyme-linked immunosorbent assay (ELISA). 
In short, 10 µg of goat-anti-mouse-IgG antibodies (Sigma-Aldrich) were coated 
onto flat-bottom 96-well Nunc-immunoplates (Thermo Scientific, Waltham, 
MA, USA) overnight. Nonspecific binding sites were blocked with 1% BSA in 
PBS-Tween (0.05%). Serial dilutions of mouse IgG1 (DAKO, Glostrup, Denmark) 
and serum samples were incubated for 1 hour at room temperature, before 
adding horseradish peroxidase (HRP)-labeled secondary goat-anti-mouse-IgG 
antibodies (1:2000; Southern Biotech, Birmingham, AL, USA). After incubation 
for another hour, 5-aminosalicyclic acid was added as a substrate, and 
absorbance was subsequently measured at 450nm.
Measurement of anti-hnRNP autoantibodies. Anti-hnRNP antibody 
levels were determined in serum of IL-1Ra-/- mice using ELISA. 0.5µg hnRNP 
protein was coated onto flat-bottom 96-well Nunc-immunoplates (Thermo 
Scientific) overnight. Nonspecific binding sites were blocked with RotiBlock 
(Carl Roth GmbH, Karlsruhe, Germany). Serum samples were incubated for 1 
hour at room temperature, before adding HRP-labeled secondary rabbit-anti-
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mouse-Ig antibodies (DAKO, Glostrup, Denmark). After 45 minutes incubation, 
SeramunBlau fast (Seramun Diagnostica GmbH, Heidesee, Germany) was 
added as a substrate, absorbance was subsequently measured at 450nm.
Statistical analysis. To determine the level of statistical significance between 
means of experimental groups, the t-test, the Kruskal-Wallis with a Dunn’s post-
test, or a one- or two-way ANOVA with a Dunn’s or Bonferonni post-test was 
used. P values less than 0.05 are considered significant. Results are expressed 
as Tukey boxplots.
RESULTS
IL-22 overexpression does not induce joint pathology in naïve mice
To determine the potency of IL-22 to induce joint inflammation and damage 
as a single cytokine, IL-22 adenovirus (AdIL22) or a negative control adenovirus 
encoding for Luciferase (AdLuc) was injected into the knee joints of naïve 
C57BL/6N mice. Efficacy of AdIL-22 transduction and functionality of resulting 
protein was assessed by determining mRNA expression and protein levels 
of IL-22 and other (pro-) inflammatory mediators in synovium and synovial 
washouts. Both IL-22 mRNA and protein levels were increased in mice receiving 
intra-articular AdIL-22, peaking up to 1300 pg/ml IL-22 at day 1, whereas no IL-
22 was detected in the AdLuc control group (Figure 1A and 1B). 
In addition, we detected significantly increased synovial mRNA expression of 
IL-6, KC, S100A9, and RANKL 6 hours after AdIL-22 transduction, as compared 
to AdLuc-injected joints. Accordingly, we observed a trend towards increased 
IL-6 and KC protein levels after 6 hours of IL-22 overexpression, but this 
proinflammatory response was already lost after one day. Other arthritis-
related cytokines like IL-1β and TNFα were not upregulated by excessive IL-22 
(data not shown). Interestingly, despite the rapid but transient upregulation of 
various proinflammatory and prodestructive mediators, the overexpression of 
IL-22 did not result in a clear influx of inflammatory cells in the synovial lining 
and joint cavity, in contrast to the pronounced joint pathology observed four 
days after IL-17, TNFα and IL-1β overexpression (Figure 1C & upper panel 1D). As 
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IL-22 has been suggested to interact with other (pro-) inflammatory cytokines 
to exert its effects [14,15], we assessed the effect of combined overexpression 
of IL-22 with a selection of arthritis-related cytokines, namely IL-17, TNFα, or IL-
1β, on inducing joint pathology. Whereas these three key-cytokines potently 
induced joint inflammation when overexpressed as single cytokine, no effects 
of an additional IL-22 overexpression were observed in this process (Figure 1C 
& lower panel 1D).
Figure 1. No effect of IL-22 overexpression on joint pathology in naïve mice. AdIL-22 or 
AdLuc control virus was injected in the knee joint of naïve mice. Synovium was isolated 6 hours 
after virus administration, and relative mRNA expression of various inflammatory and destructive 
genes in AdIL-22 receiving mice as compared to AdLuc receiving mice was determined using 
qPCR (A; IL-22 left Y-axis; TNFα, IL-6, KC, S100A9, MCP1, MMP3, MMP9, and RANKL right Y-axis). 
In addition, synovium was incubated for 1 hour in RPMI medium upon isolation 6 hours, 1 day, 
or 4 days after virus administration. Protein levels in synovial washouts were determined using 
Luminex (B). AdIL-22 was injected either alone or in combination with AdIL-17, AdTNFα, or AdIL-
1β as indicated. Joint inflammation was scored on histological slides four days after injection 
(C & D; representative images of knee joints; original magnification 50x). n=6/group; *P<0.05, 
**P<0.01, ***P<0.001 versus AdLuc; One-way ANOVA. ns, not significant.
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Overexpression of IL-22 does not aggravate joint pathology during K/BxN 
serum transfer- and SCW arthritis
As a T cell-derived cytokine, IL-22 has been studied quite extensively, and 
described to have both pro- and anti-inflammatory properties, in various 
chronic, T cell-driven arthritis models [10-14], whereas IL-22 studies using acute, 
innate-driven arthritis models are lacking. In the absence of detectable levels 
of endogenous IL-22 to follow a blocking strategy (personal observations), 
we aimed to elucidate whether overexpression of IL-22 would aggravate the 
immune-complex-dependent K/BxN serum transfer (ST) arthritis, or the toll 
like receptor (TLR) 2-driven SCW-arthritis. To ensure high IL-22 protein levels 
at time of arthritis onset, we injected C57BL/6N mice intra-articular (i.a.) with 
AdIL-22 or AdLuc one day prior to the induction of the K/BxN serum transfer 
arthritis model, which depends on the presence of immunoglobulins (Ig), 
complement, and other pro-inflammatory mediators in arthritogenic serum 
passively transferred into naïve mice [18]. Unfortunately, excessive levels of IL-
22 did not affect joint inflammation, nor did it affect cartilage PG depletion in 
the knee joints of mice during K/BxN ST arthritis (Figure 2A & B). Subsequently, 
we injected C57BL/6N mice i.a. with AdIL22 or AdLuc one day prior to the 
induction of SCW-arthritis. Once again, mice overexpressing IL-22 did not 
show any differences in severity of joint inflammation as compared to mice 
receiving AdLuc (Figure 2C & D). A minor trend was observed towards reduced 
PG depletion in the presence of IL-22, but overall IL-22 did not seem to affect 
this innate immune-driven arthritis model. 
As IL-22 has been described to be pro-inflammatory in the presence, and 
protective in the absence of IL-17 in a model for airway inflammation [15], 
we were interested in determining the effect of combined IL-22/IL-17 
overexpression in a controlled arthritis setting. As previously described [19], 
overexpression of IL-17 during SCW-arthritis significantly increased joint 
inflammation. Interestingly, no additional or synergistic effects were observed 
of combined overexpression of the two T cell cytokines IL-17 and IL-22 (Figure 
2C & D). In contrast to our hypothesis, our data suggests that the combination of 
IL-22 and IL-17 even induced a minor trend towards reduced joint inflammation 
and cartilage proteoglycan loss compared to IL-17 overexpression alone.
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Arthritis development is potently reduced in mice lacking functional 
interleukin-22 
As our K/BxN serum transfer arthritis and SCW arthritis studies indicated 
that addition of IL-22 to an acute joint inflammation does not affect innate 
immune-driven experimental arthritis, we aimed to further investigate the 
role of this cytokine in a chronic arthritis model depending on adaptive 
immunity. Hence, IL-1Ra-/- mice were crossed with mice lacking expression 
of IL-22. IL-1Ra-/- mice spontaneously develop arthritis because of excessive 
Figure 2. IL-22 overexpression does not affect K/BxN serum- or SCW- induced arthritis 
pathology. C57BL/6N mice received i.p. serum of arthritic K/BxN mice one and three days 
after AdIL-22 and AdLuc injection, to induce pathology. Mice were sacrificed 4 or 7 days after 
arthritis induction, and inflammation and PG depletion of the knee joint subsequently analyzed 
(A & B; representative images of knee joints isolated at day 4; original magnification H&E 50x, 
SafO 100x). n=6/group/day; One-way ANOVA. C57BL/6N mice received i.a. AdIL-22, AdIL-17, 
the combination of the two viruses, or AdLuc injections one day prior to SCW administration. 
Mice were sacrificed 7 days after SCW injection, and knee joint inflammation and PG depletion 
were analyzed on histological slides (C & D; original magnification H&E 50x, SafO 100x, pictures 
show representative joints per group). n=4-6/group; *P<0.05, **P<0.01, versus AdLuc; One-way 
ANOVA. Ad, adenovirus; SCW, streptococcal cell wall; ns, not significant.
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IL-1β signalling, which has previously been shown to be dependent on IL-17 
and T cells, with a prominent role for Th17 cells [20-22] [1]. While the arthritis 
incidence in regular IL-1Ra-/- mice reached up to 95% at the age of 15 weeks, 
IL-1Ra-/- mice also deficient for IL-22 only showed 50% disease onset (Figure 
3A). Concordantly, macroscopic disease severity was significantly reduced in 
IL-1Ra-/-IL-22-/- double-knockout mice that did develop arthritis as compared 
to IL-1Ra-/-IL-22+/+ mice (Figure 3B). Of note, several mice of both genotypes 
without clinical signs of arthritis showed joint inflammation and destruction on 
a histological level, therefore we included all mice in the histological analysis. 
Upon scoring the histopathology, we observed reduced joint inflammation 
Figure 3. Reduced arthritis development in IL-1Ra-/- x IL-22-/- mice. Macroscopically 
determined arthritis incidence (A; IL22+/+ n=43, IL22-/- n=52) and severity (B; IL22+/+ n=40, 
IL22-/- n=31; repeated measures ANOVA) in IL-1Ra-/- mice with (IL-22+/+) or without (IL-22-/-) 
expression of IL-22. Mice that did not develop arthritis were excluded when analyzing arthritis 
severity. Histologically scored ankle joint inflammation, PG depletion, and bone erosion (C & 
D; original magnification H&E 50x, SafO 100x, pictures show representative joints per group; 
IL22+/+ n=16, IL22-/- n=6; One-way ANOVA). *p<0.05 versus IL-22+/+.
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in IL-1Ra-/- mice deficient for IL-22, and also significant protection against 
proteoglycan (PG) loss from the cartilage and erosion of bone surfaces (Figure 
3C & D). Overall, these data show a clear proinflammatory role for IL-22 in this 
chronic arthritis model depending on adaptive immunity. 
IL-22 deficiency reduces anti-hnRNP autoantibody production by B cells, 
without affecting T cell subset composition
As IL-17/Th17 cell-mediated experimental arthritis was described to be 
independent of IL-22 [23], we aimed to confirm that IL-22-deficiency in this 
IL-1Ra-/- model did not affect T cell responses. Using flow cytometry it was 
demonstrated that Th1, Th2, Th17, and regulatory T cell (Treg) levels in draining 
lymph nodes (dLN) and spleen were indeed not changed in the absence of IL-
22 (Figure 4A). 
Subsequently, as IL-22 was shown to affect B cell immunity and drive anti-
collagen type II antibodies in collagen-induced arthritis [11], we assessed total 
IgG levels in serum to elucidate whether IL-22 is involved in (auto)antibody 
production by B cells in this arthritis model. In line with the T cell responses, 
no effect of the IL-22-deficiency was detected on total IgG levels (Figure 4B). 
However, when specifically analyzing hnRNP-targeting autoantibody titers, 
a significant reduction in anti-hnRNP-D, anti-hnRNP-DL, and anti-hnRNP-B1 
autoantibodies was detected (Figure 4C), indicating that IL-22 is associated 
with anti-hnRNP autoantibody production by B cells. 
No additional effects of combined over single IL-22/IL-17 blockade
As the IL-1Ra-/- model showed a clear role for IL-22 without affecting the Th17 
subset (Figure 4A), and this arthritis model was previously demonstrated to be 
effectively suppressed by anti-IL-17 treatment [20], we assessed the effect of 
combination blockade on the development of spontaneous arthritis in these 
mice using IL-1Ra-/- x IL-22-/- mice and neutralizing anti-IL-17 antibodies. As 
previously shown, mice solely lacking active IL-22 or IL-17 showed significantly 
reduced macroscopic arthritis scores (Figure 5A). Surprisingly, this reduction 
in clinical joint inflammation was not increased when both IL-22 and IL-17 
pathways were blocked. Our macroscopic observations were confirmed at 
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histological level, as no additional effect of the combination blockade was 
observed when quantifying the histological inflammation, cartilage PG 
depletion, and bone erosion (Figure 5B). This indicates that both IL-17 and IL-
22 contribute to this adaptive immune-driven arthritis model in what seems to 
be an overlapping downstream pathway, and that in the absence of IL-22 the 
therapeutic efficacy of anti-IL-17 treatment on arthritis progression in these 
mice is lost. 
Figure 4. Reduced anti-hnRNP-autoantibody production in IL-1Ra-/- x IL-22-/- mice. Flow 
cytometric analysis of T cell markers on cells isolated from draining lymph nodes (LN) or spleen 
of IL-22+/+ and IL-22-/- mice (A; IFNγ for Th1, IL-4 for Th2, IL-17 for Th17, FOXP3 for regulatory T 
cells; IL22+/+ n=8, IL22-/- n=6). Serum total IgG levels as measured using ELISA (B; IL22+/+ n=16, 
IL22-/- n=14). Serum anti-hnRNP-autoantibody titers as measured using ELISA (C; IL22+/+ n=16, 
IL22-/- n=14). *p<0.05, **p<0.01, versus IL-22+/+; T-Test.
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DISCUSSION
Numerous studies investigating the role of IL-22 in animal models for various 
autoinflammatory diseases have been described, and report both pro- and anti-
inflammatory properties for this cytokine. In models for inflammatory bowel 
disease (IBD), IL-22 plays a protective role [24-26], whereas it was described to 
be pathogenic in animal models for skin and airway inflammation [15,27]. In 
the latter model, mice also lacking IL-17 signaling showed exacerbated disease, 
suggesting that IL-22 is protective in the absence of IL-17. Interestingly, reported 
data describing the role of IL-22 in models for rheumatoid arthritis appear to 
Figure 5. No additive effect of IL-17 neutralization in IL-1Ra-/- mice deficient for IL-22. 
Macroscopic arthritis severity in IL-1Ra-/- mice with (IL-22+/+) or without (IL-22-/-) expression 
of IL-22, treated with neutralizing antibodies targeting IL-17 or appropriate isotype control (A; 
Two-way ANOVA). Histological joint inflammation, PG depletion, and bone erosion (B; original 
magnification H&E 50x, SafO 100x, pictures show representative joints per group; One-way 
ANOVA). *p<0.05, **p<0.01, ***p<0.001 versus IL-22+/+ + isotype; n=12/group.
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be contradictory, leaving the exact function of IL-22 in experimental arthritis 
poorly defined. Here, we show that overexpression of IL-22 in a naïve joint or 
during local experimental arthritis does not affect joint pathology. Furthermore, 
we confirm the pro-inflammatory role of IL-22 in the development of T cell-
driven experimental arthritis, without IL-17 being a determinant for the pro- or 
anti-inflammatory character of IL-22. Most interestingly, we demonstrated a 
novel role for IL-22 in the formation of anti-hnRNP autoantibodies during T 
cell-dependent experimental arthritis.  
All data reported on the function of IL-22 in experimental arthritis are 
describing studies using adaptive immune-driven models, which is from the 
point of blocking or deletion studies valid as IL-22, mainly a T cell cytokine, is 
not observed during acute inflammation. On the other hand, various in vitro 
studies showed a direct effect of IL-22 on a range of innate immune cells. For 
instance, it has been shown to stimulate osteoclastogenesis by promoting 
RANKL ligand expression on RA synovial fibroblasts (RASF) [2]. Additionally, 
stimulation of RASF with IL-22 increased their proliferation and expression of 
MCP-1, a chemokine recruiting amongst others dendritic cells and monocytes 
to inflammatory sites [28]. Hence, an effect of supplementing or overexpressing 
IL-22 in innate immune-driven arthritis might be expected, and is therefore 
worthwhile to investigate. Unexpectedly, adenoviral IL-22 overexpression did 
not induce joint pathology in naïve mice, nor did it aggravate severity of innate 
immune-driven arthritis in mice with K/BxN serum transfer- or SCW-induced 
arthritis, although it caused a rapid upregulation of proinflammatory cytokines. 
However, we also observed that the upregulation of IL-22-induced mediators 
was already greatly diminished after 24 hours, while the expression of IL-22 
peaked at this time point. This discrepancy suggests that the proinflammatory 
effects of IL-22 may be inhibited by negative feedback mechanisms (like SOCS), 
and thereby apparently too short to induce or aggravate joint pathology. 
To assess whether IL-22 interacts with other (pro-) inflammatory cytokines to 
exert its effects, we combined viral IL-22 overexpression in naïve mice with 
overexpression of a selection of arthritis-related cytokines, namely IL-17, TNFα, 
or IL-1β. Here, the joint pathology induced by these cytokines was not affected 
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by IL-22. As IL-22 was suggested to interact with IL-17 to exert pro-inflammatory 
effects in another inflammatory disease model [15], we investigated whether a 
similar mechanism applies during experimental arthritis. Hence, we combined 
overexpression of IL-22 and IL-17 in mice with SCW-induced experimental 
arthritis. Surprisingly, although IL-17 aggravated arthritis as previously 
described [19], no additional effect of dual overexpression was observed, 
indicating the suggested link between IL-22 and IL-17 is not present in this 
arthritis model. 
In contrast to what has been reported on various in vitro studies where a direct 
effect of IL-22 on various innate immune cells was observed [2,28], our studies 
show no effect of local IL-22 overexpression on joint pathology of naïve joints, as 
well as of inflamed joints during innate immune-driven experimental arthritis. 
Publications of various research groups in the field (including ours) describe 
a predominantly pro-inflammatory phenotype for IL-22 during adaptive 
immune-driven experimental arthritis. Geboes and colleagues showed that 
blocking IL-22 in C57BL/6 mice decreased both incidence and severity of CIA 
[10]. In accordance with these data, Corneth and colleagues recently showed 
reduced severity of CIA in IL-22-/- mice on C57BL/6 background. However, no 
effects of the lack of IL-22 expression on disease incidence were detected [11]. 
Concordantly, we recently showed reduced CIA severity in DBA-1 mice after 
anti-IL-22 antibody treatment during the early stage of disease development 
[29]. In line with these three CIA studies, our group previously showed 
reduced inflammation and bone erosion in IL-1Ra-/- mice after administration 
of neutralizing anti-IL-22 antibodies, suggesting that like in CIA, IL-22 plays a 
pro-inflammatory role in this arthritis model [12]. Finally, mice with a genetic 
deficiency of IL-22, and mice treated with anti-IL-22 antibodies, showed reduced 
development of antigen-induced arthritis (AIA) through an IL-1β-dependent 
mechanism [13]. In contrast, IL-22 was suggested to be anti-inflammatory in 
DBA-1 mice with CIA, as administration of recombinant IL-22 before onset 
of arthritis reduced the progression of arthritis [14]. Here, we report a clear 
pro-inflammatory role for IL-22 during spontaneous experimental arthritis 
in IL-1Ra-/- mice, as our IL-1Ra-/-IL-22-/- double knockout mice show markedly 
reduced disease development. As a previously published study described IL-
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17/Th17 cell-mediated experimental arthritis to be independent of IL-22 [23], 
we were not expecting any effect of this IL-22 deficiency on T cells. To confirm 
this hypothesis, we determined whether IL-22 affects the composition of T 
helper cell subsets in the joint draining lymph nodes and spleen of IL-1Ra-/- 
mice. As expected, no differences in T cell subset composition were detected 
in IL-1Ra-/- mice as compared to those also deficient for IL-22. In addition, we 
aimed to determine whether absence of IL-22 induced a change in the B cell 
arm of adaptive immunity. The previously mentioned study by Corneth and 
colleagues on the role of IL-22 during CIA showed reduced serum autoantibody 
titers in the absence of IL-22, whereas Geboes and colleagues reported 
increased levels of CII-specific and total IgG antibodies in IL-22-/- mice [10,11]. 
Even though the underlying cause for this difference remains unclear, it does 
become clear that IL-22 affects B cell antibody production in those studies, 
either in a stimulatory or inhibiting fashion. Interestingly, in our study using IL-
1Ra-/- mice we could not detect an effect of the lack of IL-22 on total IgG levels in 
serum, but found major reductions in serum autoantibodies targeting hnRNPs. 
Those autoantibodies are associated with a range of autoimmune diseases, 
amongst others RA [30,31]. Additionally, autoantibodies targeting various 
hnRNP family members have been described to be present both in mice [32] 
as well as in rats [33] with experimental arthritis. Interestingly, whereas up to 
now the disease development in IL-1Ra-/- mice was assumed to be relatively 
independent of autoantibodies [34], our study suggests this concept might 
have to be reconsidered. Further research on the exact function of these anti-
hnRNP antibodies in the pathogenesis of our arthritis models is required.
The spontaneous IL-1Ra-/- arthritis model was described to be dependent on T 
cells and IL-17 [20-22], and our studies indicate IL-22 to be involved in its arthritis 
development as well. As IL-17 and IL-22 are frequently observed co-expressed 
by Th17 cells, and IL-22 was proposed to be pathogenic in the presence of, 
and protective in the absence of IL-17 during airway inflammation [15], we 
aimed to elucidate whether dual blockade of IL-22 and IL-17 would increase 
disease severity in IL-1Ra-/- mice as compared to single cytokine blockade. As 
expected, we observed reduced disease severity in mice lacking either IL-22 
or IL-17 signaling. As anti-IL-22 treatment in IL-17-deficient mice was found 
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to exacerbate airway inflammation, we hypothesized a potential aggravation 
of arthritis development in IL-22-/- mice treated with IL-17-neutralizing 
antibodies as compared to IL-22+/+ mice treated with these anti-IL-17 
antibodies. Strikingly, no such effect was observed. Clinically scored arthritis 
was comparable between mice lacking IL-22 expression receiving isotype 
control antibodies, mice with functional IL-22 receiving neutralizing anti-IL-17 
antibodies, and IL-22-/- mice receiving anti-IL-17 antibodies. In contrast to the 
Sonnenberg study, we blocked IL-17 using neutralizing antibodies and not 
with a full knockout mouse. This shows that in experimental arthritis, there is 
no clear IL-17/IL-22 interdependency, as the role of IL-22 is not determined by 
the presence or absence of the key Th17 cytokine IL-17. Furthermore, our study 
indicates that IL-17 and IL-22 both drive spontaneous arthritis development in 
IL-1Ra-deficient mice in what seems to be an independent but overlapping 
manner, as blocking either the IL-17 or the IL-22 pathway equally suppresses 
arthritis.
To date, no conclusive data explaining the dual role of IL-22 in experimental 
arthritis is reported. We provided further insight into the mechanism by showing 
that IL-22 does not act locally on joint pathology during innate immune-
driven RA models, but is very important in driving adaptive immune-driven 
experimental arthritis by promoting anti-hnRNP autoantibody production. 
Most importantly, we were the first to show that as opposed to the IL-22/IL-
17 interplay in airway inflammation, IL-17 is not involved in determining the 
pro- or anti-inflammatory character of IL-22 in experimental arthritis, and that 
in the absence of IL-22, the dependence on IL-17 in arthritis progression is lost. 
Because of the high IL-22 levels correlating with various clinical markers in 
RA patients, this cytokine seems an attractive therapeutic target. However, 
until more knowledge is gathered on the interplay between IL-22 and the 
inflammatory environment, caution is required when targeting IL-22 in 
rheumatoid arthritis. 
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Systemic IL-22 overexpression induces SOCS3 
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ABSTRACT
Objective. High levels of IL-22 are present in serum and synovial fluid of 
patients with rheumatoid arthritis (RA). As both pro- and anti-inflammatory 
roles for IL-22 have been described in studies using animal models for 
rheumatoid arthritis, its exact function in experimental arthritis remains poorly 
defined. With this study, we aimed to further unravel the mechanism by which 
IL-22 exerts its effects, and to decipher its role during experimental arthritis by 
overexpression of IL-22 either locally or systemically during collagen-induced 
arthritis.
Methods. Collagen-induced arthritis was induced in DBA-1 mice by 
administering immunization and booster injections with bovine collagen 
type II (CII). Before arthritis onset, IL-22 was overexpressed either locally or 
systemically using an adenoviral construct, and clinical arthritis was scored for 
a period of 10 days. Mice were subsequently sacrificed, and joints were isolated 
for histological analysis of arthritis severity. Additionally, mRNA expression 
and protein production of various inflammatory mediators was determined in 
synovium, spleen, and serum.
Results. Local IL-22 overexpression increased local arthritis severity, whereas 
systemic overexpression of IL-22 potently reduced disease incidence and 
severity. Mice systemically overexpressing IL-22 showed significantly lower 
mRNA levels of IFNγ and SOCS3 in spleen, elevated SOCS3 expression 
correlated significantly with reduced serum levels of TNFα and MIP1α.
Conclusion. With this study, we revealed local pro-inflammatory effects of 
intra-articular IL-22 overexpression, and clear anti-inflammatory effects of 
systemic IL-22 overexpression during collagen-induced arthritis. Additionally, 
we were the first to show that the protective effect of systemic IL-22 during 
experimental arthritis is likely orchestrated via upregulation of the negative 
regulator SOCS3.
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INTRODUCTION
Interleukin (IL)-22 was first described in mouse as the IL-10-related T cell-
derived Inducible Factor α (IL-TIFα). This cytokine is a member of the IL-10 
family and shows 22% amino acid identity with IL-10 [1,2]. Moreover, murine 
IL-22 strongly resembles its human ortholog with an amino acid similarity of 
78% [2]. Major IL-22-producers are the T helper (Th)17 cells, CD4+ T cells that 
are characterized by their production of IL-17 [3]. Additionally, Th22 cells [4,5], 
γδ T cells [6,7], natural killer (NK) cells [8,9], and innate lymphoid cells [8,10] 
have been shown to produce IL-22. Responses to IL-22 are initiated by binding 
of the cytokine to its receptor, a complex consisting of an IL-22 receptor (R)1 
and an IL-10R2 subunit, the latter being shared with family member IL-10 [11]. 
While the IL-10R2 subunit is ubiquitously expressed, the expression of the IL-
22R1 subunit is restricted to non-hematopoietic cells [12]. In addition to this 
membrane-bound receptor complex, a soluble IL-22-binding protein (IL-22BP) 
has been identified. This protein binds IL-22, thereby neutralizing the activity 
of this cytokine [13,14].
Increased levels of IL-22 have been observed in serum of patients with 
Rheumatoid Arthritis (RA) as compared to healthy controls (HC) [15-17], and in 
RA synovial fluid as compared to osteoarthritis (OA) patients [16]. The increased 
IL-22 serum level in RA patients correlated with multiple clinical disease 
parameters, like disease activity score (DAS)28 [17], serum levels of rheumatoid 
factor (RF) [16,17] and anti-cyclic citrullinated peptide antibodies (ACPA) [16]. 
Furthermore, bone erosions were shown to be more severe in patients with 
high IL-22 serum levels [15,17]. Recombinant (r)IL-22 increases proliferation of 
RA Synovial Fibroblasts (RASF), and production of MCP-1 by those fibroblasts 
[18]. IL-22 promotes osteoclastogenesis by upregulating RANKL mRNA and 
protein expression on RASF in a dose-dependent manner [16,19]. The role of IL-
22 in animal models for various auto-inflammatory diseases has been studied 
extensively. In animal models for inflammatory bowel diseases (IBDs) IL-22 
was shown to play a protective role. Overexpression of IL-22 led to reduced 
intestinal inflammation [20,21], whereas blocking of IL-22 aggravated disease 
[22]. In contrast, neutralization of IL-22 ameliorated disease development in 
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Table 1. IL-22-directed interventions during experimental arthritis.
CIA, collagen-induced arthritis; AIA, antigen-induced arthritis; SCW, streptococcal cell wall; 
r, recombinant; Ad, adenoviral; α, anti; wk, week; i.p., intraperitoneal; s.c., subcutaneous; i.a., 
intra articular; PFU, plaque forming units; N/A, not applicable.
Re
fe
re
nc
e
St
ra
in
M
od
el
In
te
rv
en
ti
on
Ti
m
in
g
Re
sp
on
se
Ro
le
 IL
-2
2
Sa
rk
ar
 [2
5]
 
D
BA
-1
Ch
ic
ke
n 
CI
A
rIL
-2
2 
(1
x/
da
y 
5 
µg
 i.
p.
)
Be
fo
re
 o
ns
et
Re
du
ce
d 
di
se
as
e
A
nt
i-
in
fla
m
m
at
or
y
Pi
ne
da
 [2
6]
 
D
BA
-1
D
BA
-1
D
BA
-1
Bo
vi
ne
 C
IA
Bo
vi
ne
 C
IA
Bo
vi
ne
 C
IA
rIL
-2
2 
(1
x/
da
y 
1 
µg
 i.
p.
)
rIL
-2
2 
(2
x/
w
k 
0.
25
 µ
g 
s.c
.)
rIL
-2
2 
(2
x/
w
k 
0.
25
 µ
g 
s.c
.)
Be
fo
re
 o
ns
et
Be
fo
re
 o
ns
et
A
t o
ns
et
N
o 
re
sp
on
se
En
ha
nc
ed
 d
is
ea
se
N
o 
re
sp
on
se
- Pr
o-
in
fla
m
m
at
or
y
-
Pi
nt
o 
[2
7]
C5
7B
L/
6
A
IA
rIL
-2
2 
(1
x 
0.
1-
3 
ng
 i.
a.
)
Be
fo
re
 o
ns
et
En
ha
nc
ed
 d
is
ea
se
Pr
o-
in
fla
m
m
at
or
y
Ro
el
ev
el
d 
[2
8]
C5
7B
L/
6
C5
7B
L/
6
C5
7B
L/
6
N
aï
ve
 m
ic
e
SC
W
K/
Bx
N
 S
T
Ad
IL
-2
2 
(1
x 
10
7 
PF
U
 i.
a.
)
Ad
IL
-2
2 
(1
x 
10
7 
PF
U
 i.
a.
)
Ad
IL
-2
2 
(1
x 
10
7 
PF
U
 i.
a.
)
N
/A
Be
fo
re
 o
ns
et
Be
fo
re
 o
ns
et
N
o 
re
sp
on
se
N
o 
re
sp
on
se
N
o 
re
sp
on
se
- - - 
G
eb
oe
s 
[1
9]
 
C5
7B
L/
6
Ch
ic
ke
n 
CI
A
IL
-2
2-
/-
Be
fo
re
 o
ns
et
Re
du
ce
d 
di
se
as
e
Pr
o-
in
fla
m
m
at
or
y
Co
rn
et
h 
[2
9]
 
C5
7B
L/
6
Ch
ic
ke
n 
CI
A
IL
-2
2-
/-
Be
fo
re
 o
ns
et
Re
du
ce
d 
di
se
as
e
Pr
o-
in
fla
m
m
at
or
y
Ju
st
a 
[3
0]
 
D
BA
-1
D
BA
-1
Ch
ic
ke
n 
CI
A
Ch
ic
ke
n 
CI
A
αI
L-
22
 (1
x/
da
y 
10
0 
µg
 i.
p.
)
αI
L-
22
 (1
x/
da
y 
10
0 
µg
 i.
p.
)
Be
fo
re
 o
ns
et
Es
ta
bl
is
he
d
En
ha
nc
ed
 d
is
ea
se
Re
du
ce
d 
di
se
as
e
A
nt
i-
in
fla
m
m
at
or
y
Pr
o-
in
fla
m
m
at
or
y
Pi
ne
da
 [2
6]
 
D
BA
-1
D
BA
-1
Bo
vi
ne
 C
IA
Bo
vi
ne
 C
IA
αI
L-
22
 (2
x/
w
k 
10
0 
µg
 i.
p.
)
αI
L-
22
 (2
x/
w
k 
10
0 
µg
 i.
p.
)
Be
fo
re
 o
ns
et
A
t o
ns
et
Re
du
ce
d 
di
se
as
e
Re
du
ce
d 
di
se
as
e
Pr
o-
in
fla
m
m
at
or
y
Pr
o-
in
fla
m
m
at
or
y
G
ee
st
 [3
1]
 
D
BA
-1
D
BA
-1
Bo
vi
ne
 C
IA
Bo
vi
ne
 C
IA
αI
L-
22
 (3
x/
w
k 
20
0 
µg
 i.
p.
)
αI
L-
22
 (3
x/
w
k 
20
0 
µg
 i.
p.
)
Be
fo
re
 o
ns
et
A
t o
ns
et
Re
du
ce
d 
di
se
as
e
N
o 
re
sp
on
se
Pr
o-
in
fla
m
m
at
or
y
-
D
BA
-1
Bo
vi
ne
 C
IA
αI
L-
22
 (3
x/
w
k 
20
0 
µg
 i.
p.
)
Es
ta
bl
is
he
d
N
o 
re
sp
on
se
-
Pi
nt
o 
[2
7]
 
C5
7B
L/
6
A
IA
αI
L-
22
 (1
x 
5 
µg
 i.
a.
)
Be
fo
re
 o
ns
et
Re
du
ce
d 
di
se
as
e
Pr
o-
in
fla
m
m
at
or
y
M
ar
ijn
is
se
n 
[3
2]
 
IL
-1
Ra
-/
-
Sp
on
ta
ne
ou
s
αI
L-
22
 (3
x/
w
k 
20
0 
µg
 i.
p.
)
Es
ta
bl
is
he
d
Re
du
ce
d 
di
se
as
e
Pr
o-
in
fla
m
m
at
or
y
Ro
el
ev
el
d 
[2
8]
 
IL
-1
Ra
-/
-
Sp
on
ta
ne
ou
s
IL
-2
2-
/-
Be
fo
re
 o
ns
et
Re
du
ce
d 
di
se
as
e
Pr
o-
in
fla
m
m
at
or
y
523905-L-bw-Roeleveld
Processed on: 13-9-2018 PDF page: 129
6
129
SYSTEMIC IL-22 OVEREXPRESSION INDUCES EXPRESSION OF SOCS3
mice with inflamed skin, while administration with recombinant IL-22 induced 
development of this inflammatory skin disease model [23]. In an animal model 
for airway inflammation, blocking IL-22 ameliorated disease development. 
Interestingly, mice also deficient for IL-17 showed exacerbated airway 
inflammation, suggesting that in the absence of IL-17, IL-22 is protective in this 
model [24].  
Interestingly, reported data describing the role of IL-22 in animal models for 
rheumatoid arthritis appear to be conflicting, showing both pro- and anti-
inflammatory roles for this cytokine. However, blocking endogenous IL-22 
by neutralizing antibodies or gene deficiency reduced arthritis development 
in most studies. A summary of the multiple studies on IL-22 in experimental 
arthritis with their varying characteristics and outcome is provided in table 1. 
As IL-22 is predominantly a T cell cytokine, the animal models used to study 
the effect of IL-22 were almost exclusively driven by the adaptive immune 
system. Despite the abundance of IL-22 studies, the exact role and mechanism 
of IL-22 during experimental and rheumatoid arthritis remains unclear. With 
the current study, we aimed to investigate the disease-modifying effect of 
overexpression of IL-22 either locally or systemically during collagen-induced 
arthritis.
MATERIALS AND METHODS
Mice. Female wild type (WT) DBA/1JRj mice were purchased from Janvier-
Elevage (Le Genest Saint Isle, France). Animals were used between 10 and 
12 weeks of age unless specified otherwise, and were housed in filter-top 
cages under specific pathogen-free conditions. A standard diet and water 
were provided ad libitum. All animal procedures were approved by the ethics 
committee of the Radboud University Nijmegen.
CIA induction. Collagen-induced arthritis (CIA) was induced by an intradermal 
injection at the base of the tail with 100 µg bovine type II collagen (CII; Radboud 
umc in house production, batch 03-04-08) at a concentration of 2 mg/ml in 
0.05M acetic acid, emulsified in equal volumes of Freund’s complete adjuvant 
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(2 mg/ml of Mycobacterium tuberculosis strain H37Ra; Difco Laboratories, 
Detroit, MI, USA). After 21 days mice received an intra peritoneal (i.p.) injection 
of 50 µg CII dissolved in PBS, the onset of arthritis occurred a few days after this 
booster. Arthritis development was macroscopically scored three times a week 
using an arbitrary scoring system from 0-2 per paw, according to changes in 
redness and/or swelling of the paws. After 10 days, mice were anesthetized 
using 2-3% isoflurane and serum was collected, before being sacrificed by 
cervical dislocation. 
Adenoviral vectors. The adenoviral expression vector for murine (m)IL-22 
(AdIL-22) was kindly provided by Dr. J.K. Kolls (Children’s Hospital of Pittsburgh, 
Pittsburgh), and the control adenoviral expression vector for luciferase (AdLuc) 
was generated in-house. All viruses are replication-deficient and have the 
transgene under control of a CMV promoter. 21 days after immunization with 
CII, 1 x 107 plaque-forming units (PFU) of adenoviruses were injected intra-
articularly (i.a.) into the knee joint for local overexpression, or 3 x 108 PFU of 
adenoviruses were injected intravenously (i.v.) for systemic overexpression in 
immunized mice without clinical signs of CIA.
Histology. Isolated joints were fixed for at least four days in 4% formaldehyde, 
decalcified in 5% formic acid, and subsequently dehydrated and embedded 
in paraffin. Standard frontal sections of 7 µm were mounted on SuperFrost 
slides (Menzel-Gläser, Braunschweig, Germany). Haematoxylin and eosin (H&E) 
staining, and Safranin O (SO) staining were performed to study pathologic 
features of the joint. The severity of arthritis in the joints was scored on an 
arbitrary scale of 0-3, where 0 = no pathology and 3 = maximal pathology, 
as previously described for three different parameters (joint inflammation, 
proteoglycan (PG) depletion from the cartilage matrix, and bone erosion) [33]. 
Histopathological changes were scored on three semiserial sections of the 
joint, spaced 70 µm apart, in a blindfolded manner.
mRNA purification and quantitative real-time PCR. For mRNA isolation of 
the synovial tissue, lateral and medial pieces were punched out from mouse 
synovium surrounding the patella using a 3 mm biopsy punch (Stiefel, 
Wachtersbach, Germany). The synovial punches were pooled per knee 
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joint and immediately frozen in liquid nitrogen. Subsequently, the punches 
were disrupted and homogenized using the MagNA Lyzer (Roche, Basel, 
Switzerland). Total RNA was isolated using TRIzol reagent (Sigma-Aldrich, Saint 
Louis, MO, USA), according to manufacturer’s protocol. After isolation, RNA 
was treated with DNAse, and reverse-transcribed into complementary DNA 
(cDNA) as previously described [32]. Gene expression levels were determined 
by QPCR on the StepOnePlus sequence detection system (Applied Biosystems, 
Foster City, CA, USA) using SYBR Green technology (Applied Biosystems) and 
2 µM primers (Biolegio, Malden, the Netherlands). Primer sequences were as 
follows: Gapdh 5’-GGC-AAA-TTC-AAC-GGC-ACA-3’ (forward) and 5’-GTT-AGT-
GGG-GTC-TCG-CTC-CTG-3’ (reverse); Il-22 5’-GGT-GCC-TTT-CCT-GAC-CAA-AC-3’ 
(forward) and 5’-CGT-CAC-CGC-TGA-TGT-GAC-A-3’ (reverse); Ifnγ 5’-TCT-TCT-
TGG-ATA-TCT-GGA-GGA-ACT-G-3’ (forward) and 5’-AGA-GAT-AAT-CTG-GCT-
CTG-CAG-GAT-3’ (reverse); Tnfα 5’-CAG-ACC-CTC-ACA-CTC-AGA-TCA-TCT-3’ 
(forward) and 5’-CCT-CCA-CTT-GGT-GGT-TTG-CTA-3’ (reverse); Mip1α 5’-CAA-
GTC-TTC-TCA-GCG-CCA-TAT-G-3’ (forward) and 5’-TCT-TCC-GGC-TGT-AGG-AGA-
AGC-3’ (reverse); Il-10 5’-ATT-TGA-ATT-CCC-TGG-GTG-AGA-A-3’ (forward) and 
5’-ACA-CCT-TGG-TCT-TGG-AGC-TTA-TTA-A-3’ (reverse); Socs1 5’-CCG-TGG-GTC-
GCG-AGA-AC-3’ (forward) and 5’-AAG-GAA-CTC-AGG-TAG-TCA-CGG-AGT-A-3’ 
(reverse); Socs3 5’-TAG-ACT-TCA-CGG-CTG-CCA-AC-3’ (forward) and 5’-CGG-
GGA-GCT-AGT-CCC-GAA-3’ (reverse). Specific gene expression was normalized 
for expression of the reference gene Gapdh. To allow for statistical analysis, the 
-ΔCt value of samples with mRNA levels below detection limit was set at -25.
Cytokine and chemokine measurements. Cytokine levels in murine serum 
samples were determined using the Luminex multi-analyte technology, in 
combination with BioRad cytokine kits (BioRad) according to manufacturer’s 
protocol.
Statistical analysis. To determine the level of statistical significance between 
means of experimental groups, the t test, or a two-way ANOVA was used 
as indicated. P values less than 0.05 are considered significant. Results are 
expressed as Tukey boxplots or as column bar graphs.
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RESULTS
Intra-articular overexpression of IL-22 enhances local, but not systemic, 
arthritis pathology
To determine the effects of local IL-22 overexpression on the development 
of experimental arthritis, IL-22 adenovirus (AdIL-22) or control luciferase 
adenovirus (AdLuc) were injected in the knee joints of mice immunized 
with bovine CII, before clinical disease onset. We previously reported on the 
profile and kinetics of IL22 after viral overexpression, peaking at day 1 after 
virus injection [28]. In our study, we could still detect elevated levels of IL-22 
in serum of mice 10 days after i.a. injection with AdIL-22 (Figure 1A). Although 
we previously described upregulation of proinflammatory mediators by 
AdIL-22 injected into a naïve knee joint [28], the enhanced IL-22 levels in CIA-
immunized mice did not affect synovial mRNA expression (Figure 1B) or protein 
serum levels (Figure 1C) of various pro- and anti-inflammatory markers, at least 
not detectable 10 days after virus injection.
Concordantly, both arthritis incidence and severity (Figure 2A and 2B 
respectively) were unaffected by IL-22 overexpression when scoring clinical 
arthritis in all four legs. Interestingly, when only the hind paws, of which 
the ipsilateral knee joints received the virus injections, were included in the 
analysis, overexpression of IL-22 increased severity of clinical arthritis (Figure 
2C), indicating a local pro-inflammatory effect of the cytokine. By histological 
analysis, the effect of IL-22 overexpression on arthritis severity was studied in 
more detail for the knee joints that had been injected with the viral vectors. As 
demonstrated in figure 3A and 3B, arthritis pathology was already quite severe 
in the control virus group, and no differences were observed between AdIL-
22 and AdLuc-injected knee joints at day 31 of CIA upon scoring of various 
histological parameters of arthritis pathology.
Systemic IL-22 overexpression potently reduces arthritis pathology
In addition to the observed proinflammatory effects of local IL-22 
overexpression during CIA, we were interested in determining whether 
systemic IL-22 overexpression would accelerate arthritis onset and aggravate 
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arthritis severity. Strikingly, arthritis incidence levels were lower (Figure 4A) 
and significantly reduced macroscopic scores were detected in arthritic mice 
receiving systemic IL-22 adenovirus as compared to the AdLuc-injected control 
group (Figure 4B). In line with macroscopic inflammation, histological analysis 
showed significantly reduced cellular influx. Additionally, PG depletion from 
ankle cartilage was dramatically reduced. Furthermore, small but significant 
protective effects of IL-22 overexpression on bone erosion were observed 
(Figure 4C and D).
Figure 1. Local IL-22 overexpression does not induce changes in synovial mRNA expression 
and serum protein levels of inflammatory mediators. Mice were injected i.a. with AdIL-22 or 
AdLuc control virus after receiving CII booster at day 21. Mice were sacrificed 10 days after virus 
injection (day 31 of CIA), and serum was collected to determine protein levels using Luminex 
(A&C; n=17 mice/group; ***P<0.001;  Mann-Whitney). Relative mRNA expression in isolated 
synovium punches was subsequently determined in AdIL-22 receiving mice as compared to 
AdLuc receiving mice using qPCR (B; n=6 joints/group).
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Figure 2. Arthritis pathology of the hind legs is increased after local IL-22 overexpression. 
Macroscopically scored collagen-induced arthritis incidence (A) and severity (B) of the four 
paws. Macroscopically scored arthritis severity of the hind paws (C). N=17 mice/group; *P<0.05; 
Repeated measures ANOVA.
Figure 3. Histological parameters of knee arthritis pathology are unaltered after local IL-
22 overexpression. Mice were sacrificed 10 days after virus injection (day 31 of CIA), knee joints 
were subsequently isolated for histological analysis of cartilage PG depletion (SafO stain, original 
magnification 100x), inflammation, and bone erosion (both H&E stain, original magnification 
50x) (A & B; AdLuc n=16, AdIL-22 n=12 joints/group).
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Systemic IL-22 overexpression reduces expression of various inflammatory 
mediators
The effects observed after overexpression of IL-22 differed strikingly when 
injected locally into the knee joint, or systemically via the tail vein. To explain for 
this protective effect after systemic overexpression of IL-22, we were expecting 
reduced mRNA and protein levels of various proinflammatory markers in mice 
systemically overexpressing IL-22. However, despite the strong effects on 
macroscopic and clinical scores, no significant differences in synovial mRNA 
expression of IFNγ, TNFα, MIP1α, and IL-10 were observed between mice 
receiving i.v. AdIL-22 and AdLuc (Figure 5A). Highly increased protein levels of 
IL-22 in serum of mice receiving the IL-22 virus were detected, confirming virus 
Figure 4. Systemic IL-22 overexpression reduces arthritis pathology. Mice were injected i.v. 
with AdIL-22 or AdLuc virus after receiving i.p. CII booster at day 21. Macroscopically scored 
arthritis incidence (A) and severity (B) of the four paws (n=12 mice/group; repeated measures 
ANOVA). Mice were sacrificed 10 days after virus injection, ankle joints were subsequently 
isolated for histological analysis of cartilage PG depletion (SafO stain, original magnification 
100x), inflammation, and bone erosion (both H&E stain, original magnification 50x) (C & D; n=24 
joints/group; Mann Whitney). *P<0.05, **P<0.01, ***P<0.001.
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functionality (Figure 5B). Even though systemic levels of the pro-inflammatory 
mediators IL-1β, IL-17, GM-CSF, and MCP1 were unaltered in AdIL-22-receiving 
mice (data not shown), potent reductions in protein levels of IFNγ, TNFα, MIP1α, 
and IL-10 were detected in those mice (Figure 5C). As intravenous injection 
of adenoviruses has been shown to lead to high transgene expression levels 
in the spleen [34], we subsequently analyzed splenic mRNA expression levels 
for this panel of monocyte/macrophage-derived cytokines (Figure 5D). Here, 
levels of IFNγ, but not of the other inflammatory mediators, were significantly 
reduced in AdIL-22-receiving mice. 
Figure 5. Expression of inflammatory mediators in synovium, serum and spleen after 
systemic overexpression of IL-22 during CIA. Mice were injected i.v. with AdIL-22 or AdLuc 
virus after receiving CII booster at day 21. Mice were sacrificed 10 days after virus injection, 
synovium punches (A; n=6 mice/group) and splenic tissue (D; n=6 mice/group; t-test) was 
subsequently isolated for analysis of relative mRNA expression in AdIL-22 receiving mice as 
compared to AdLuc receiving mice using qPCR, and serum was collected to determine protein 
levels using Luminex (B & C; n=12 mice/group; t-test). *P<0.05, **P<0.01, ***P<0.001.
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Systemic overexpression of IL-22 reduces splenic SOCS3 mRNA expression
To explain for the anti-inflammatory effect of IL-22, we studied the effect of AdIL-
22 on the expression of the mRNA encoding for the anti-inflammatory protein 
suppressor of cytokine signaling (SOCS), an important negative regulator of 
the immune system [35]. Highly interesting, a strongly significant upregulation 
of mRNA encoding SOCS3 was detected in spleen, but not synovium, of mice 
systemically overexpressing IL-22 (Figure 6B and 6A respectively). To confirm 
that this is a systemic effect, we determined synovial SOCS mRNA expression 
levels in mice receiving i.a. AdIL-22. As expected, no effect of local IL-22 
overexpression on SOCS mRNA expression in synovium was detected (Figure 
6C).
Interestingly, a significant negative correlation between splenic SOCS3 mRNA 
expression and serum levels of TNFα and MIP1α was detected, which is in 
line with our hypothesis that the observed reduction in the cytokine levels is 
mediated in a SOCS3-dependent manner (Figure 7).
Figure 6. Splenic SOCS3 mRNA expression increased after systemic IL-22 overexpression. 
Mice with CIA were sacrificed 10 days after AdIL-22 or AdLuc virus injection (day 31 of CIA). 
Subsequently, synovium punches of mice receiving virus i.v. (A) and i.a. (C), and splenic tissue 
of mice receiving virus i.v. (B) was isolated. Relative mRNA expression of SOCS genes in AdIL-22 
receiving mice as compared to AdLuc receiving mice was determined using qPCR. N=6 mice/
group; **P<0.01; unpaired t test.
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DISCUSSION
Despite the numerous animal studies performed to delineate the role of IL-22 
in the development and progression of experimental arthritis, no consensus 
on this subject has been reached up to now. Some groups state IL-22 is pro-
inflammatory during disease development [19,26-29,31,32], whereas others 
claim an anti-inflammatory role for this cytokine [25]. As many others, our group 
previously showed a clear pro-inflammatory role for IL-22 in experimental 
arthritis driven by the adaptive immune system [28]. Although our recent 
study suggested a role for IL-22 in the production of autoantibodies, the exact 
mechanisms by which IL-22 exerted its pathogenic function remains unclear. 
With this study, we showed that local IL-22 overexpression aggravates arthritis 
severity, whereas systemic overexpression of IL-22 reduces the development of 
experimental arthritis. Most interestingly, we show that the anti-inflammatory 
effect of IL-22 is associated with an upregulation of SOCS3.
Figure 7. Splenic SOCS3 expression negatively correlates with serum levels of TNFα and 
MIP1α. Relative splenic SOCS3 mRNA expression (2-ΔCt x 100) was plotted against serum levels 
of IFNγ (A), TNFα (B), MIP1α (C) and IL-10 (D). N=12 mice; Pearson r correlation.
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While most studies focusing on IL-22 in experimental arthritis use IL-
22-targeting antibodies or recombinant proteins, we were interested in 
using a different approach: investigating the effect of IL-22 on disease 
development and progression with increased levels of local or systemic IL-22 
in mice with collagen-induced arthritis by using adenoviral expression vectors. 
Unexpectedly, we found striking differences in arthritis development between 
mice receiving local and systemic AdIL-22 injections. While mice injected 
intra-articularly with AdIL-22 showed increased local disease development 
as compared to AdLuc-receiving mice, a highly potent reduction in disease 
incidence and severity was observed when mice were injected i.v. with the IL-
22 virus. These observations of a protective effect of systemic overexpression of 
IL-22 during CIA were confirmed by Apparailly et al (personal communications) 
and intriguingly, the therapeutic responses were clinically quite similar to 
those in a paper previously published by our group, where systemic adenoviral 
overexpression of SOCS3 significantly reduced arthritis development [34]. 
Explaining the protective effects of IL-22 through SOCS3 induction could 
make sense, as IL-22 mainly signals through STAT3 [36], which may in turn 
lead to the activation of a negative feedback mechanism via SOCS3 [37]. 
SOCS3 is, as its suppressor of cytokine signaling-family members, a protein 
negatively regulating various cytokine signaling pathways [35]. Whereas 
our group previously showed that local SOCS3 overexpression during CIA 
did not protect from arthritis development, systemic SOCS3 overexpression 
resulted in the generation of tolerogenic APCs, impairing antigen-specific T 
cell activation and thereby suppressing arthritis. The fact that IL-22 has been 
shown to induce SOCS3 expression in lung epithelial cells [37] and liver cells 
[38], lead to the hypothesis that a similar SOCS3-dependent mechanism may 
apply to the present study. Indeed, a significant increase in SOCS3 mRNA 
expression was detected in splenocytes, but not synoviocytes, isolated from 
mice receiving i.v. AdIL-22 as compared to the AdLuc control group. This fits 
with our hypothesis, and provides us with a plausible mechanism by which 
IL-22 overexpression reduces arthritis incidence and severity on a systemic 
level. In line with the increased SOCS3 levels, we observed potent reductions 
in IFNγ, TNFα, MIP1α, and IL-10 serum levels in mice receiving systemic AdIL-
22 as compared to AdLuc receiving mice. This typical cytokine profile suggest 
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that the anti-inflammatory effect of IL-22 mainly affects cytokine production 
by monocytes/macrophages. The increased SOCS3 expression in splenocytes 
negatively correlated with serum levels of TNFα and MIP1α, and a negative 
trend was detected for both IFNγ and IL-10, strengthening our hypothesis 
that the observed anti-inflammatory effect of systemic IL-22 overexpression is 
mediated via a SOCS3-dependent pathway. No differences in synovial SOCS3 
expression were detected between mice receiving intra-articular AdLuc or 
AdIL-22, suggesting this IL-22-induced expression of SOCS3 and subsequent 
disease suppression is a systemic process. 
Even though our IL-22-induced SOCS3 concept explains our current data, 
it cannot fully account for historic data on the role of IL-22 in experimental 
arthritis. The IL-22-induced responses appear to depend on whether the 
cytokine is endogenously expressed, or exogenously administered [19,26-
29,31,32]. Additionally, it seems that the location of recombinant protein/
viral vector injection is important for the outcome of the intervention 
[25-27]. In general, studies blocking endogenous IL-22 using systemically 
applied neutralizing antibodies or genetically modified mice show reduced 
development of experimental arthritis [19,26-29,31,32], indicating a pro-
inflammatory role for endogenous IL-22. Accordingly, and in line with the 
current study, locally injected rIL-22 before arthritis onset exaggerated disease 
severity [26,27]. On the contrary, and again in line with our study, systemic 
injection of high levels of rIL-22 reduced the development of arthritis [25], 
suggesting an anti-inflammatory role for the cytokine systemically. Finally, the 
inflammatory context seems to affect the pro- and anti-inflammatory potency 
of IL-22 during experimental arthritis: neutralization of the cytokine before 
arthritis onset potently reduces disease severity, whereas these effects have 
been described to be absent when neutralizing IL-22 during later stages of 
arthritis development [31]. Possibly, other players like autoantibodies or other 
pro-inflammatory mediators have become involved in the disease process 
once arthritis has developed, resulting in inefficiency of IL-22-neutralization in 
reducing further progression of experimental arthritis.
With this study, we revealed a local pro-inflammatory effect of IL-22 after 
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i.a. overexpression, and a clear anti-inflammatory effect of systemic IL-22 
overexpression during experimental arthritis. We hereby showed that the role 
of IL-22 depended on the site of administration, and that the anti-inflammatory 
effects were associated with increased gene regulation of the SOCS3 pathway. 
To date, both pro- and anti-inflammatory roles have been described for IL-22 
during experimental arthritis, making it a debatable target in the treatment 
of RA. However, as only high, non-physiological concentrations of exogenous 
IL-22 were demonstrated to be anti-inflammatory, and IL-22 was shown to 
drive the local arthritis process, therapeutic targeting of endogenous IL-22 is 
expected to contribute to reduced pathology and symptoms in the treatment 
of RA.
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ABSTRACT
Objectives. Rheumatoid arthritis (RA) is a chronic autoimmune disease leading 
to progressive destruction of cartilage and bone. RA patients show elevated IL-
22 levels and the amount of IL-22-producing T helper cells positively correlates 
with the extent of erosive disease, suggesting a role for this cytokine in RA 
pathogenesis. The purpose of this study was to determine the feasibility of 
SPECT/CT imaging with 111In-labeled anti-FAP antibody (28H1) to monitor the 
therapeutic effect of neutralizing IL-22 in experimental arthritis.
Methods. Mice (6 mice/group) with collagen-induced arthritis (CIA) received 
anti-IL-22 or isotype-control antibodies. To monitor therapeutic effects after 
treatment, SPECT/CT images were acquired 24h after injection of 111In- 28H1. 
Imaging results were compared with macroscopic, histologic, and radiographic 
arthritis scores.
Results. Neutralizing IL-22 before CIA onset effectively prevented arthritis 
development, reaching a disease incidence of only 50%, versus 100% in the 
control group. SPECT imaging showed significantly lower joint tracer uptake 
in mice treated early with anti-IL-22 antibodies compared to the control-
treated group. Reduction of disease activity in those mice was confirmed by 
macroscopic, histological and radiographic pathology scores. However, when 
treatment was initiated in a later phase of CIA, progression of joint pathology 
could not be prevented.
Conclusion. These findings suggest that IL-22 plays an important role in CIA 
development, and neutralizing this cytokine seems an attractive new strategy 
in RA treatment. Most importantly, SPECT/CT imaging with 111In-28H1 can 
be used to specifically monitor therapy responses, and is potentially more 
sensitive in disease monitoring than the gold standard method of macroscopic 
arthritis scoring.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting up to 1% 
of the world population. The synovial inflammation characterizing RA leads 
to destructions of cartilage and bone, thereby disabling patients in their daily 
life. Increasing evidence suggests an important role for T cells in RA pathology 
[1-3], in particular for the T helper (Th)17 cell subset. Th17 cells produce 
various pro-inflammatory cytokines such as IL-17, IL-21, and IL-22, thereby 
protecting the host from bacterial and fungal infections, but also promoting 
the development of autoimmune diseases when present at elevated levels [4-
7]. In the synovium and in the circulation in RA patients elevated levels of IL-
22 are observed [8-10], which positively correlates with disease activity score 
(DAS)28 [11], serum rheumatoid factor (RF) [9-11], and anti-cyclic citrullinated 
peptide (CCP) antibodies [9]. Interestingly, reports on the role of IL-22 in various 
arthritis mouse models show that this cytokine is not only pro-inflammatory, 
but also might exert anti-inflammatory activities during experimental arthritis. 
In collagen-induced arthritis (CIA) for instance, an IL-22-deficiency in the early 
phases of the disease reduced the susceptibility to arthritis development [12], 
whereas absence of the cytokine during the later phases aggravated joint 
pathology [13]. Further insights into the role of IL-22 in experimental and 
rheumatoid arthritis are crucial when evaluating the potency of this cytokine 
as a new therapeutic target in RA treatment.
Since RA is characterized by disease exacerbations, not only early diagnosis is 
of utmost importance for an adequate treatment. In addition, monitoring of 
disease progression and early response monitoring after therapy are crucial for 
the prevention of progressive destruction. Considering that the response to 
therapy varies significantly among patients, personalized treatment based on 
accurate therapy response monitoring is essential. Molecular imaging of disease 
activity can be a valuable tool to accurately and timely monitor therapeutic 
efficacy. Specific tracer uptake can be quantified and can be assessed 
objectively. However, in most cases the tracer is not specific for arthritis at the 
molecular level [14,15]. Terry et al. demonstrated therapy response monitoring 
with tracers directed against targets which were specific biomarkers for 
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arthritis [16]. One of the tracers was the radiolabeled anti-FAP antibody 28H1. 
28H1 is a non-internalizing antibody with high affinity for human and murine 
fibroblast activation protein (FAP). FAP is dominantly expressed by activated 
fibroblast-like synoviocytes in arthritic joints [17,18]. Specificity of 28H1 for 
FAP was shown in in vitro binding assays and by immunohistochemistry in 
arthritic joints. 111In-28H1 SPECT/CT imaging showed a significant correlation 
between the uptake of 111In-28H1 in inflamed joints and the severity of arthritis 
[18]. In the present study, we investigated the feasibility of 111ln-28H1 SPECT/
CT imaging of FAP-expressing synovium to monitor the therapeutic potential 
of neutralizing IL-22 during various phases of experimental arthritis, and 
compared its potency to our standard clinical, radiographical, and histological 
disease scoring methods.
METHODS
Mice. Male DBA-1/J mice were purchased from Janvier-Elevage (Le Genest 
Saint Isle, France). Mice, 10 - 12 weeks old, were housed in filter-top cages 
under specific pathogen-free conditions. Mice had unlimited access to a 
standard diet and water. All procedures performed on animals in this study 
were in accordance with established guidelines and regulations, and were 
reviewed and approved by the animal ethics committee of the Radboud 
University Nijmegen.
Study design. CIA was induced as described previously [19]. Arthritis 
development was macroscopically scored on a scale of 0-2 per paw, according 
to changes in redness and/or swelling of the paws. Animals were divided in 
6 experimental groups (6 mice/group): 1 and 2: no clinical arthritis (‘before 
onset’); 3 and 4: arthritis score of 0.5 to 1.0 (‘at onset’); 5 and 6: arthritis score 
of 1.5 or higher (‘established disease’). Mice in group 1, 3, and 5 were the 
control groups, receiving rat IgG1 control antibodies (Pfizer), while mice in 
group 2, 4, and 6 were treated with rat anti-mouse IL-22 antibody (Pfizer, New 
York, NY, USA). Antibodies (8 mg/kg) were administered intraperitoneally (i.p.) 
three times per week for a total period of 12 days. This regimen was based on 
previous studies [20].
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SPECT/CT images were acquired 12 days after start of treatment. After 
image acquisition, mice were euthanized, organs were isolated to determine 
tissue distribution of the tracer, and ankle joints were isolated for X-ray and 
histological analysis.
Antibody conjugation and radiolabeling. The humanized monoclonal 
anti-FAP antibody 28H1 (Roche, Schlieren, Switzerland) has a high picomolar 
affinity for both murine and human FAP. 28H1 was conjugated with the chelator 
isothiocyanatobenzyl-diethylenetriaminepentaacetic acid (p-SCN-Bz-DTPA, 
Macrocyclics, Inc., Dallas, TX, USA) as described previously [16]. Radiolabeling 
with 111InCl3 was performed as described previously [21]. Labeling efficiencies, 
determined by thin-layer chromatography (ITLC), exceeded 99%.
Micro-SPECT/CT imaging. All mice were injected intravenously with 50 μg 
of 111In-28H1 (15 MBq). At 24 h p.i., image acquisition with the U-SPECT-II/CT 
(MILabs, Utrecht, The Netherlands) was performed [22]. Mice were scanned 
under general anesthesia (isoflurane and air) for 25 minutes while in prone 
position, using a 1.0 mm pinhole ultra-high sensitivity mouse collimator. SPECT 
scans were followed by CT scans for anatomical reference (spatial resolution of 
160 μm, 65kV, 615 μA). SPECT scans were reconstructed with software from 
MILabs, using an ordered subset expectation maximization algorithm, with a 
voxel size of 0.375 mm. Reconstructed micro-SPECT scans were coregistered 
with micro-CT images using Inveon Research Workplace 4.1 software (Siemens 
Preclinical Solutions, Knoxville, TN, USA). To allow for quantitative SPECT 
analysis, 3-dimensional regions of interest were drawn on the CT images 
and transferred to the SPECT images to obtain mean voxel intensities of the 
SPECT data corresponding to those regions. Mean voxel intensity values were 
converted to %ID/g. 
Histology. Murine joints were fixed for at least 4 days in 4% formaldehyde, 
decalcified in 5% formic acid, dehydrated and embedded in paraffin. 
Frontal sections of 7 µm were mounted on SuperFrost slides (Menzel-Gläser, 
Braunschweig, Germany), and stained with haematoxylin and eosin (H&E) 
for analysis of joint inflammation and bone erosion, or with Safranin O 
(SafO) to determine cartilage damage (average of scored cartilage erosion, 
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proteoglycan (PG) depletion, and chondrocyte death). Joint inflammation and 
destruction was scored on an arbitrary scale of 0-3, as previously described 
[23]. Histopathological changes were scored on three semiserial joint sections, 
in a blindfolded manner.
X-ray analysis of knee and ankle joints. X-ray images from knee and ankle 
joints were taken using a Faxitron MX20 instrument (Faxitron Bioptics, Tucson, 
AZ, USA) and analyzed using Faxitron software. Bone destruction was scored 
on an arbitrary scale from 0 to 4 per paw, where joints without pathology were 
scored as 0, and with maximal pathology as 4. 
FAP Immunohistochemistry. Knee joint synovium pieces were fixed and 
frozen in Tissue-Tek O.C.T. Compound (Sakura, Torrance, CA, USA) upon 
isolation. 7 µm sections were cut, dried on SuperFrost slides (Menzel-Gläser, 
Braunschweig, Germany), and stained with human anti-mouse/human FAP 
Ab (28H1-IgG; 0.1 µg/ml; Roche, Indianapolis, IN, USA), or human IgG control 
Ab (DP47GS; 0.1 µg/ml; Roche). Subsequently, sections were incubated with 
biotinylated goat-anti-human secondary antibodies (BA-3000; 1.5 mg/ml; 
Vector Laboratories, Burlingame, CA, USA), and labeled with streptavidin-
horseradish peroxidase (PK-6101; Vector Laboratories). Finally, peroxidase 
activity was developed with diaminobenzidine (DAB; D-5637; Sigma-Aldrich, 
Saint Louis, MO, USA), and counterstained with haematoxylin.
mRNA isolation and quantitative real-time PCR. Knee synovium biopsies 
were collected using a 3 mm biopsy punch (Stiefel, Wachtersbach, Germany), 
and subsequently disrupted and homogenized using the MagNA Lyser 
(Roche). mRNA was isolated, treated with DNAse, and reverse transcribed as 
previously described [20]. Gene expression levels were determined on the 
StepOnePlus sequence detection system (Applied Biosystems, Foster City, 
CA, USA) using SYBR Green technology (Applied Biosystems). 2 µM of murine 
FAP primers (Biolegio, Nijmegen, the Netherlands) were used in the reaction 
(5’-GTC-ACC-TGA-TCG-GCA-ATT-TGT-3’ (forward) and 5’-TCG-TAG-ATG-TAG-TAT-
GTC-GCT-GT-3’ (reverse)). Gene of interest expression levels were normalized 
for expression of the reference gene GAPDH (5’-GGC-AAA-TTC-AAC-GGC-
ACA-3’ (forward) and 5’-GTT-AGT-GGG-GTC-TCG-CTC-CTG-3’ (reverse)). To 
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allow for statistical analysis, the –ΔCt value of samples with mRNA levels below 
detection limit was set at -30.
Statistics. To determine the level of statistical significance between the 
experimental groups, the Mann-Whitney or Spearman correlation test 
was applied, using GraphPad Prism version 5. P values less than 0.05 were 
considered significant. Results were expressed as bar graphs, Tukey boxplots, 
or correlation plots.
RESULTS
Severity of experimental arthritis correlates with synovial FAP expression
To determine the correlation between severity of experimental arthritis and 
FAP expression levels in the synovium, CIA was induced in DBA1/J mice. Mice 
were euthanized at various stages of the disease. Analysis of isolated synovium 
by qPCR and immunohistochemistry showed that both FAP mRNA and protein 
expression increased with progressive disease severity (Figures 1A and 1B, 
respectively).
Decreased synovial FAP expression after early anti-IL-22 treatment 
111In-28H1 SPECT/CT is an excellent tool to monitor synovial FAP expression 
[18]. In order to test the potency of this tracer to monitor responses to arthritis 
therapy, mice in various stages of CIA (group divisions as depicted in Figure 
2) were treated with IL-22-neutralizing antibodies or a control treatment, 
and subsequently FAP expression was visualized using 111In-28H1 SPECT/CT. 
Arthritic joints were specifically visualized with 111In-28H1 in all groups (Figure 
3A-F). Images showed lower uptake of 111In-28H1 when mice received anti-IL-22 
treatment before onset of macroscopic symptoms (Figure 3D), as compared 
with mice in the control group (Figure 3A). 
Interestingly, tracer uptake was unaffected in mice that were treated around 
onset (Figure 3E) or during established disease (Figure 3F) with this IL-22 
neutralizing antibody, as compared with mice receiving the control antibody 
(Figure 3B-C). Quantitative analysis of the SPECT images confirmed that tracer 
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Figure 1. FAP expression increases in synovium of mice with more severe collagen-
induced arthritis. mRNA expression levels depicted as -ΔCT levels as determined using 
qPCR (A), and immunohistochemistry slides (B) of synovium isolated from mice with various 
severities of collagen-induced arthritis, depicted as macroscopic scores (MS) on a scale of 0 to 
2. Slides are stained with anti-FAP antibodies or appropriate isotype control antibodies (original 
magnification 200x).
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uptake in the joints was lower in joints after treatment with anti-IL22-antibodies 
before onset of disease (Figure 3G-I). For example, ankle joint uptake of 111In-
28H1 (Figure 3G) was significantly higher (p=0.02) in control-treated mice than 
in anti-IL-22 treated mice. Additionally, a significant reduction in tracer uptake 
(p=0.03) was found in the knee joints of anti-IL-22-treated mice compared to 
control-treated mice, as depicted in Figure 3H. No significant differences were 
found for 111In-28H1 uptake in other joints, such as the wrists (Figure 3I), and 
for tissue uptake in joints of mice that were treated in a later stage of disease. 
Neutralizing IL-22 in an early phase reduces macroscopic arthritis 
incidence and severity, correlating with tracer uptake
In line with the reduced levels of 111In-28H1 uptake in synovium, we observed 
reduced clinical arthritis incidence (50% vs. 100% at day 12 after start of 
treatment; Figure 4A) as well as ankle (Figure 4B), but not wrist (Figure 4C), 
joint swelling in mice treated with anti-IL-22 antibodies before disease onset 
as compared to mice that received control antibodies. As with SPECT/CT 
measured joint tracer uptake, macroscopically scored ankle joint swelling was 
not inhibited in mice in which anti-IL-22 treatment was initiated during later 
phases of the disease in this arthritis model (Figure 4B). Noteworthy, a strong 
positive correlation was found between synovial uptake of 111In-
Figure 2. Macroscopic scores of the various experimental groups before treatment. 
Treatment with either IgG isotype control antibodies or anti-IL-22 antibodies was initiated when 
mice reached a macroscopic score of 0 (group 1 and 2), 0.5-1.0 (group 3 and 4), or higher than 1.5 
(group 5 and 6). Group division based on macroscopic scores at the time of treatment initiation 
depicted as Tukey’s boxplots (n=6 mice/group).
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28H1 and macroscopic arthritis scores of the ankle joint (Spearman r=0.7937, 
p<0.0001; Figure 4D). Interestingly, relatively high levels of FAP-tracer uptake 
were detected in ankle joints of several mice without clinical signs of arthritis 
(score 0; Figure 4D). With macroscopic scoring, only the clinical signs of arthritis 
in wrists, ankles and digits of front and hind paws are included. As CIA is a 
Figure 3. Early anti-IL-22-treatment reduces tissue uptake of radiolabeled FAP-tracer, 
indicating reduced severity of collagen-induced arthritis. SPECT/CT images of mice injected 
with the FAP tracer 111In-28H1 (A-F) and tissue uptake based quantitative SPECT analysis in 
ankles (G), knees (H) and wrists (I). SPECT/CT imaging was performed after 2 weeks of treatment, 
with an isotype control antibody (A-C) or with the αIL-22 antibody (D-F). IL-22 signaling was 
neutralized before onset (A +D, macroscopic start score 0), around onset (B + E, macroscopic 
start score 0.5-1.0), or in established CIA (C + F, macroscopic start score ≥1.5). Tissue uptake 
(%ID/g) per ankle, knee and wrist joints (n=6 mice/group) are shown (G, H; Tukey’s boxplot; 
*p<0.05; Mann Whitney test).
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systemic model also affecting larger synovial joints like the knee joints, hip, 
elbow and shoulders, not all affected joints can be scored using this system. 
Using FAP-based SPECT-CT in vivo, arthritis incidence and severity in those 
other affected areas can be detected (Figures 3A-F). 
Figure 4. Early anti-IL-22-treatment reduces macroscopically scored severity of collagen-
induced arthritis, correlating with tissue uptake of FAP-tracer. IL-22 signaling was neutralized 
in mice either before onset (macroscopic start score 0), around onset (macroscopic start score 
0.5-1.0), or in established CIA (macroscopic start score ≥1.5). Disease incidence of mice treated 
before onset (A), and disease severity in ankle joints (B) and wrists (C) of all experimental groups 
at day 12, as scored macroscopically on a scale of 0 to 2 per paw (Tukey’s boxplot; **p<0.01, 
Mann Whitney test; n=12 joints/group). Correlation between FAP- tracer uptake by the tissue 
as measured using SPECT-CT and macroscopic arthritis severity scores (D; n=72 ankle joints; 
Spearman correlation).
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Ankle and knee histopathology and radiographic ankle bone damage 
correlate with synovial tracer uptake after treatment
In agreement with SPECT/CT and macroscopic data, reduced inflammation 
and cartilage damage was observed on a histological level in the ankle joints 
of mice treated with anti-IL-22 antibodies before disease onset, as compared 
to the control group (Figure 5A and 5B). In line with tracer uptake and clinical 
scoring, neutralization of IL-22 could not prevent histological damage in ankles 
of mice with starting or established disease. Interestingly, again a strong and 
highly significant correlation between joint damage and anti-FAP antibody 
uptake was apparent (Spearman r=0.7100, p<0.0001; Figure 5C). Additionally, 
radiographic ankle bone damage, as measured using X-ray, was significantly 
reduced in the ankle joints after early anti-IL-22 antibody treatment as 
compared to control treatment (0.4 vs. 1.5 respectively on a scale of 0-4, p<0.05; 
Figure 5D and 5E). No effect of the IL-22-neutralizing antibody treatment was 
detected when treatment was initiated in mice with clinical signs of arthritis. 
Ankle tissue tracer uptake and radiological bone damage showed a strong, 
positive correlation (Spearman r=0.6993, p<0.0001; Figure 5F).
In accordance with SPECT/CT images and observations in ankle joints, knee 
joint histopathology was reduced in mice treated with anti-IL-22 antibodies 
before disease onset, as compared to the control group (Figure 6A and 6B). 
Histopathological scores positively correlated with FAP-tracer uptake in 
the knee joints (Spearman r=0.6710, p<0.0001; Figure 6C). As opposed to 
the significantly reduced bone damage in the knees as observed during 
histological analysis, radiological scored knee bone damage was unaffected 
after early anti-IL-22 antibody treatment (Fig. 6D and 6E). An effect of the anti-
IL-22 antibody was detected neither on a histological, nor on a radiographic 
level when treatment was initiated in mice with starting or established disease. 
When linking tissue uptake of the tracer with radiological ankle bone damage, 
again a strong positive correlation between the readout parameters was 
observed (Spearman r=0.7206, p<0.0001; Fig. 6F).
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Figure 5. Reduced histopathology and radiographic damage of ankle joints after αIL-
22-treatment before arthritis onset. Mice received anti-IL-22-antibodies before onset 
(macroscopic score (MS) 0), around onset (MS 0.5-1.0), or during established CIA (MS≥1.5). 
Haematoloxylin & eosin (H&E), or Safranin O (SafO)- stained ankle joint sections (A; Tukey’s 
boxplot; *p<0.05, Mann-Whitney test; n=12 joints/group). Images represent average scores 
of mice treated before disease onset (B; original magnification H&E stained sections 50x, SafO 
stained sections 100x). Correlation between ankle FAP-tracer uptake and the sum of the three 
histologically scored parameters (C; n=72 joints; Spearman correlation). Bone damage as 
scored using X-ray (D; Tukey’s boxplot; *p<0.05, Mann-Whitney test; n=12 joints/group). Images 
represent average scores of mice treated before disease onset (E). Correlation between ankle 
FAP-tracer uptake and radiological bone damage (F; n=72 joints; Spearman correlation).
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Figure 6. Reduced histopathology of the knee joint. Mice received anti-IL-22 antibodies either 
before onset (macroscopic score (MS) 0), around onset (MS 0.5-1.0), or during established CIA (MS 
≥1.5). Histopathology of haematoloxylin & eosin (H&E), or Safranin O (SafO)-stained knee joints 
(A; Tukey’s boxplot; *p<0.05, Mann-Whitney test; n=12 joints/group). Images represent average 
scores of mice treated before disease onset (B; original magnification H&E stained sections 50x, 
SafO stained sections 100x). Correlation between knee FAP-tracer uptake and the sum of the 
three histologically scored parameters (C; n=72 joints; Spearman correlation). Bone damage as 
scored using X-ray (D; Tukey’s boxplot; *p<0.05, Mann-Whitney test; n=12 joints/group). Images 
represent average scores of mice treated before disease onset (E). Correlation between knee 
FAP-tracer uptake, and radiological bone damage (F; n=72 joints; Spearman correlation).
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DISCUSSION
We demonstrated, using 111In-28H1 SPECT imaging, that IL-22-neutralization 
only in the early phase of disease effectively suppressed the development of 
collagen-induced arthritis. Most importantly, we showed that this response 
to anti-IL-22 treatment can be monitored non invasively, specifically and 
objectively using quantitative SPECT/CT imaging of the inflamed synovium 
using 111In-labeled anti-FAP antibody as a tracer.
Previous SPECT/CT studies with radiolabeled anti-FAP antibodies showed high 
quality images [16,18,24]. Additionally, a better correlation between tissue 
uptake of the imaging tracer and severity of disease was found compared 
to the correlation found with the widely-used 18F-FDG-PET, which has been 
suggested as a tool to monitor therapeutic response in arthritis [14,18,25]. 
These studies also emphasized the feasibility to use 111In- 28H1 SPECT to 
specifically monitor therapy response at a molecular level.  
IL-22 is a cytokine to which both pro- and anti-inflammatory properties have 
been attributed. Even though most studies on the role of IL-22 in experimental 
arthritis hint towards a pro-inflammatory effect [12,19,26,27], the exact 
mechanism by which it is involved in RA pathology remains unclear. The 
therapeutic potential of specifically neutralizing IL-22 in experimental arthritis 
was clearly shown by the highly efficient reduction in disease incidence 
when treatment was initiated early in disease development. Additionally, 
disease severity was lowered as demonstrated by significantly reduced clinical 
arthritis, histological damage, and radiographic bone damage. Of note, a minor 
discrepancy between histological and radiographic scored bone damage 
in ankle and knee joints was observed. On the histological level, ankle joint 
damage was not significantly reduced after IL-22 neutralization, while this 
was the case on a radiographic level. Knee joints on the other hand, showed 
significantly less histological bone damage after anti-IL-22 treatment, while no 
effects were observed on a radiographic level. This might appear contradictive, 
but the two different methods visualize different aspects of bone damage. On 
a histological level, microscopic bone erosions can be detected, whereas bone 
density and larger areas of damage to the bone can clearly be observed using 
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X-ray imaging. 
As this study was designed to investigate whether SPECT/CT imaging with 111In-
labeled anti-FAP antibodies could be used to monitor response to anti-IL-22 
therapy, we did not focus on deciphering the mechanism of IL-22 in experimental 
arthritis. Nevertheless, the difference in effectiveness of IL-22-neutralization in 
reducing arthritis severity between treatment-initiation before disease onset 
versus at onset or during established disease is highly interesting. Based on 
the results of our previous study, which showed efficacy of IL-22 neutralization 
during established disease in IL-1Ra-/- mice [20], we hypothesize that the 
inadequacy of anti-IL-22 treatment in a later stage of disease is partly caused by 
the progressive and aggressive character of the arthritis during CIA. Although 
CIA is the most commonly studied animal model for rheumatoid arthritis and 
has become the ‘gold standard’ in preclinical rheumatology research over the 
past three decades, it is possible that disease development cannot be inhibited 
using IL-22-neutralizing antibodies once mice suffer from such a progressive 
form of autoimmune experimental arthritis. Another explanation might be the 
changing role of IL-22 during disease development. As suggested previously 
by Pineda and colleagues [13], the role of IL-22 might be pathogenic during 
early, but not during later phases of CIA. Hence, neutralizing this cytokine later 
in disease development would not affect joint pathology. Interestingly, Justa 
and colleagues showed a protective role for IL-22 early in CIA development, and 
a pathogenic role during later phases of the disease [28]. This is not only the 
opposite of what has been described by Pineda, but is also not in line with our 
current studies, where we observed a pathogenic role for IL-22 during the early 
stages of CIA development. Possibly, this is the consequence of differences in 
the inflammatory environment (e.g. cytokine milieu, level of inflammation), 
influencing the pro- or anti-inflammatory character of IL-22. IL-22 has been 
shown to be pathogenic in the presence, and protective in the absence, of IL-17 
in an animal model for airway inflammation [29], this cooperative mechanism 
with IL-17 or other pro- or anti-inflammatory cytokines might be present in 
experimental arthritis as well. This can provide a possible mechanism by which 
IL-22 exerts its pro- and anti-inflammatory activities respectively. Altogether, 
we conclude that IL-22 is an important mediator during the early phases of 
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CIA and has potential as a target in treating early RA. Still, further studies into 
the exact mechanism of action are required before testing the druggability of 
anti-IL-22 treatment in the clinic.
Here, we showed the feasibility of 111In-28H1 SPECT/CT as a specific and 
quantifiable tool to assess therapy response after IL-22 neutralization in 
experimental arthritis. As a result of the objectivity and specificity of this 
method, molecular imaging using radiolabeled anti-FAP antibodies as a tracer 
can be of additive value to existing methods of therapy monitoring in patients 
such as clinical macroscopic scoring (DAS28), MRI, ultrasound or conventional 
radiography. Additionally, the high sensitivity of 111In-28H1 SPECT/CT to detect 
experimental arthritis was shown, due to the relatively high tissue uptake of 
111In-28H1 in joints that were macroscopically scored as not affected (score 0), 
thus not showing any clinical signs. We suggest that the uptake of the tracer in 
the joints reflects increased FAP expression during subclinical synovitis and that 
these joints will show symptoms of inflammation upon disease progression, 
indicating a potential predictive value of 111In-28H1 SPECT/CT.
In conclusion, 111In-28H1 SPECT/CT imaging of the inflamed synovium can 
be used to specifically monitor response to therapy in an objective and 
quantitative manner, and is potentially more sensitive in disease monitoring 
compared to the standard methods of clinical arthritis scoring.
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SUMMARY
Th17 cells are important members of the adaptive immune system, and 
produce various cytokines like IL-17 and IL-22. Hereby, the cells protect the host 
from a wide range of bacterial and fungal infections, but may also promote the 
development of autoimmune diseases like RA [1]. RA is a chronic autoimmune 
disease affecting up to 1% of the population worldwide. It is characterized 
by progressive inflammation and subsequent destruction of synovial joints, 
resulting in pain and functional disabilities in patients suffering from this 
disease [2]. The role of Th17 cells and their key cytokine IL-17 have been 
studied extensively, as both have been shown to be significantly increased in 
RA synovium and serum compared with healthy and OA controls. Both Th17 
cell and effector cytokine levels correlate with a number of clinical parameters, 
like CRP level and number of swollen joints of RA patients [3-5]. As still about 
30% of RA patients fail to evoke a sufficient clinical response to currently 
available agents, the identification of new therapeutic targets remains a high 
priority [6]. Interestingly, in patients not responding to treatment with anti-
TNFα agents during RA therapy, circulating Th17 cell numbers and IL-17 levels 
were significantly increased compared to patients responding to the TNFα-
antibody treatment [7,8]. In this thesis the therapeutic potential of targeting 
the Th17 pathway in rheumatoid arthritis is studied in a preclinical setting. 
To provide a comprehensive overview of the current stage of using the Th17 
pathway as a therapeutic target in RA, we have reviewed published data on the 
involvement of Th17 cells and Th17-related cytokines in disease development, 
and of clinical trials using the IL-17-neutralizing agents ixekizumab and 
secukinumab (Chapter 1). The latter studies showed small but clinically 
relevant responses upon antibody administration in RA patients who failed 
to respond to previous treatment with synthetic and/or biologic DMARDs 
[9-13]. Despite the therapeutic value of these anti-IL-17 antibodies in RA 
treatment, pharmaceutical companies are shifting the application of their IL-
17-neutralizing agents to other rheumatic diseases like psoriatic arthritis and 
ankylosing spondylitis. Obtained clinical effects of this targeted inhibition of 
IL-17 in RA were most likely below expectation, especially when comparing 
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with the impressive clinical responses in patients suffering from plaque 
psoriasis [14-17]. As Th17 cells and Th17-derived cytokines are still considered 
important players in arthritis pathology [3,18-20], identifying novel/additional 
ways to effectively target this Th17 pathway in rheumatic diseases remains a 
high priority. Therapeutic efficacy might be enhanced when targeting Th17 
cells in full, rather than solely targeting its effector cytokine IL-17. Furthermore, 
alternative Th17 cytokines like IL-22 might be attractive mediators to target, 
either alone, or combined with IL-17 inhibition. 
Targeting the differentiation of Th17 cells
Here, we investigated options to inhibit differentiation of Th17 cells, thereby 
preventing them from contributing to joint pathology. Th17 cells develop 
from naïve CD4+ T cells after stimulation with a number of cytokines, the most 
important ones being TGF-β, and IL-6 or IL-21 [21,22]. The differentiation process 
is enhanced by two pro-inflammatory cytokines known to be important in RA 
pathogenesis: TNFα and IL-1β [22]. After initial differentiation, IL-23 synergizes 
with IL-6, enhancing survival and stabilization of Th17 cells [23]. IL-21 is a 
pleiotropic cytokine with the property of inducing both pro- as well as anti-
inflammatory effects [24]. We studied the dual role of IL-21 in experimental 
arthritis in relation to Th17 development using IL-21 receptor-deficient (IL-
21R-/-) and wild-type mice (Chapter 2). Lack of IL-21R expression protected 
against severe inflammation and joint destruction during antigen-induced 
arthritis (AIA) and chronic streptococcal cell wall (SCW) arthritis. IL-17 serum 
levels were reduced during AIA, and during SCW arthritis IL-17+IFNγ+ synovial 
T cells were detected less frequently in IL-21R-/- mice. Interestingly, significantly 
higher clinical arthritis scores were observed in mice lacking the IL-21R during 
the acute phases of SCW arthritis. IL-21R-/- mice showed to be less capable of 
up-regulating the expression of the anti-inflammatory suppressor of cytokine 
signaling (SOCS)-1 and SOCS3 mRNA, providing a possible mechanism for the 
anti-inflammatory actions of IL-21.
Interestingly, in  mice with SCW arthritis, an effect of the IL-21R deficiency on 
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the classical IL-17+IFNγ- Th17 cells was lacking. This might be explained by the 
presence of IL-6, which, in combination with TGF-β, is a very important cytokine 
in driving Th17 differentiation [21]. Hence, we subsequently investigated 
whether a combination blocking of IL-6 and IL-21 would have a superior 
protective effect on Th17 differentiation and development of experimental 
arthritis, over single cytokine blockade (Chapter 3). In vitro Th17 differentiation 
was unaffected in the absence of IL-21 signaling, while the absence of IL-6 
significantly reduced development of this T cell subset. Interestingly, a clear, 
synergistic reduction in Th17 levels was observed in the absence of both IL-21 
and IL-6 signaling pathways, suggesting that combined IL-21/IL-6 inhibition 
may suppress Th17-driven arthritis more efficiently. In contrast to what was 
detected in our in vitro Th17 differentiation study, in vivo a clear reduction in 
levels of CD4+IL-17+ cells was detected in IL-21R-/- as compared with WT control 
mice during AIA. This might appear contradictory to our previous findings 
where we did not detect an effect of IL-21R deficiency on classical Th17 cells, 
but it is important to keep in mind that in the latter study the cell population 
includes IL-17+IFNγ+ cells, and that a different arthritis model was used which 
possibly affects the role of IL-21. A clear difference observed between the AIA 
and SCW arthritis models is the effect of the lack of IL-21R on synovial IL-6 
levels, as those were highly reduced in IL-21R deficient mice during AIA, while 
during SCW arthritis IL-6 levels were unaffected or even increased. In addition 
to the clear reduction in CD4+IL-17+ cells observed in IL-21R-deficient mice 
during AIA arthritis, IL-6 deficiency resulted in significantly reduced Th17 
development in arthritic Bl6 mice as well. But, in line with our in vitro study, 
differentiation of Th17 cells was impaired to the highest extent when both 
IL-6 and IL-21 pathways were blocked. Arthritis development was reduced in 
IL-6-/- and IL-21R-/- single knockout mice, but the highest level of protection 
from arthritis progression was observed in mice lacking expression of both 
IL-6 and IL-21R. Concordantly, strongest suppression of arthritis development 
and progression was observed after treatment of mice in the induction phase 
of CIA with both anti-IL-6R antibodies and soluble (s)IL-21R.Fc. Collectively, 
these results suggest that dual IL-6/IL-21 inhibition may be a more efficacious 
therapeutic strategy compared to single cytokine blockade to suppress Th17-
driven arthritis development.
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Targeting novel Th17 effector cytokines
In addition to exploring options to inhibit the development of Th17 cells, we 
investigated the potential of the Th17 cytokine IL-22 as a therapeutic target 
in RA treatment, either alone or in combination with the key Th17 effector 
cytokine IL-17. To this end, we initiated by reviewing published reports on the 
role of both cytokines in RA pathogenesis, as well as on recent development in 
immunotherapies targeting IL-17 or IL-22 (Chapter 4). As IL-17 is clearly linked 
to RA pathogenesis by its expression and functionality in human and animal 
studies, this cytokine was the first Th17 effector cytokine to be a likely candidate 
for the development of new anti-rheumatic drugs. Another plausible option to 
target is IL-22. Like IL-17, IL-22 promotes osteoclastogenesis by stimulating the 
expression of RANKL by synovial fibroblasts [18]. In addition, it increases the 
proliferation of those synovial cells as well as the expression of the chemokine 
monocyte chemoattractant protein 1 (MCP-1) [25], which recruits a variety of 
immune cells to the joint (e.g. dendritic cells, monocytes). Multiple studies 
demonstrated increased IL-22 serum levels in a majority of RA patients as 
compared with healthy controls [18,20,26]. Here, IL-22 levels in RA patients 
positively correlate with serum titers of rheumatoid factor (RF) and anti-cyclic 
citrullinated peptide (anti-CCP) antibodies [18]. Additionally, elevated IL-22 
levels in serum have been significantly associated with erosive RA [20].
Multiple reports have been published on the role of IL-22 in various animal 
models for rheumatoid arthritis, and interestingly, they showed both pro- 
and anti-inflammatory properties for this cytokine [27-31]. Data appear 
contradictory, leaving the exact mechanism of IL-22 in RA pathology poorly 
understood. Therefore, we aimed to further elucidate the role of IL-22 in 
experimental arthritis, and to determine the therapeutic potential of targeting 
this cytokine in RA treatment. We studied cytokine interactions of IL-22 within 
the inflammatory environment, using a range of approaches like adenoviral 
overexpression, IL-22 deficient (IL-22-/-) mice, and cytokine-directed antibody 
treatment (Chapter 5). IL-22 overexpression failed to induce joint inflammation 
in naïve mice, and did not aggravate or alleviate disease severity during 
innate immune-driven experimental arthritis in mice with SCW-induced or 
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K/BxN serum transfer arthritis. In addition, IL-17-, IL-1β-, or TNFα-induced joint 
inflammation was unaffected by excessive IL-22. As IL-22 has been suggested 
to be pro-inflammatory in the presence, and anti-inflammatory in the absence 
of IL-17 in an airway inflammation model [32], we combined overexpression 
of IL-22 and IL-17 in mice with SCW-induced arthritis to determine whether a 
similar mechanism applied during experimental arthritis. In this arthritis model, 
no additional effect of combined IL-22/IL-17 overexpression was observed, 
indicating there is no IL-17/IL-22 cytokine interplay during SCW arthritis. With 
these studies, we were the first to report on the role of IL-22 during innate 
immune-driven experimental arthritis. Additionally, we examined the role of 
IL-22 in arthritis models driven by adaptive immunity.
Previous reports mainly describe a pro-inflammatory phenotype for IL-
22 during adaptive immune-driven experimental arthritis, although the 
mechanism remains unknown. Concordantly, we observed strongly reduced 
joint pathology in the absence of IL-22, using the spontaneous IL-1Ra-/- 
mouse model for arthritis. The observed effect could not be explained by a 
change in T cell subset profile. However, when studying antibody levels, 
in particular RA-related autoantibody levels, a potent reduction in hnRNP-
directed autoantibodies was detected in mice lacking IL-22. Remarkably, 
although this model has been described as a Th17/IL-17-driven model [33], 
no effect on arthritis progression was observed upon neutralization of IL-17 
in IL-22-deficient IL-1Ra-/- mice, indicating that (1) blocking either one or both 
Th17 cytokines results in the same net effect, without further additional or 
synergistic effects between IL-17 and IL-22, and (2) the presence or absence of 
IL-17 does not affect the role of IL-22 in this arthritis model. 
After observing this pro-inflammatory effect of IL-22 in IL-1Ra-/- mice, we 
expected that IL-22 overexpression during CIA would accelerate arthritis 
onset and aggravate disease severity (Chapter 6). When overexpressing IL-22 
locally, indeed we observed increased local arthritis severity, confirming the 
pro-inflammatory role of IL-22. Strikingly, mice appeared to be protected from 
arthritis development after systemic administration of the IL-22 adenovirus, 
indicating an anti-inflammatory role for IL-22. Mice receiving systemic IL-
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22 adenovirus showed significantly increased splenic SOCS3 expression, 
indicating that as with IL-21, the protective effect on disease development of 
excessive systemic IL-22 might be mediated via a SOCS3-dependent pathway. 
With these studies we provided further insight on the role and mechanism 
of IL-22 during experimental arthritis, promoting arthritis via the induction 
of anti-hnRNP autoantibodies, but also capable of suppressing inflammation 
via SOCS as negative feedback mechanism. To determine the potency of 
IL-22 as a new drug target during various stages of arthritis development, 
we treated mice with collagen-induced arthritis with IL-22-neutralizing 
antibodies (Chapter 7). Additionally, within this target validation study 
we tested the feasibility and potential of using SPECT/CT imaging with the 
111Indium-labeled anti-FAP antibody (28H1) to monitor therapy responses, as 
compared with conventional disease readouts. Fibroblast activation protein 
(FAP) is predominantly expressed by activated fibroblast-like synoviocytes in 
arthritic joints [34,35], and a significant correlation between the uptake of the 
111Indium-labeled anti FAP antibody in inflamed joints and arthritis severity 
has previously been shown [35]. Neutralization of IL-22 in the early phase of 
disease effectively suppressed CIA development. However, no therapeutic 
effects were observed when initiating treatment during later phases of 
CIA, an observation that might result from the progressiveness of the used 
model. Furthermore, autoantibodies might have already been formed before 
blocking IL-22, which would therefore have no effect on antibody formation 
and disease development. The therapeutic effects of IL-22 neutralization were 
monitored noninvasively, specifically, and objectively using quantitative FAP-
based SPECT/CT imaging of the joints. In addition, this imaging strategy was 
shown to be highly sensitive for detection of joint inflammation, as relatively 
high levels of 111In-28H1 tissue uptake were detected in joints that were 
macroscopically scored as not affected, indicating subclinical inflammation. 
Therefore, this technique can be of additional value to existing methods of 
monitoring disease activity in patients, like clinical macroscopic scoring 
(DAS28), MRI, ultrasound, or conventional radiography. 
523905-L-bw-Roeleveld
Processed on: 13-9-2018 PDF page: 176
CHAPTER 8
176
CONCLUSION AND FINAL CONSIDERATIONS
The results delineated in this thesis provide a solid platform for future 
fundamental and clinical studies on targeting cells and cytokines involved in 
the Th17 pathway during rheumatoid arthritis development and progression. 
We demonstrated the potency of targeting this pathway in a preclinical 
setting during various phases of experimental arthritis. Firstly, we showed the 
superiority of blocking both IL-6 and IL-21 signaling pathways in inhibiting 
Th17 and arthritis development over single cytokine blockade, demonstrating 
the potency of adding an IL-21-inhibitor to existing anti-IL-6 therapies. 
Subsequently, we provided further insights on the role and mechanism of IL-22 
during experimental arthritis, as well as on its potency as a therapeutic target. 
In all of our studies inhibition of IL-22 ameliorated the disease, showing the 
therapeutic potency of blocking the cytokine during inflammatory arthritis. 
Finally, we showed the feasibility of using FAP-based SPECT/CT imaging in 
monitoring therapy responses during CIA, and indicate this technique might 
be of great additive value to existing methods of disease monitoring.
Even though results of clinical trials testing the use of IL-17-neutralizing agents 
as RA therapy are disappointing, IL-17 has been shown to be important in a 
subset of RA patients [9-13] as well as in patients with other rheumatic diseases 
like psoriatic arthritis. Preclinical studies testing an anti-IL-17 antibody using RA 
synovium-SCID mice demonstrated a high level of therapeutic efficacy when 
engrafting mice with human RA synovial tissue in which inflammation was 
characterized by high numbers of CD3+ T cells [36]. Hence, the future challenge 
will be to identify local or systemic biomarkers than can predict responsiveness 
to Th17-directed RA therapy, and aid to apply more personalized medicine. 
Taken together, targeting the Th17 pathway via IL-6/IL-21 and IL-22 shows 
great therapeutic value in preclinical studies for RA, and along with other new 
developments, has potential to have a significant impact on the quality of life 
of patients suffering from rheumatoid arthritis and other, even more Th17-
driven rheumatic diseases like PsA and AS.
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Th17 cellen zijn belangrijke leden van het adaptieve immuunsysteem en 
produceren verschillende cytokines waaronder IL-17 en IL-22. Hierdoor 
beschermen de cellen de gastheer tegen een grote verscheidenheid aan 
bacteriële en virale infecties, maar kunnen ze ook de ontwikkeling van een 
auto-immuunziekte als RA stimuleren. RA is een chronische auto-immuunziekte 
die tot 1% van de wereldpopulatie treft. De ziekte wordt gekarakteriseerd 
door progressieve ontsteking en daaropvolgende destructie van synoviale 
gewrichten, wat leidt tot pijn en functionele beperkingen in patiënten die 
leiden aan deze ziekte. De rol van Th17 cellen en zijn belangrijkste cytokine 
IL-17 is uitvoerig bestudeerd, aangezien beiden in significant verhoogde 
hoeveelheden aanwezig bleken te zijn in RA synovium en serum vergeleken 
met gezonde en OA controles. Zowel Th17 cellen als effector cytokine levels 
correleren met een aantal klinische parameters, zoals CRP level en het aantal 
gezwollen gewrichten van RA patiënten. Aangezien ongeveer 30% van de RA 
patiënten nog steeds geen goede klinische respons ontwikkeld op medicijnen 
die momenteel beschikbaar zijn, blijft het enorm belangrijk om nieuwe 
therapeutische doelwitten te identificeren. Interessant genoeg bleken in RA 
patiënten die niet voldoende reageerden op behandeling met anti-TNFα 
medicatie, het aantal circulerende Th17 cellen en het IL-17 level significant 
verhoogd vergeleken met patiënten met een goede behandelrespons. In dit 
proefschrift wordt de therapeutische potentie van het aanvallen van de Th17 
pathway in reumatoïde artritis beschreven in een preklinische setting. 
Om een compleet overzicht te geven van de huidige stand van zaken 
rondom het gebruik van de Th17 pathway als doelwit in RA, hebben we 
reeds gepubliceerde data over de rol van Th17 cellen en Th17-gerelateerde 
cytokines in ziekte ontwikkeling, en van klinische studies waarin de IL-17-
neutraliserende medicijnen ixekizumab and secukinumab worden onderzocht 
gereviewd (Hoofdstuk 1). Die laatste studies lieten een kleine, maar klinisch 
relevante, respons zien op antilichaamtoediening in RA patiënten die op 
eerdere behandeling met synthetische en/of biologische DMARDs gefaald 
hadden. Ondanks de therapeutische waarde van deze anti-IL-17 antilichamen 
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in de behandeling van RA, verschuiven farmaceutische bedrijven het gebruik 
van deze IL-17-neutraliserende medicatie naar andere reumatische ziektes 
als artritis psoriatica en spondylitis anklylopoetica. Waarschijnlijk waren 
de behaalde klinische effecten van deze gerichte remming van IL-17 in RA 
beneden verwachting, vooral wanneer deze vergeleken worden met de 
indrukwekkende klinische responsen in patiënten die leiden aan plaque 
psoriasis. Aangezien Th17 cellen en Th17-gerelateerde cytokines nog altijd 
worden gezien als belangrijke spelers in de pathologie van artritis, blijft het 
van hoge prioriteit om nieuwe/additionele manieren om deze Th17 pathway in 
reumatische ziektes effectief aan te vallen te identificeren. Het therapeutische 
effect kan mogelijk vergroot worden wanneer de volledige Th17 cel, in plaats 
van alleen zijn effector cytokine IL-17, aangevallen wordt. Daarnaast zijn 
andere Th17 cytokines als IL-22 mogelijk interessant als therapeutisch doelwit, 
zowel alleen als gecombineerd met de neutralisatie van IL-17.
Het aanvallen van de differentiatie van Th17 cellen
In dit proefschrift hebben we opties onderzocht om de differentiatie van 
Th17 cellen te remmen, waardoor voorkomen wordt dat ze kunnen bijdragen 
aan gewrichtsschade. Th17 cellen ontwikkelen zich uit naïeve CD4+ T cellen 
na stimulatie met een aantal cytokines, waarbij TGF-β en IL-6 of IL-21 het 
belangrijkst zijn. Het differentiatie proces wordt versterkt door twee pro-
inflammatoire cytokines waarvan bekend is dat ze belangrijk zijn in de 
pathogenese van RA: TNFα en IL-1β. Na initiële differentiatie werkt IL-23 in 
synergie met IL-6, waardoor het overlevingsvermogen en de stabilisatie van 
Th17 cellen wordt vergroot. IL-21 is een pleiotroop cytokine met de eigenschap 
dat deze zowel pro- als anti-inflammatoire effecten kan hebben. Wij hebben 
deze duale rol van IL-21 in experimentele artritis onderzocht in relatie tot de 
Th17 ontwikkeling door gebruik te maken van IL-21 receptordeficiënte (IL-
21R-/-) en wildtype muizen (Hoofdstuk 2). Het gebrek aan IL-21R expressie 
beschermde tegen ernstige ontsteking en destructie van het gewricht tijdens 
antigen-geïnduceerde artritis (AIA) en chronische streptokokken celwand 
(SCW) artritis. De IL-17 levels in serum waren verlaagd tijdens AIA, en tijdens 
SCW artritis waren het aantal synoviale IL-17+IFNγ+ T cellen minder frequent 
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gedetecteerd in IL-21R-/- muizen. Interessant was dat significant hogere 
klinische artritis scores werden gezien in muizen zonder IL-21R expressie tijdens 
de acute fases van SCW artritis. IL-21R-/- muizen waren minder goed in staat 
om de expressie van het anti-inflammatoire ‘suppressor of cytokine signaling’ 
(SOCS)-1 en SOCS3 mRNA te verhogen, wat mogelijk het mechanisme achter 
de anti-inflammatoire acties van IL-21 geeft.
Interessant genoeg was in muizen met SCW artritis geen effect te zien van 
de IL-21R deficiëntie op de klassieke IL-17+IFNγ- Th17 cellen. Dit kan mogelijk 
verklaard worden door de aanwezigheid van IL-6, welke, in combinatie met 
TGF-β, een erg belangrijk cytokine is in het stimuleren van de Th17 differentiatie. 
Daarom hebben we vervolgens onderzocht of een gecombineerde blokkade 
van IL-6 en IL-21 een superieur beschermend effect zou hebben op de 
differentiatie van Th17 en op de ontwikkeling van experimentele artritis, ten 
opzichte van het blokkeren van een enkele cytokine (Hoofdstuk 3). In vitro Th17 
differentiatie bleef onveranderd in afwezigheid van IL-21, terwijl de afwezigheid 
van IL-6 zorgde voor een significantie verlaging in de ontwikkeling van deze 
T cel subset. Erg interessant is dat een duidelijke, synergetische verlaging in 
Th17 level werd gezien in afwezigheid van zowel IL-21 als IL-6, wat de suggestie 
wekt dat gecombineerde IL-21/IL-6 inhibitie Th17-gedreven artritis efficiënter 
zou kunnen onderdrukken. In tegenstelling tot wat gevonden is in onze in vitro 
Th17 differentiatie studie, zien we in vivo een duidelijke verlaging in CD4+IL-17+ 
level in IL-21R-/- muizen vergeleken met WT controle muizen tijdens AIA. Dit 
lijkt tegenstrijdig vergeleken met onze eerdere bevindingen waar we geen 
effect detecteerden van IL-21R deficiëntie op klassieke Th17 cellen, maar het 
is belangrijk hierbij te bedenken dat de celpopulatie van de laatste studie ook 
IL-17+IFNγ+ cellen bevat, en dat een ander artritis model gebruikt is wat de 
rol van IL-21 mogelijk heeft beïnvloed. Een duidelijk verschil tussen de AIA 
en SCW artritis modellen is het effect van een gebrek aan IL-21R expressie op 
synoviale IL-6 levels, welke sterk verlaagd waren in IL-21R deficiënte muizen 
tijdens AIA, terwijl deze tijdens SCW artritis niet veranderd of zelfs verhoogd 
waren. Naast de verlaging in CD4+IL-17+ cellen in IL-21R-deficiënte muizen 
tijdens AIA, resulteerde IL-6 deficiëntie ook in een significante verlaging van 
de Th17 ontwikkeling in Bl6 muizen met artritis. Maar, in lijn met onze in vitro 
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studie, de differentiatie van Th17 cellen was het meest verstoord wanneer 
zowel de IL-6 als de IL-21 pathway geblokkeerd waren. De ontwikkeling van 
artritis was verlaagd in IL-6-/- en IL-21R-/- enkelvoudige knock-out muizen, 
maar de grootste mate van bescherming tegen artritis progressie werd gezien 
in muizen die zowel een gebrek aan IL-6 als aan IL-21R expressie hadden. 
Daarop aansluitend werd de grootste mate van onderdrukking van de artritis 
ontwikkeling en progressie gezien na behandeling van muizen in de inductie 
fase van CIA met zowel anti-IL-6R antilichamen als met soluble (s)IL-21R.Fc. 
Alles tezamen wekken deze resultaten de suggestie dat tweevoudige IL-6/IL-
21 inhibitie een effectievere therapeutische strategie kan zijn vergeleken met 
enkelvoudige cytokine remming in het onderdrukken van de ontwikkeling 
van Th17-gedreven artritis.  
Het aanvallen van nieuwe Th17 effector cytokines
Naast het onderzoeken van opties om de ontwikkeling van Th17 cellen te 
blokkeren, hebben we de potentie van het Th17 cytokine IL-22 als therapeutisch 
doelwit in RA behandeling bestudeerd, zowel enkelvoudig als in combinatie 
met key Th17 cytokine IL-17. Daartoe hebben we allereerst reeds gepubliceerde 
data over de rol van beide cytokines in de pathogenese van RA, en over recente 
ontwikkelingen op het gebied van immunotherapieën gericht tegen IL-17 of IL-
22 gereviewd (Hoofdstuk 4). Aangezien IL-17 duidelijk verband houdt met de 
pathogenese van RA door zijn expressie en gebleken functionaliteit in humane 
en dierstudies, was dit de eerste Th17 effector cytokine die een veelbelovende 
kandidaat zou zijn voor de ontwikkeling van nieuwe antireumatische 
medicijnen. Een andere aannemelijke optie om therapieën tegen te richten 
was IL-22. Net als IL-17, promoot IL-22 osteoclastogenese door de expressie 
van RANKL door synoviale fibroblasten te stimuleren. Daarnaast vergroot het 
cytokine de proliferatie van die synoviale cellen, alsook de expressie van het 
chemokine monocyte chemoattractant protein 1 (MCP-1), welke verschillende 
immuuncellen (zoals dendritische cellen en monocyten) naar het gewricht 
rekruteert. Verschillende studies laten verhoogde IL-22 serum levels zien in een 
meerderheid van RA patiënten vergeleken met gezonde controles. Deze IL-22 
levels in RA patiënten correleren positief met reumafactor (RF) en anti-cyclisch 
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gecitrullineerde peptide (anti-CCP) antilichaam serum titers. Daarnaast worden 
verhoogde IL-22 levels in het serum significant geassocieerd met erosieve RA. 
Verschillende publicaties zijn geschreven over de rol van IL-22 in verschillende 
diermodellen voor reumatoïde artritis, en laten interessant genoeg, zowel 
pro- als anti-inflammatoire eigenschappen zien voor dit cytokine. Data 
lijken tegenstrijdig, waardoor het exacte mechanisme van IL-22 in de RA 
pathologie slecht begrepen blijft. Daarom hadden wij als doel om de rol van 
IL-22 in experimentele artritis verder op te helderen, en om het therapeutisch 
potentieel van het aanvallen van dit cytokine in de behandeling van RA te 
bepalen. We hebben cytokine interacties van IL-22 binnen het inflammatoire 
milieu bestudeerd door gebruik te maken van een verscheidenheid aan 
technieken zoals adenovirale overexpressie, IL-22 deficiënte (IL-22-/-) muizen, 
en cytokine-gerichte antilichaam behandeling (Hoofdstuk 5). Overexpressie 
van IL-22 leidde niet tot de inductie van gewrichtsontsteking in naïeve 
muizen, en vergrote of verzachte de ernst van de ziekte tijdens experimentele 
artritis gedreven door het aangeboren immuunsysteem in muizen met SCW-
geïnduceerde of K/BxN serum transfer artritis niet. Daarnaast werd de door 
IL-17-, IL-1β-, of TNFα-geïnduceerde gewrichtsontsteking niet beïnvloed 
door excessief IL-22. Aangezien is gesuggereerd dat IL-22 pro-inflammatoir 
is in aanwezigheid, en anti-inflammatoir is in afwezigheid van IL-17 in een 
model voor luchtwegontsteking, hebben we overexpressie van IL-22 en IL-17 
gecombineerd in muizen met SCW-geïnduceerde artritis om te bepalen of een 
vergelijkbaar mechanisme geldt tijdens experimentele artritis. In dit artritis 
model werd helaas geen additioneel effect van gecombineerde IL-22/IL-17 
overexpressie waargenomen, wat erop wijst dat er geen IL-17/IL-22 cytokine 
wisselwerking is tijdens SCW artritis. Met deze studies zijn we de eersten die 
de rol van IL-22 tijdens experimentele artritis gedreven door het aangeboren 
immuunsysteem beschrijven. Daarnaast hebben we de rol bestudeerd van IL-22 
in artritis modellen die worden gedreven door het adaptieve immuunsysteem. 
Eerder gepubliceerde data beschrijven hoofdzakelijk een pro-inflammatoir 
fenotype voor IL-22 tijdens experimentele artritis gedreven door het adaptieve 
immuunsysteem, hoewel het mechanisme onbekend blijft. In lijn met 
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deze data hebben wij een sterk gereduceerde pathologie van het gewricht 
waargenomen in afwezigheid van IL-22, gebruik makend van het spontane IL-
1Ra-/- muismodel voor artritis. Dit effect kon niet verklaard worden door een 
verandering in het T cel subset profiel. Maar wanneer we de antilichaam levels 
bestudeerden, met name de levels van RA-gerelateerde autoantilichamen, 
werd een potente verlaging van hnRNP-gerichte autoantilichamen 
gedetecteerd in muizen met een gebrek aan IL-22. Opmerkelijk hierbij was 
dat, hoewel dit model beschreven is als een Th17/IL-17-gedreven model, geen 
effect op artritis progressie werd waargenomen na neutralisatie van IL-17 in 
IL-22-deficiënte IL-1Ra-/- muizen, wat erop duidt dat (1) het blokkeren van één 
of beide Th17 cytokines resulteert in hetzelfde effect, zonder additionele of 
synergetische effecten tussen IL-17 en IL-22, en dat (2) de aan- of afwezigheid 
van IL-17 de rol van IL-22 in dit artritis model niet beïnvloed.
Na dit pro-inflammatoire effect van IL-22 in IL-1Ra-/- muizen waargenomen te 
hebben, verwachtten we dat overexpressie van IL-22 tijdens CIA de opkomst 
zou versnellen en de ziekte ernst zou vergroten (Hoofdstuk 6). Na lokale 
overexpressie van IL-22 zagen we inderdaad een verhoging van de lokale ziekte 
ernst, wat de pro-inflammatoire rol van IL-22 bevestigd. Opvallend genoeg 
bleken muizen beschermd tegen de ontwikkeling van artritis na systemische 
toediening van het IL-22 adenovirus, wat duidt op een anti-inflammatoire 
rol voor IL-22. Muizen die systemisch IL-22 adenovirus toegediend kregen 
hadden een significant verhoogde SOCS3 expressie in hun milt, erop wijzend 
dat zoals bij IL-21, het beschermende effect van excessief systemisch IL-22 op 
de ontwikkeling van de ziekte mogelijk via een SOCS3-afhankelijke pathway 
geregeld wordt.
Met deze studies hebben we gezorgd voor meer inzicht in de rol en het 
mechanisme van IL-22 tijdens experimentele artritis, waarbij het cytokine 
de ontwikkeling van artritis kan promoten via de inductie van anti-hnRNP 
autoantilichamen, maar de ontsteking ook kan remmen via SOCS als een 
negatief feedback mechanisme. Om de potentie van IL-22 als een nieuw 
therapeutisch doelwit tijdens verschillende stadia in de ontwikkeling van artritis 
te bepalen, hebben we muizen met collageen-geïnduceerde artritis behandeld 
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met IL-22-neutraliserende antilichamen (Hoofdstuk 7). Daarnaast hebben we 
binnen deze doelwit-validatie studie de bruikbaarheid en het potentieel van 
SPECT/CT imaging met het 111Indium-gelabelde anti-FAP antilichaam (28H1) 
om therapie respons te meten getest, en vergeleken met conventionele ziekte 
uitlezen. FAP wordt voornamelijk tot expressie gebracht door geactiveerde 
fibroblast-achtige synoviocyten in artritische gewrichten, en een significante 
correlatie tussen de opname van het 111Indium-28H1 antilichaam in ontstoken 
gewrichten en de ernst van artritis is al eerder aangetoond. Neutralisatie 
van IL-22 in de vroege fase van de ziekte onderdrukte de ontwikkeling van 
CIA effectief. Er werden echter geen therapeutische effecten waargenomen 
wanneer de behandeling tijdens een latere fase van CIA werd geïnitieerd, 
een observatie die mogelijk het resultaat is van de progressiviteit van het 
gebruikte artritis model. Daarnaast waren autoantilichamen mogelijk reeds 
aanwezig voordat IL-22 werd geblokkeerd, waardoor deze blokkade geen 
effect meer zou hebben op de ontwikkeling van de antilichamen en de 
ontwikkeling van de ziekte. De therapeutische effecten van IL-22 neutralisatie 
zijn niet-invasief, specifiek, en objectief gemonitord door gebruik te maken 
van kwantitatieve FAP-gebaseerde SPECT/CT imaging van de gewrichten. 
Daarnaast bleek deze imaging strategie uitzonderlijk gevoelig voor de 
detectie van gewrichtsontsteking, aangezien relatief hoge levels van 111In-
28H1 weefselopname werden waargenomen in gewrichten die macroscopisch 
als niet-aangedaan waren beoordeeld, duidend op subklinische ontsteking. 
Daarom kan deze techniek van additionele waarde zijn naast bestaande 
methodes van ziekte activiteit monitoring in patiënten zoals het klinisch 
macroscopisch scoren (DAS28), MRI, ultrasound, of conventionele radiografie. 
CONCLUSIE EN SLOTOVERWEGINGEN
De resultaten beschreven in dit proefschrift bieden een solide platform voor 
toekomstig fundamenteel en klinisch onderzoek naar het gebruik van cellen en 
cytokines onderdeel uitmakend van de Th17 pathway als therapeutisch doelwit 
tijdens de ontwikkeling en progressie van reumatoïde artritis. We hebben de 
potentie van het gebruik van deze pathway als doelwit in een preklinische 
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setting tijdens verschillende fases van experimentele artritis aangetoond. 
Allereerst hebben we de superioriteit laten zien van het blokkeren van zowel 
IL-6 als IL-21 pathways in het blokkeren van Th17 en artritis ontwikkeling ten 
opzichte van enkelvoudige cytokine blokkade, waarmee we de potentie van 
het toevoegen van een IL-21-remmer aan bestaande anti-IL-6 therapieën 
hebben aangetoond. Vervolgens hebben we voor verdere inzichten gezorgd 
met betrekking tot de rol en het mechanisme van IL-22 tijdens experimentele 
artritis, alsook over de potentie van dit cytokine als therapeutisch doelwit. In 
al onze studies zorgt een blokkade van IL-22 voor verlichting van de ziekte, 
waarmee het therapeutisch potentieel van remming van dit cytokine tijdens 
inflammatoire artritis is aangetoond. Tenslotte hebben we de bruikbaarheid 
van het gebruik van FAP-gebaseerde SPECT/CT imaging in het monitoren 
van therapie respons tijdens CIA aangetoond, en hebben hiermee laten zien 
dat deze techniek van grote toegevoegde waarde kan zijn naast bestaande 
methodes van ziekte monitoring.
Ook al vallen de resultaten van klinische trials waarin het gebruik van IL-
17-neutraliserende medicijnen als RA therapie worden getest tegen, er is 
aangetoond dat IL-17 belangrijk is in een groep RA patiënten en in patiënten 
met andere reumatische ziektes zoals artritis psoriatica. Een preklinische 
studie waarin een anti-IL-17 antilichaam is getest in RA synovium-SCID muizen 
liet grote therapeutische effectiviteit zien wanneer deze muizen een humaan 
RA synoviaal weefsel biopt geïmplanteerd kregen waarin de ontsteking 
werd gekarakteriseerd door hoge aantallen van CD3+ T cellen. Daarom 
zal de toekomstige uitdaging zijn om lokale of systemische biomarkers te 
identificeren die de responsiviteit op Th17-gerichte RA therapie kunnen 
voorspellen, en zo kunnen helpen bij het toepassen van meer gepersonaliseerde 
medicatieverschaffing.
Alles tezamen laat het aanvallen van de Th17 pathway via IL-6/IL-21 en IL-22 
grote therapeutische waarde zien in preklinische studies voor RA, en heeft het 
samen met andere ontwikkelingen, potentie om een significante impact te 
hebben op de levenskwaliteit van patiënten die leiden aan reumatoïde artritis 
en andere, Th17-gedreven reumatische ziektes als PsA en AS.
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Insights into our theme ‘Regenerative Medicine & Microenvironment’
Insights into our theme ‘Immune regulation’
Insights into our theme ‘Genetic & Epigenetic Pathways of Disease’
Chemistry of ubiquitination, proteolysis and antigen presentation
Insights into our theme ‘Infection and Inflammation’
Zebrafish as a model system to study the function and pathology of new 
genes
Spatiotemporal regulation of cytokine receptor plasticity
Interpreting cellular heterogeneity
From clinical vignette to basic science, and back
Antigen presenting cells: orchestrators of immune responses
Using chemical tools to track and target proteases involved in cancer, 
inflammation and infection
Nanomedicine tools for imaging and modulating cellular behavior
Taking advantage of multivalency: engineering biomolecular switches for 
antibody sensing and actuation
Computational biology of RNA editing and circular RNAs
Rare cancers
Optimizing anti-TNF therapy in inflammatory diseases
ILCs: Effectors and regulators of innate immunity and tissue remodeling
Nanomedicine
From bench to bedside
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Attended (inter)national symposia & congresses
March 2013 European Workshop for Rheumatology 
Research (EWRR) – Poster presentation
Prague, Czech 
Republic
May 2013 Radboud RIMLS PhD retreat – Poster 
presentation
Wageningen, the 
Netherlands
September 2013 BTCure Meeting – Poster presentation Prague, Czech 
Republic
September 2013 Nederlandse Vereniging voor 
Reumatologie (NVR) Najaarsmeeting – Oral 
presentation
Arnhem, the 
Netherlands
November 2013 Radboud New Frontiers Nijmegen, the 
Netherlands
March 2014 International congress on Autoimmunity – 
2 oral presentations
Nice, France
April 2014 Dutch Society for Immunology (NVVI) Lunteren, the 
Netherlands
May 2014 Radboud RIMLS PhD retreat – Poster 
presentation
Wageningen, the 
Netherlands
June 2014 European League Against Rheumatism 
(EULAR) – Oral and poster presentation
Paris, France
May 2015 Radboud RIMLS PhD retreat – Poster 
presentation
Veldhoven, the 
Netherlands
September 2015 European Workshop on Immune-Mediated 
Inflammatory Diseases – Oral presentation
Amsterdam, the 
Netherlands
September 2015 Nederlandse Vereniging voor 
Reumatologie (NVR) Najaarsmeeting – Oral 
presentation
Arnhem, the 
Netherlands
November 2015 American College of Rheumatology (ACR) – 
Poster presentation
San Francisco, 
USA
November 2015 Radboud New Frontiers Nijmegen, the 
Netherlands
December 2015 Dutch Society for Immunology (NVVI) – 
Oral presentation
Noordwijkerhout, 
the Netherlands
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Attended (inter)national symposia & congresses
February 2016 European Workshop for Rheumatology 
Research (EWRR) – Poster presentation
York, Great Britain
April 2016 International congress on Autoimmunity – 
Oral presentation
Leipzig, Germany
April 2016 Radboud RIMLS PhD retreat – Oral 
presentation
Veldhoven, the 
Netherlands
May 2016 BTCure Meeting Stockholm, 
Sweden
June 2016 European League Against Rheumatism 
(EULAR) – Oral presentation
London, Great 
Britain
September 2016 Nederlandse Vereniging voor 
Reumatologie (NVR) Najaarsmeeting – Oral 
presentation
Arnhem, the 
Netherlands
September 2016 Radboud Young Investigator Immunology 
Day – Organizing committee
Nijmegen, the 
Netherlands
December 2016 British (BSI) & Dutch (NVVI) Society 
for Immunology joint congress – Oral 
presentation
Liverpool, Great 
Britain
February 2017 BTCure Meeting Prague, Czech 
Republic
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RESEARCH DATA MANAGEMENT
Findable
The (meta)data of the results described in this thesis are indexed as Roeleveld_
Th17project and stored at the department of Experimental Rheumatology of 
the Radboud university medical center in Nijmegen, the Netherlands.
Accessible
The (meta)data will be stored long term, and are available according to 
a standardized communications protocol by submitting a request at the 
department of Experimental Rheumatology of the Radboud university medical 
center in Nijmegen, the Netherlands.
Interoperable
The (meta)data are documented according to the FAIR principles and include 
qualified references to other (meta)data.
Reusable
The (meta)data are documented to be reusable for future research and 
processing.
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Na een aantal jaren van hard werken, veel leerzame momenten, frustratie, af 
en toe wanhoop maar vooral toch ook heel veel plezier, is het dan eindelijk 
zover: mijn promotieonderzoek is afgerond! Dit had ik zeker niet alleen kunnen 
en willen doen, daarom wil ik graag een aantal mensen ontzettend bedanken 
voor hun hulp en steun tijdens deze periode.
Ik kan niet anders dan beginnen met het bedanken van jou, Marije. Als master 
student bood je me de kans om in jouw werkgroep mijn afstudeerstage te 
lopen, een tijd waarin ik veel geleerd heb en me enorm welkom heb gevoeld. 
Voor mij was er dan ook geen twijfel dat het voortzetten van deze studie in de 
vorm van een promotieonderzoek de perfecte eerste (en na later bleek ook de 
laatste ;)) stap zou zijn in mijn wetenschappelijke loopbaan, en wat ontzettend 
fijn dat jij me die kans opnieuw kon bieden. Jouw manier van supervisie sloot 
vanaf het begin perfect aan bij mijn behoeftes: je liet me vrij, liet me mijn 
fouten maken, maar stuurde ook bij als het nodig was. Met vragen kon ik altijd 
bij je terecht, zowel voor werk-gerelateerde, maar zeker ook voor privé zaken 
was je er. Lieve Marije, dankdankdank voor wie je voor me geweest bent, je 
sturing en je vertrouwen.
Ook wil ik graag mijn promotoren, Wim van den Berg en Peter van der Kraan 
bedanken. Wim, ook al ben je niet gedurende mijn gehele traject op het 
lab geweest, je adviezen in de beginperiode van mijn onderzoek hebben 
zeker bijgedragen aan de kwaliteit van de studies die nu in dit proefschrift 
beschreven staan, dank hiervoor. Peter, ook jou wil ik graag danken voor de 
input die ik heb ontvangen tijdens de vele lijndiscussies en werkbesprekingen.
Martijn, co-promotor 2(.0). Tijdens werkbesprekingen was jij vaak diegene die 
precies die vraag wist te stellen waar je de rest van de dag nog over na aan het 
denken was. Je input was altijd gericht op het beter maken van een studie en 
je grappen op het beter maken van iemands dag, of het nou die van mij of die 
van jezelf was. Bedankt Martijn! 
Peter van Lent en Fons van de Loo bedankt voor jullie nuttige, meestal 
opbouwende, kritieken op mijn werk tijdens de verschillende labmeetings.
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Lieve Birgitte, Monique en Liduine, zonder jullie zou dit proefschrift 
waarschijnlijk alleen uit reviews bestaan. Ontzettend bedankt voor alle hulp 
die ik van jullie heb gehad tijdens de voorbereiding, uitvoering, en verwerking 
van de verschillende (dier)experimenten. Birgitte en Monique, ongelooflijk 
hoe bedreven en respectvol jullie omgaan met de muizen, ik heb genoten 
van al onze dagen samen op het dierenlab. Monique, ik vind het super dat 
je vandaag naast me staat als paranimf. Liduine, erg fijn om iemand in onze 
groep gehad te hebben die altijd bereid is een PCR of Luminex te runnen. 
Naast dat jullie mij 6 extra handen gaven, heb ik ook veel gebruik gemaakt van 
jullie oren. Altijd open voor een gesprek, dank dat jullie die jaren voor mij niet 
alleen leerzaam, maar zeker ook leuk hebben gemaakt.
Rebecca, Claire en Stephanie, wat kan ik zeggen. Naast ontzettend fijne 
collega’s, superlieve vriendinnen waar ik enorm van en mee kan genieten. Of 
het nou gaat om een (illegaal) congresbezoek met citytrip daaraan vastgeplakt, 
het eten van een frietei en een veel te grote ijscoupe, het (onder dwang) opzij 
zetten van je angsten in een spookhuis, het ontsnappen uit een gevangenis, 
of gewoon om lekker tegen elkaar aan kruipen op de bank tijdens het kijken 
van een film, ik had het niet willen missen. Ik ga er ook vanuit dat ik het niet 
hoef te missen. Menig traan hebben we gedeeld, zowel van het lachen als van 
het huilen. Jullie weten dat ik het ontzettend knap vind hoe goed jullie het 
doen, in goede en mindere tijden. Bedankt ladies! Rebecca, jij bent als mede-
werkgroeplid altijd nauw betrokken en ontzettend behulpzaam geweest bij 
mijn studies. Als U-genoten hebben we daarnaast ontzettend veel lol gehad, 
met een prachtig uitzicht op Ryan eh.. het dierenlab. Ik heb enorm veel aan je 
gehad de afgelopen jaren en ben blij dat je ook tijdens dit laatste moment van 
mijn PhD-studenschap als paranimf een bijzondere rol speelt.
Shahla, door je vertrek naar NY hebben we de laatste jaren wat minder 
contact gehad, maar zeker in de beginperiode van mijn onderzoek heb je met 
je kritische blik veel bijgedragen aan mijn manier van onderzoek doen. Fijn 
om een postdoc in onze groep gehad te hebben waarbij je terecht kon voor 
onderzoek-gerelateerde vragen, en die ook nog eens de beste tips voor een 
citytrip in één van de mooiste steden van de wereld kon geven, bedankt!
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Het fijne aan het werken bij lab reuma was dat buiten de serieuze zaken, er 
ook veel tijd was voor gezelligheid. De dagelijkse koffiepauzes, maar ook de 
spelletjesavonden, filmnachten, pubquizzen, sinterklaasfeesten en natuurlijk 
de lablympics hebben er altijd voor gezorgd dat ik het enorm naar mijn zin heb 
gehad op het lab. Hiervoor, en uiteraard voor de input die jullie allen hebben 
geleverd op mijn studies, wil ik graag iedereen van lab reuma die ik nog niet 
genoemd heb bedanken. Postdocs Edwin, Niels, Arjen, Esmeralda, Guus, Henk, 
Marieke en Silke. Analisten Annet, Elly, Miranda en Onno.  Mede-promovendi 
Annemarie, Marijn, Daphne, Renoud, Rik, Wouter, Irene, Giuliana, Laurie, Arjan, 
Dennis, Wojciech, Ellen, Eva, Renske, Mathijs, Onno, Eline en Bartijn. In het 
bijzonder dank aan Marianne, die ervoor zorgt dat het lab draaiende blijft. 
Enorm bedankt voor al je werk-gerelateerde hulp, maar zeker ook voor je 
oprechte belangstelling en lieve knuffels.
Loreto, thank you for your efforts during your MSc internship. I really saw you 
grow during this period, and am sure you’ll do very well as a PhD student in 
Amsterdam.
Dan een uitstapje buiten mijn eigen vertrouwde clubje van lab reuma, 
naar nucleaire geneeskunde. Tessa, ontzettend bedankt voor de fijne 
samenwerking die geresulteerd heeft in een erg mooie paper en hoofdstuk 7 
van dit proefschrift. Datgene dat we zelf in de hand hadden verliep vlekkeloos, 
we wisten wat we aan elkaar hadden en zaten qua ideeën op één lijn. Dat er 
daarbuiten het één en ander niet liep zoals gehoopt was erg jammer, maar 
heeft ons er niet van weerhouden er een goed stuk van te maken. Dank voor 
de fijne samenwerking! 
Hoewel ik weet dat het lastig is om te begrijpen wat het inhoudt om 
promotieonderzoek te doen als je niet zelf in dat wereldje zit, heb ik altijd 
het gevoel gehad dat ik een hele club van lieve vrienden om me heen had 
die erg hun best deden (of het in ieder geval zo deden overkomen ;)) om 
het te begrijpen. Allereerst lieve Karlijn: hoewel jij wel bekend bent met het 
promoveren, staat het gebied van de medische biologie iets verder van je af. 
Ik ben altijd onder de indruk geweest van hoe goed je toch in staat was om te 
vertellen over wat ik deed op het lab, en vond het erg prettig om zo nu en dan 
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lekker tegen je aan te kunnen zeuren als het even niet lekker liep. Marjolein, 
Henriette, Maartje, Robin, Mathijs, Renze en Rick: fijn om zulke leuke mensen 
om me heen te hebben die altijd geïnteresseerd waren in hoe het ging met 
mijn onderzoek, en waarmee ik heerlijk kan lachen tijdens dagjes/weekendjes 
weg of gewoon tijdens een borrel of een kop thee. 
Lieve, lieve familie: ik ben enorm dankbaar voor jullie allemaal. Meestal, althans. 
Soms moest ik even tot tien tellen als er weer een vraag kwam over hoe het 
ging met mijn verslag, of over wanneer ik ging afstuderen, maar het was goed 
bedoeld, moest ik maar denken. Schoonfamilie Herman, Annie, Martin, Mieke, 
Anne, Bart, Frank en Romy: bedankt voor jullie interesse en support. Ik weet 
dat ze zeggen dat je de man met wie je trouwt kiest en dat je zijn familie erbij 
krijgt, maar ik had me niet beter kunnen wensen. 
Maartje, naast mijn grote zus ook één van mijn liefste vriendinnen. Ontzettend 
bedankt dat je het leven zoveel makkelijker voor me maakt: in onze tienerjaren 
al doordat ik je paspoort mee kon nemen naar het café, ik altijd welkom was 
in jullie keet en je leuke jongens uit je klas aan me voorstelde, en de afgelopen 
tijd door me veel tips te geven over onze kleine en gewoon door er te zijn. Ik 
hoop voor jullie dochters op net zo’n succesverhaal als het onze. Tim, bedankt 
voor je hulp bij dit proefschrift! Erg fijn, een broertje die zulke mooie dingen 
kan in ontwerpprogramma’s waar ik het liefst zo ver mogelijk bij vandaan blijf. 
Renze en Annelot, bedankt voor jullie steun en interesse in mijn onderzoek, 
maar ook voor hoe gelukkig jullie mijn zus en broertje maken. Goed om te zien 
dat ze allebei iemand gevonden hebben die de betweter kan uithangen als ik 
niet in de buurt ben. 
Pap en mam, jullie bijdrage aan dit proefschrift begint vooraan: bij de keuze 
voor het onderwerp van mijn promotie. Pap, jij weet heel goed hoe het is om 
met reuma te leven, en daardoor weet ik heel goed wat dit met een persoon en 
zijn familie doet. Toch wist ik over het ziektebeeld zelf nog niet zoveel, maar mijn 
interesse was uiteraard gewekt. Deze interesse voor de medische wetenschap 
is ook niet uit het niets ontstaan, de medische wereld heeft me altijd getrokken 
en mam, ik denk dat dit stiekem iets is wat ik van jou heb meegekregen. Via 
mijn medische opleiding dus binnen de reumatologie terecht gekomen en nu 
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hebben jullie mijn boekje dan eindelijk in jullie handen. Niet alleen hebben 
jullie bijgedragen aan de keuzes die ik gemaakt heb, jullie hebben me ook 
altijd gesteund te doen wat ik zelf wilde. Lieve pap en mam: bedankt!
Lieve Edwin, soms vond ik het jammer dat ik niet precies met je kon bespreken 
hoe mijn werk geweest was na een dag op het lab, zeker als dingen niet 
gegaan waren als gehoopt. Maar vaak vond ik het juist wel prettig, als ik thuis 
kwam ging de knop om: werk – uit, privé – aan. Ondanks je totaal verschillende 
interessegebied wist je verrassend goed uit te leggen wat mijn werk inhield, 
en merkte ik aan de vragen die je stelde dat je de essentie ook best begreep. 
Nooit reageerde je vervelend als ik weer eens op congres moest of als ik 
chagrijnig was na een mislukt experiment, je wist wanneer je me even moest 
laten en wanneer ik behoefte had aan een knuffel. Jouw nuchterheid, humor 
en vertrouwen hielden mij met beide benen op de grond en gaven mij het 
vertrouwen dat het allemaal wel zou gaan lukken. Als (hele dikke) kers op de 
taart hebben we de laatste maanden gewerkt aan een gezamenlijk project: 
lieve Pepin! Peppi, ook al ben je nog zo klein, je hebt al een erg belangrijke 
bijdrage geleverd aan dit proefschrift. Dankzij jou had ik namelijk de tijd om 
het laatste deel af te ronden en er een mooi verhaal van te schrijven. Lieve Pep, 
bedankt kleine vent dat je zo’n lieverd bent! Ed, bedankt voor je support, je 
humor, je lieve woorden, je prachtige zoon, je alles.
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